<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006849.pub3" GROUP_ID="LUNGCA" ID="761906110209111751" MERGED_FROM="" MODIFIED="2015-07-31 10:43:26 +0100" MODIFIED_BY="Corynne Marchal" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;Julia Walters 23/03/15&lt;/p&gt;&lt;p&gt;Good to see the new studies are now included. The review overall does not make it lcear how many new studies have been included since original review. reporting is not confirming to many of the the MECIR standards for reporting in the abstract or main text. Summary of findings table is not included and is highly desirable. author team needs to make a decision on meeting MECIR recomendations.&lt;/p&gt;" NOTES_MODIFIED="2015-07-31 11:33:47 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="IA1" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2015-07-31 10:43:26 +0100" MODIFIED_BY="Corynne Marchal">
<TITLE MODIFIED="2008-07-31 15:33:46 +0200" MODIFIED_BY="[Empty name]">Platinum versus non-platinum chemotherapy regimens for small cell lung cancer</TITLE>
<CONTACT MODIFIED="2015-07-31 10:43:26 +0100" MODIFIED_BY="Corynne Marchal"><PERSON ID="455B48F982E26AA200E154977F63CA19" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Isuru</FIRST_NAME><MIDDLE_INITIALS>U</MIDDLE_INITIALS><LAST_NAME>Amarasena</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>isurua@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>43 Collins Street</ADDRESS_1><CITY>Hobart</CITY><ZIP>7005</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-07-31 10:43:26 +0100" MODIFIED_BY="Corynne Marchal"><PERSON ID="455B48F982E26AA200E154977F63CA19" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Isuru</FIRST_NAME><MIDDLE_INITIALS>U</MIDDLE_INITIALS><LAST_NAME>Amarasena</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>isurua@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><ADDRESS_1>43 Collins Street</ADDRESS_1><CITY>Hobart</CITY><ZIP>7005</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="z1305070438394925814834929612820" ROLE="AUTHOR"><FIRST_NAME>Saion</FIRST_NAME><LAST_NAME>Chatterjee</LAST_NAME><POSITION>Medical Resident</POSITION><EMAIL_1>scha125@student.monash.edu</EMAIL_1><EMAIL_2>saionturn@hotmail.com</EMAIL_2><ADDRESS><ORGANISATION>Monash University and the Alfred Hospital</ORGANISATION><CITY>Victoria</CITY><ZIP>3800</ZIP><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON><PERSON ID="12527" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Julia</FIRST_NAME><MIDDLE_INITIALS>AE</MIDDLE_INITIALS><LAST_NAME>Walters</LAST_NAME><POSITION>NHMRC Primary Care Research Fellow</POSITION><EMAIL_1>Julia.Walters@utas.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>NHMRC Centre of Research Excellence for Chronic Respiratory Disease</DEPARTMENT><ORGANISATION>School of Medicine, University of Tasmania</ORGANISATION><ADDRESS_1>MS1, 17 Liverpool Street</ADDRESS_1><ADDRESS_2>PO Box 23</ADDRESS_2><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 3 6226 4798</PHONE_1><PHONE_2>+61 422 266 158</PHONE_2><FAX_1>+61 3 6226 7704</FAX_1></ADDRESS></PERSON><PERSON ID="12536" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><LAST_NAME>Wood-Baker</LAST_NAME><POSITION>Clinical Professor</POSITION><EMAIL_1>Richard.WoodBaker@utas.edu.au</EMAIL_1><MOBILE_PHONE>0407641077</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Tasmania</ORGANISATION><CITY>Hobart</CITY><ZIP>7001</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 6226 4805</PHONE_1><PHONE_2>0407 641 077</PHONE_2></ADDRESS></PERSON><PERSON ID="4624" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kwun</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Fong</LAST_NAME><EMAIL_1>kwun_fong@health.qld.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Thoracic Medicine</DEPARTMENT><ORGANISATION>The Prince Charles Hospital</ORGANISATION><ADDRESS_1>Rode Road</ADDRESS_1><CITY>Brisbane</CITY><ZIP>4032</ZIP><REGION>Queensland</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-05-18 16:48:05 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="8" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="8" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-27 20:07:52 +0200" MODIFIED_BY="Denise M Mitchell">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-12 18:16:52 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>New author for update - Saion Chatterjee</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-18 16:46:42 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>A new search was run in August 2014</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-07-27 20:07:52 +0200" MODIFIED_BY="Denise M Mitchell">
<DATE DAY="18" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>3 new studies were identified (<LINK REF="STD-Baka-2008" TYPE="STUDY">Baka 2008</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Sekine-2014" TYPE="STUDY">Sekine 2014</LINK>). A meta-analysis was carried out. Conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-18 16:46:15 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-05-18 16:46:15 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 14:39:14 +0100" MODIFIED_BY="José Angel Exposito">
<DATE DAY="8" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The Australian Lung Foundation / Lung Cancer Consultative Group Cochrane Review Scholarship</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-07-31 11:33:47 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-07-31 15:58:02 +0200" MODIFIED_BY="[Empty name]">A comparison of platinum-based and non-platinum-based chemotherapy regimens for the treatment of small cell lung cancer</TITLE>
<SUMMARY_BODY MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>Do patients with small cell lung cancer (SCLC) who receive platinum-based chemotherapy treatment live longer than those who receive non-platinum-based chemotherapy treatment?</P>
<P>Other questions include: do these patients also respond better to treatment, experience fewer side-effects and have a better quality of life?</P>
<P>
<B>Background</B>
</P>
<P>SCLC is a type of cancer that originates in the lungs. It is a very aggressive form of cancer that tends to grow and spread throughout the body quickly. As a result, chemotherapy is often the first type of treatment used for this type of cancer. Another type of treatment used for SCLC is radiotherapy, which is often given to the lung or to the brain.</P>
<P>A combination of a number of chemotherapy drugs used together is called a &#8216;chemotherapy regimen&#8217;. Currently, there are two main chemotherapy regimens used for treating SCLC:</P>
<P>&#8226; platinum-based chemotherapy regimens &#8211; containing a chemotherapy drug known as a &#8220;platinum agent&#8221; in combination with other chemotherapy drugs and;</P>
<P>&#8226; non-platinum-based chemotherapy regimens &#8211; containing other chemotherapy drugs without a &#8220;platinum agent&#8221;.</P>
<P>Over the past years, many studies have been done comparing the use of platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens in SCLC.</P>
<P>We carried out a study, called a meta-analysis, which included patients with SCLC who took part in randomised controlled trials comparing platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched for studies up to 1st August 2014. A total of 32 studies were part of this review and included 6,075 patients in total. The studies were carried out in many different countries throughout Europe, Asia and North America. The studies were conducted between 1981 and 2014.</P>
<P>
<B>Key results</B>
</P>
<P>The review showed that patients who received platinum-based chemotherapy were not any more likely to be alive at 6 months, 12 months and 24 months after treatment compared with patients who received non-platinum-based chemotherapy.</P>
<P>Platinum-based chemotherapy, however, showed higher rates of complete tumour response (the complete disappearance of tumours, at least for a period of time after treatment) compared to non-platinum-based chemotherapy. Platinum-based chemotherapy also caused some more side effects, including nausea and vomiting, and low platelets.</P>
<P>Only four studies looked at quality of life but because they each used different methods to measure the effects, their results could not be combined. However, in each study there was no difference in the quality of life between the platinum-based chemotherapy group and the non-platinum-based chemotherapy group.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-07-29 22:55:03 +0200" MODIFIED_BY="Denise M Mitchell">
<ABS_BACKGROUND MODIFIED="2015-05-08 02:19:54 +0200" MODIFIED_BY="[Empty name]">
<P>Small cell lung cancer (SCLC) is a very fast growing form of cancer and is characterised by early metastasis. As a result, chemotherapy is the mainstay of treatment. A number of different platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens have been used for the treatment of SCLC, with varying results. This review was conducted to analyse the data from these studies in order to compare their effectiveness.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-31 15:39:44 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of platinum chemotherapy regimens compared with non-platinum chemotherapy regimens in the treatment of SCLC with respect to survival, tumour response, toxicity and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-23 14:18:38 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the biomedical literature databases CENTRAL (The<I>Cochrane Library 2014, Issue 7</I>), MEDLINE, EMBASE and CINAHL from 1966 to August 2014. In addition, we handsearched reference lists from relevant resources.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-04-20 05:13:18 +0200" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials involving patients with pathologically confirmed SCLC (including both limited-stage disease and extensive-stage disease) and the use of a platinum-based chemotherapy regimen in at least one treatment arm and a non-platinum-based chemotherapy regimen in a separate arm.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-07-29 22:54:35 +0200" MODIFIED_BY="Denise M Mitchell">
<P>We used standard methodological procedures expected by the Cochrane Collaboration. Two authors independently assessed search results. We assessed included studies for methodological quality and recorded the following outcome data: survival, tumour response, toxicity and quality of life. We combined the results of the survival, tumour response and toxicity data in a meta-analysis. Quality-of-life data were analysed individually.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-07-29 22:54:59 +0200" MODIFIED_BY="Denise M Mitchell">
<P>A total of 32 studies involving 6075 patients with SCLC were included in this systematic review. The majority of studies were multi-centre randomised controlled trials conducted throughout Europe, North America and Asia with the earliest study publishing data in 1981 and the latest in 2014. The duration of studies ranged from 12 to 72 months with a median of 32 months. The median age of patients in the vast majority of studies was between 60 and 65 years of age. Eighteen studies presented data on extensive-stage disease. Nine studies presented data on limited-stage disease. Eleven studies did not present data based on the disease stage. These data were analysed separately in subgroup analyses. Sixteen (50%) studies were of good quality with a low risk of bias and the data from these studies were analysed separately in a heterogeneity analysis.</P>
<P>There was no statistically significant difference between treatment groups in terms of survival at 6 months, 12 months and 24 months. There was also no statistically significant difference in terms of overall tumour response. However, platinum-based treatment regimens did have a significantly higher rate of complete response. Platinum-based chemotherapy regimens had significantly higher rates of nausea and vomiting and thrombocytopenia toxicity. Four trials presented quality-of-life data, but, due to the different systems used to measure quality of life this data could not be combined in a meta-analysis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-29 22:55:03 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Platinum-based chemotherapy regimens did not offer a statistically significant benefit in survival or overall tumour response compared with non-platinum-based regimens. However, platinum-based chemotherapy regimens did increase complete response rates, at the cost of higher adverse events including nausea and vomiting, anaemia and thrombocytopenia toxicity. These data suggest non-platinum chemotherapy regimens have a more advantageous risk-benefit profile. This systematic review highlights the lack of quality-of-life data in trials involving chemotherapy treatment for SCLC. With poor long-term survival associated with both treatment groups, the issue of the quality of the survival period takes on even more significance. It would be beneficial for future trials in this area to include a quality-of-life assessment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-07-31 11:33:47 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-07-29 22:56:04 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Lung cancer is one of the most common cancers in the world, both in terms of incidence and mortality (<LINK REF="REF-Dela-Cruz-2011" TYPE="REFERENCE">Dela Cruz 2011</LINK>). Smoking is the biggest risk factor for lung cancer and is associated with 90% of cases (<LINK REF="REF-Alberg-2003" TYPE="REFERENCE">Alberg 2003</LINK>). Other risk factors include occupational and environmental exposure, for example asbestos (<LINK REF="REF-Heintz-2010" TYPE="REFERENCE">Heintz 2010</LINK>). Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on histological appearance. SCLC makes up about 20% of lung cancers (<LINK REF="REF-Le-Pechoux-2004" TYPE="REFERENCE">Le Pechoux 2004</LINK>).</P>
<P>SCLC is divided into two stages - limited disease stage and extensive disease stage. Based on the Veterans' Administration Lung Study Group (VALG) classification, The International Association for the Study of Lung Cancer (IASLC) defined limited disease (LD-SCLC) as: <I>"Disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and ipsilateral and contralateral supraclavicular nodes and should also include patients with ipsilateral pleural effusion independent of whether cytology is positive or negative"</I> (<LINK REF="REF-Micke-2002" TYPE="REFERENCE">Micke 2002</LINK>).</P>
<P>Extensive disease (ED-SCLC) was given the definition: <I>"All patients with sites of disease beyond the definition of limited disease"</I> (<LINK REF="REF-Micke-2002" TYPE="REFERENCE">Micke 2002</LINK>).</P>
<P>In SCLC, long-term survival is quite poor. Untreated, the median survival is 4 to 12 weeks (<LINK REF="REF-Chan-2013" TYPE="REFERENCE">Chan 2013</LINK>). Because SCLC is a very aggressive type of cancer and early metastasis (both local and distant) is common, chemotherapy is the first line treatment (<LINK REF="REF-Stinchcombe-2010" TYPE="REFERENCE">Stinchcombe 2010</LINK>). Even with treatment, long-term survival is poor. Median survival is in the order of 15 to 20 months for LD-SCLC and 8 to 13 months for ED-SCLC. Two- and five-year survival rates for LD-SCLC range from 20% to 40% and 10% to 13% respectively. For ED-SCLC, survival rates are even poorer - less than 5% at two years and 1% to 2% at five years (<LINK REF="REF-Glisson-2014" TYPE="REFERENCE">Glisson 2014</LINK>).</P>
<P>Chemotherapy is the most common treatment for SCLC because of early metastatic spread. Platinum therapy has been widely used and is regarded as first line treatment, as it has been considered one of the most efficacious agents. It is often combined with the non-platinum agent etoposide (<LINK REF="REF-Stinchcombe-2010" TYPE="REFERENCE">Stinchcombe 2010</LINK>). Platinum agents are cytotoxic alkylating agents that are active throughout the cell cycle (<LINK REF="REF-Chabner-2010" TYPE="REFERENCE">Chabner 2010</LINK>). The most widely used platinum agents in SCLC are cisplatin (cis-diamine-dichloroplatinum II) and carboplatin (cis-diamine-(1,1-cyclobutanedicarboxylate) platinum) (<LINK REF="REF-Stinchcombe-2010" TYPE="REFERENCE">Stinchcombe 2010</LINK>).</P>
<P>Non-platinum agents for SCLC include vincristine, doxorubicin (Adriamycin), cyclophosphamide and ifosfamide. All of these agents have been shown to have anti-tumour activity and have also been used in combination regimens in SCLC (<LINK REF="REF-Pujol-2000" TYPE="REFERENCE">Pujol 2000</LINK>). One of the most common non-platinum combinations that has been shown to be effective in SCLC is the vincristine, doxorubicin and cyclophosphamide regimen (<LINK REF="REF-Stinchcombe-2010" TYPE="REFERENCE">Stinchcombe 2010</LINK>).</P>
<P>As the available treatments have varying success rates and the different treatments have various advantages and disadvantages, a systematic review will be useful in determining optimal treatment regimens for SCLC.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-06-23 14:19:38 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of platinum chemotherapy regimens compared with non-platinum chemotherapy regimens in the treatment of small cell lung cancer (SCLC) with respect to survival, tumour response, toxicity and quality of life. </P>
</OBJECTIVES>
<METHODS MODIFIED="2015-07-31 11:33:47 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-07-29 22:56:11 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-06-23 14:19:41 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) that compared platinum-based chemotherapy regimens with other non-platinum-based chemotherapy regimens.</P>
<P>Inclusion criteria:</P>
<UL>
<LI>Studies involving only patients with pathologically confirmed (cytological or histological) small cell lung cancer.</LI>
<LI>Studies with at least one platinum-based treatment group.</LI>
<LI>Studies with at least one non-platinum-based treatment group.</LI>
</UL>
<P>Exclusion criteria:</P>
<UL>
<LI>Studies with platinum agents used in all treatment groups.</LI>
<LI>Studies with no platinum agent used in any treatment groups.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-07-29 22:56:04 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Adult patients of either sex with pathologically confirmed (cytological or histological) small cell lung cancer.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-07-29 22:56:07 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Platinum agents at any dose or for any number of cycles compared with any other chemotherapy regimen [P versus A].</LI>
<LI>Platinum agents at any dose or for any number of cycles in combination with other chemotherapy regimens versus the same chemotherapy regimen without the platinum agent (i.e. non-platinum chemotherapy is identical in both interventions) [(P+A) versus A].</LI>
<LI>Platinum agents at any dose or for any number of cycles in combination with any other chemotherapy regimen versus any other chemotherapy regimen not containing platinum agents [(P+A) versus B].</LI>
</UL>
<P>(Where P = platinum chemotherapy agents, A = non-platinum chemotherapy regimens and B = non-platinum chemotherapy regimens (different from A)).</P>
<P>Studies where platinum agents were administered to the control group were excluded from this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Radiotherapy</HEADING>
<P>RCTs that involve the use of radiotherapy (RT) were included, provided that RT was planned to be given in an identical way (dose, fractionation, timing and technique) in both treatment arms. If RT was given unequally to a treatment arm, or if the chemotherapy regimen to which patients were randomised routinely affected the way in which the RT was given, then the RCT was excluded.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-29 22:56:11 +0200" MODIFIED_BY="Denise M Mitchell">
<P>The primary outcome measure was survival at 6 months, 12 months and 24 months of follow up. Other outcome measures, such as tumour response, treatment-related toxicity and quality of life were also considered. Tumour response for objective overall response and complete response were defined as per World Health Organization (WHO) guidelines for tumour response evaluation (<LINK REF="REF-Park-2003" TYPE="REFERENCE">Park 2003</LINK>). Toxic events were classified (if they had not already been) according to the WHO scale (<LINK REF="REF-WHO-1979" TYPE="REFERENCE">WHO 1979</LINK>) and only grades 3 and 4 of toxicity were analysed. The following toxic events were considered: toxic death, nausea and vomiting, alopecia, infection, anaemia, leukopenia, thrombocytopenia and granulocytopenia. Quality-of-life data were recorded qualitatively.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-31 11:33:47 +0200" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for the search strategies used in the original review and current update, respectively</P>
<P>In 2007, we designed a search strategy to search the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library 2007, Issue 2</I>), MEDLINE (accessed through PubMed), EMBASE and CINAHL (accessed through EBSCO). The date of the search was from 1966 to April 2007. The search strategy was not restricted by date or language.</P>
<P>The search strings used to retrieve studies are reported in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</P>
<P>For this update, a search strategy generated by the Cochrane Lung Cancer Group was used to search the following databases:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (the <I>Cochrane Library 2014, issue 7</I>)</LI>
<LI>MEDLINE (accessed through PubMed) (1966 to 1 August 2014)</LI>
<LI>EMBASE (accessed through Ovid) (1966 to 1 August 2014)</LI>
</UL>
<P>The search strings used are reported in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>The strategy was combined with a validated filter to retrieve clinical trials (see section 6.4.11 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>)).</P>
<P>In addition to the search strategy, we handsearched references from relevant studies to identify any further studies. We contacted principal authors to identify any further studies or data that may be relevant to this review.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-07-29 22:56:24 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Two authors (IA and SC) assessed eligibility of articles retrieved via the search strategy from the title and abstract, with differences resolved through the input of a third author (JW). When there was insufficient information for assessment, the authors reviewed the full articles.</P>
<P>Two authors (IA and SC) independently evaluated all RCTs found in the search in order to rule out those that did not meet the inclusion criteria. We evaluated those studies for probable inclusion by critical reading of the whole article. There was no blinding of the author as to the origin or conclusions of the article for eligibility assessment, data extraction or quality assessment.</P>
<P>If necessary, we sought information from the principal investigator of the trial concerned. Two authors (IA and SC) independently extracted the data to ensure validity, and we resolved any discrepancies by an open discussion between all investigators (IA, SC, JW, KF).</P>
<P>To evaluate the methodological quality of selected studies, the authors independently assessed the studies with respect to the criteria set out in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Version 5.1.0.(<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>)</P>
<P>Each author independently undertook the extraction and registration of data from each study using data and study forms specifically designed for this review. The data extracted included details of the methodology used, the characteristics of the study participants, the type of interventions undertaken, the comparison groups, and the results obtained including the follow-up period.</P>
<P>We resolved any disagreement by consensus, or with the input of a third member (JW) of the review team.</P>
<P>We analysed all patients initially randomised on an intention-to-treat (ITT) basis. The ITT population was defined as randomised patients, irrespective of whether they received any form of treatment. For dichotomous variables, we calculated risk ratio (RR) with a 95% confidence interval (CI). We used a random-effects model for the pooled analysis. We undertook the meta-analysis in Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>).</P>
<P>We also calculated the proportion of people alive at 6, 12 and 24 months from both treatment groups. This data was used to generate survival curves for each of the subgroups.</P>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis</HEADING>
<P>We performed subgroup analyses for the outcomes of survival (at 6 months, 12 months and 24 months) and tumour response. We categorised data from included studies into the subgroups:<BR/>
</P>
<UL>
<LI>'undifferentiated' - if the study did not differentiate between patients with limited disease and extensive disease small cell lung cancer;</LI>
<LI>LD-SCLC - if the study presented data specifically from patients with limited disease small cell lung cancer;</LI>
<LI>ED-SCLC - if the study presented data specifically from patients with extensive disease small cell lung cancer.</LI>
</UL>
<P>This was undertaken in order to determine if there are differences between the treatment groups depending on the stage of the SCLC.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity assessment</HEADING>
<P>Where substantial heterogeneity occurred, we explored the effect of potential sources of heterogeneity in an attempt to identify the cause of the heterogeneity. Substantial heterogeneity was considered to exist when the I<SUP>2</SUP> value was greater than 50% (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>We identified the following potential sources of heterogeneity (postulated <I>a priori</I>).</P>
<UL>
<LI>Quality of studies. We deemed studies to be of higher quality if they satisfied the following criteria in the risk of bias assessment:</LI>
</UL>
<UL>
<UL>
<LI>incomplete outcome data addressed for all assessed outcomes;</LI>
<LI>free of selective reporting;</LI>
<LI>free of other bias.</LI>
</UL>
</UL>
<P>(Please refer to the 'Risk of bias' table for quality assessment).</P>
<P>In the current update, the studies were also assessed for quality using the GRADE approach as described in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0(<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). Using this method, studies were given a quality rating of High, Moderate, Low or Very Low.</P>
<UL>
<LI>Full article publication versus abstract publication.</LI>
</UL>
<UL>
<LI>Use of radiotherapy as a co-intervention.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We performed a sensitivity analysis, systematically excluding studies from the overall analysis based on the potential sources of heterogeneity hypothesised above. This included conducting a sensitivity analysis involving only studies that used radiotherapy treatment in order to explore the potential influence of platinum-based chemotherapy regimens and the use of radiotherapy on toxicity.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<STUDY_DESCRIPTION MODIFIED="2015-07-29 22:56:35 +0200" MODIFIED_BY="Denise M Mitchell">
<SUBSECTION>
<HEADING LEVEL="3">Search results</HEADING>
<P>The search strategies used for this review are outlined in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (strategy for the original review) and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (strategy for the update). The search yielded 3669 search results. We excluded 112 results as they were duplicates. A further 3525 records were excluded by abstract as they did not meet the inclusion criteria. This left 32 studies to be included in the review, including 29 from the original review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study characteristics</HEADING>
<P>The 32 studies included 6075 participants who were randomised. Of these, 3036 were assigned to platinum-based chemotherapy and 3039 to non-platinum-based chemotherapy regimens. All studies reported ITT analyses, thus recomputation of outcomes was not required.</P>
<P>Of the included studies, nineteen were conducted in centres throughout Europe, nine in North America, three in Asia and one (<LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK>) conducted in both Canada and Europe. All studies were one or more years in duration. The shortest study, <LINK REF="STD-Wolf-1987" TYPE="STUDY">Wolf 1987</LINK>, lasted 12 months and the longest study, <LINK REF="STD-Urban-1999a" TYPE="STUDY">Urban 1999a</LINK>, lasted six years.</P>
<P>A summary of the included studies is presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. A detailed description of each study is presented in the section '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
<SUBSECTION>
<HEADING LEVEL="4">Study chemotherapy interventions</HEADING>
<P>The most common platinum agent was cisplatin, used in 24 studies (75%). Carboplatin was used in the remaining eight studies (25%). The most common non-platinum agents used were etoposide (26 trials, 81.25%), cyclophosphamide (24 trials, 75%), doxorubicin (20 trials, 62.5%) and vincristine (18 trials, 56.25%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Radiotherapy as a co-intervention</HEADING>
<P>Of the 32 included studies, seven used only prophylactic cranial irradiation (PCI), three used only thoracic radiotherapy (TRT), and thirteen used both. The remaining nine studies did not involve any form of radiotherapy. The use of radiotherapy by study is presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroups</HEADING>
<P>The 32 studies were also divided a priori into subgroup comparisons according to disease staging, as indicated in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-29 22:56:42 +0200" MODIFIED_BY="Denise M Mitchell">
<P>We assessed study quality according to the criteria set out in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>)). The individual assessment for each study is set out in the 'Risk of bias' graph (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Twenty-six of the 32 studies (89.66%) did not report the randomisation process clearly. Hence, they were given an 'Unclear' rating for both sequence generation and allocation concealment. <LINK REF="STD-Baka-2008" TYPE="STUDY">Baka 2008</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Havemann-1987" TYPE="STUDY">Havemann 1987</LINK>; <LINK REF="STD-Sekine-2014" TYPE="STUDY">Sekine 2014</LINK>; <LINK REF="STD-Urban-1999a" TYPE="STUDY">Urban 1999a</LINK>; and <LINK REF="STD-Urban-1999b" TYPE="STUDY">Urban 1999b</LINK>, were the studies that did describe the randomisation process. Of these, all adequately described sequence generation, but not allocation concealment.</P>
<P>No study described the use of blinding for any participants, investigators or any of the outcomes.</P>
<P>Seventeen of the 32 studies (53.13%) addressed the issue of incomplete survival data. The same seventeen studies also addressed the issue of incomplete tumour response data - the only exception was <LINK REF="STD-Sundstrom-2002" TYPE="STUDY">Sundstrom 2002</LINK> which did not report tumour response data as an outcome. Fourteen of the 32 studies (43.75%) addressed the issue of incomplete toxicity data. No study addressed the issue of incomplete quality of life data.</P>
<P>Fourteen of the 32 studies (43.75%) were judged to be free of selective reporting. <LINK REF="STD-Creech-1982" TYPE="STUDY">Creech 1982</LINK> was given a rating of 'high risk' for this criterion because it did not report survival data, an outcome that would be expected from studies in this area. The remaining 17 studies were given a rating of 'Unclear'.</P>
<P>All studies were deemed to be free from other bias, except <LINK REF="STD-Souhami-1997" TYPE="STUDY">Souhami 1997</LINK>. This is due to the skewed treatment protocol used in the study - the non-platinum treatment arm consisting of a single oral agent compared with the platinum treatment arm consisting of multiple intravenous agents.</P>
<P>It was noted that one study, <LINK REF="STD-Sekine-2014" TYPE="STUDY">Sekine 2014</LINK>, had to be terminated early due to treatment-related toxicity in the non-platinum arm.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<SUBSECTION>
<HEADING LEVEL="3">Survival</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Survival at six months</HEADING>
<P>Thirty studies involving 5755 participants were included in the six-month survival analysis. The included studies that did not present survival data were <LINK REF="STD-Creech-1982" TYPE="STUDY">Creech 1982</LINK> and <LINK REF="STD-Baka-2008" TYPE="STUDY">Baka 2008</LINK>. Of the participants, 2874 of 5755 received a platinum-based chemotherapy regimen and the remaining 2881 received a non-platinum-based chemotherapy regimen. At six months, 4066 participants were alive: 2083 from the platinum-based groups and 1983 from the non-platinum-based treatment groups. There was no statistically significant difference between interventions (risk ratio (RR) 1.04, 95% confidence interval (CI) 1.00 to 1.09). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 44%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: 'undifferentiated'</HEADING>
<P>Ten studies reported data from six-month survival comparisons, but did not differentiate between limited and extensive disease. This included 1808 participants, 901 receiving a platinum-based and 907 receiving a non-platinum-based regimen. At six months, 1231 participants were alive: 624 from the platinum-based arm and 607 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.02, 95% CI 0.94 to 1.10). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 36%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: LD-SCLC</HEADING>
<P>Eight studies reported data from six-month survival comparisons for participants with limited disease, involving 1044 participants. Of these 516 received a platinum-based and 528 received a non-platinum-based regimen. At six months, 926 participants were alive: 459 from the platinum-based arm and 467 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.00, 95% CI 0.94 to 1.07). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 45%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: ED-SCLC</HEADING>
<P>Eighteen studies reported data from six-month survival comparisons for participants with extensive disease, involving 2903 participants. Of these, 1457 received a platinum-based and 1446 received a non-platinum-based regimen. At six months, 1909 participants were alive: 1000 from the platinum-based arm and 909 from the non-platinum-based arm. In contrast to the other subgroups above, there was a statistically significant effect favouring platinum-based regimens (RR 1.09, 95% CI 1.02 to 1.17). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 37%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Survival at 12 months</HEADING>
<P>31 studies involving 6034 participants were included in the 12-month survival analysis. The only included study that did not present survival data was <LINK REF="STD-Creech-1982" TYPE="STUDY">Creech 1982</LINK>. Of these participants, 3015 received a platinum-based chemotherapy regimen and 3019 received a non-platinum-based chemotherapy regimen. At 12 months, 2146 participants were alive: 1100 from the platinum-based groups and 1046 from the non-platinum-based treatment groups. Similar to six-month survival, at 12 months there was no statistically significant difference between interventions (RR 1.06, 95% CI 0.97 to 1.16). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 37%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: 'undifferentiated'</HEADING>
<P>Ten studies reported data from 12-month survival comparisons, but did not differentiate between limited and extensive disease. This included 1808 participants, 901 receiving a platinum-based and 907 receiving a non-platinum-based regimen. At 12 months, 559 participants were alive: 278 from the platinum-based arm and 281 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.00, 95% CI 0.82 to 1.22). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 46%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: LD-SCLC</HEADING>
<P>Nine studies reported data from 12-month survival comparisons for participants with limited disease, involving 1209 participants. Of these, 597 received a platinum-based and 612 received a non-platinum-based regimen. At 12 months, 701 participants were alive: 363 from the platinum-based arm and 338 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.15, 95% CI 0.95 to 1.39). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 64%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: ED-SCLC</HEADING>
<P>Nineteen studies reported data from 12-month survival comparisons for participants with extensive disease, involving 3017 participants. Of these, 1517 received a platinum-based and 1500 received a non-platinum-based regimen. At 12 months, 886 participants were alive: 459 from the platinum-based arms and 427 from the non-platinum-based arm. In contrast to the corresponding subgroup at six months, there was no statistically significant difference between interventions (RR 1.06, 95% CI 0.94 to 1.18). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 4%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Survival at 24 months</HEADING>
<P>Twenty seven studies involving 5398 participants were included in the 24-month survival analysis. The four studies that were included in the 12-month survival analyses, but that did not report 24-month survival data were <LINK REF="STD-Evans-1987" TYPE="STUDY">Evans 1987</LINK>, <LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK>, <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK> and <LINK REF="STD-Sekine-2014" TYPE="STUDY">Sekine 2014</LINK>. All were part of the ED-SCLC subgroup. The remaining 27 studies were the same as those included for 12-month survival. Of the participants, 2698 of 5398 received a platinum-based chemotherapy regimen and the remaining 2700 received a non-platinum-based chemotherapy regimen. At 24 months, 566 participants were alive: 287 from the platinum-based groups and 279 from the non-platinum-based treatment groups. As with 12-month survival, there was no statistically significant difference between interventions (RR 1.06, 95% CI 0.85 to 1.31). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 31%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: 'undifferentiated'</HEADING>
<P>Ten studies reported data from 24-month survival comparisons, but did not differentiate between limited and extensive disease. This included 1808 participants, 901 receiving a platinum-based and 907 receiving a non-platinum-based regimen. At 24 months, 146 participants were alive: 70 from the platinum-based arm and 76 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 0.97, 95% CI 0.71 to 1.33). There was no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: LD-SCLC</HEADING>
<P>Nine studies reported data from 12-month survival comparisons for participants with limited disease, involving 1209 participants. Of these, 597 received a platinum-based and 612 received a non-platinum-based regimen. At 24 months, 255 participants were alive: 133 from the platinum-based arm and 122 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.07, 95% CI 0.7 to 1.65). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 57%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: ED-SCLC</HEADING>
<P>Fifteen studies reported data from 24-month survival comparisons for participants with extensive disease, involving 2381 participants. Of these, 1200 received a platinum-based and 1181 received a non-platinum-based regimen. At 24 months, 165 participants were alive: 84 from the platinum-based arms and 81 from the non-platinum-based arm. There was no statistically significant difference between interventions (RR 1.11, 95% CI 0.71 to 1.75). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 35%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Survival by subgroup</HEADING>
<P>The proportion of people alive at 6, 12 and 24 months from both treatment groups is presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>. <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> illustrates the survival curves data based on the subgroup data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tumour response</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Overall response</HEADING>
<P>Thirty-one studies involving 5651 participants were included in the overall response analysis. Of the 31 studies, 30 were the same as for 12-month survival. The difference was due to the exclusion of <LINK REF="STD-Sundstrom-2002" TYPE="STUDY">Sundstrom 2002</LINK> (presented survival data but not response data) and the inclusion of <LINK REF="STD-Creech-1982" TYPE="STUDY">Creech 1982</LINK> (presented response data but not survival data). Of the participants, 2824 of 5651 received a platinum-based chemotherapy regimen and the remaining 2827 received a non-platinum-based chemotherapy regimen. The number of participants with a recorded overall response was 3562, consisting of 1846 participants from the platinum arm and 1716 participants from the non-platinum arm. There was no statistically significant difference between interventions (RR 1.06, 95% CI 0.98 to 1.13). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 66%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: 'undifferentiated'</HEADING>
<P>Eleven studies reported data from overall response comparisons, but did not differentiate between limited and extensive disease. This included 2225 participants, 1105 receiving a platinum-based and 1120 receiving a non-platinum-based regimen. A total of 1339 participants recorded an overall response, consisting of 682 participants from the platinum arm and 657 participants from the non-platinum arm. There was no statistically significant difference between interventions (RR 1.04, 95% CI 0.89 to 1.21). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 77%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: LD-SCLC</HEADING>
<P>Eight studies reported data from overall response comparisons for limited disease. This included 809 participants, 402 receiving a platinum-based and 407 receiving a non-platinum-based regimen. A total of 613 participants recorded an overall response, consisting of 312 participants from the platinum arm and 301 participants from the non-platinum arm. There was no statistically significant difference between interventions (RR 1.03, 95% CI 0.94 to 1.12). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 23%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: ED-SCLC</HEADING>
<P>Eighteen studies reported data from overall response comparisons for participants with ED-SCLC. This subgroup consisted of 2617 participants, with 1317 receiving a platinum-based chemotherapy regimen and 1300 receiving a non-platinum-based chemotherapy regimen. A total of 1610 participants recorded an overall response, consisting of 852 participants from platinum arms and 758 participants from non-platinum arms. Similar to other subgroups above, there was no statistically significant difference between interventions (RR 1.07, 95% CI 0.96 to 1.19). There was substantial heterogeneity present in the data (I<SUP>2</SUP> = 66%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complete response</HEADING>
<P>Thirty studies involving 5599 participants were included in the complete response analysis. <LINK REF="STD-Creech-1982" TYPE="STUDY">Creech 1982</LINK> (included in overall response) was excluded because it did not present complete response data. Of the 5599 participants, 2799 received a platinum-based chemotherapy regimen and the remaining 2800 participants received a non-platinum-based chemotherapy regimen. Of the participants, 1243 recorded a complete response, consisting of 701 participants from the platinum arm and 542 participants from the non-platinum arm. There was a statistically significant effect favouring platinum-based chemotherapy regimens (RR 1.32, 95% CI 1.14 to 1.54). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 46%).</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: 'Undifferentiated'</HEADING>
<P>Ten studies reported data from complete response comparisons, but did not differentiate between limited and extensive disease. This included 2175 participants, 1080 receiving a platinum-based and 1095 receiving a non-platinum-based regimen. A total of 427 participants recorded a complete response, consisting of 252 participants from the platinum arm and 212 participants from the non-platinum arm. In contrast to the other subgroups below, there was no statistically significant difference between interventions (RR 1.26, 95% CI 0.90 to 1.77). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 72%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: LD-SCLC</HEADING>
<P>Eight studies reported data from complete response comparisons for limited disease. This included 809 participants, 402 receiving a platinum-based and 407 receiving a non-platinum-based regimen. A total of 332 participants recorded a complete response, consisting of 181 participants from the platinum arm and 151 participants from the non-platinum arm. There was a statistically significant effect favouring platinum-based regimens (RR 1.19, 95% CI 1.02 to 1.40). There was no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup: ED-SCLC</HEADING>
<P>Eighteen studies reported data from complete response comparisons for extensive disease. This subgroup consisted of 2615 participants, with 1317 receiving a platinum-based chemotherapy regimen and 1298 receiving a non-platinum-based chemotherapy regimen. A total of 447 participants recorded a complete response, consisting of 268 participants from platinum arms and 179 participants from non-platinum arms. There was a statistically significant effect, favouring platinum-based chemotherapy regimens (RR 1.45, 95% CI 1.17 to 1.80). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 24%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Toxic death</HEADING>
<P>Twenty studies reported data regarding toxic death, involving 3696 (60.83%) participants. Overall, 1840 of these participants were from platinum-based chemotherapy groups and 1856 from non-platinum-based chemotherapy groups. Of these 183 died from a toxicity-related cause, 98 from platinum-based groups and 85 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 1.08, 95% CI 0.72 to 1.62). There was no substantial heterogeneity present in the data (I<SUP>2 </SUP>= 35%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Nausea and vomiting</HEADING>
<P>Twenty-two studies reported toxicity data regarding nausea and vomiting, involving 3961 (65.20%) participants. Of those, 1978 were from platinum-based chemotherapy groups and 1983 from non-platinum-based chemotherapy groups. Overall, 721 participants experienced nausea and vomiting toxicity, 430 from platinum-based groups and 291 from non-platinum-based groups. There was a statistically significant difference between interventions, with higher rates of nausea and vomiting toxicity in platinum-based chemotherapy regimens (RR 1.52, 95% CI 1.22 to 1.88). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 57%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Alopecia</HEADING>
<P>Eight studies reported toxicity data regarding alopecia, involving 1526 (25.12%) participants. Of those, 753 were from platinum-based chemotherapy groups and 773 from non-platinum-based chemotherapy groups. Overall, 884 participants experienced alopecia toxicity, 470 from platinum-based groups and 414 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 1.14, 95% CI 1.00 to 1.30). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 58%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Infection</HEADING>
<P>Twelve studies reported toxicity data regarding infection, involving 2184 (35.95%) participants. Of those, 1096 were from platinum-based chemotherapy groups and 1088 from non-platinum-based chemotherapy groups. Overall, 293 participants experienced infections, 98 from platinum-based groups and 195 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 0.69 95% CI 0.43 to 1.09). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 60%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Anaemia</HEADING>
<P>Twelve studies reported toxicity data regarding anaemia, involving 2219 (36.53%) participants. Of these, 1112 were from platinum-based chemotherapy groups and 1107 from non-platinum-based chemotherapy groups. Overall, 316 participants experienced anaemia toxicity, 169 from platinum-based groups and 147 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 1.19, 95% CI 0.86 to 1.67). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 52%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Leukopenia</HEADING>
<P>Seventeen studies reported toxicity data regarding leukopenia, involving 2556 (42.07%) participants. Of these, 1277 were from platinum-based chemotherapy groups and 1279 from non-platinum-based chemotherapy groups. Overall, 1175 participants experienced leukopenia toxicity, 526 from platinum-based groups and 649 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 0.84, 95% CI 0.67 to 1.05). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 87%)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Thrombocytopenia</HEADING>
<P>Nineteen studies reported toxicity data regarding thrombocytopenia, involving 3276 (53.93%) participants. Of those, 1637 were from platinum-based chemotherapy groups and 1639 from non-platinum-based chemotherapy groups. Overall, 467 participants experienced thrombocytopenia toxicity, 305 from platinum-based groups and 162 from non-platinum-based groups. There was a statistically significant difference between interventions, with higher rates of thrombocytopenia toxicity in platinum-based chemotherapy regimens (RR 1.89, 95% CI 1.37 to 2.61). There was substantial heterogeneity present in the data (I<SUP>2 </SUP>= 62%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Granulocytopenia</HEADING>
<P>Five studies reported toxicity data regarding granulocytopenia, involving 1229 (22.22%) participants. Of those, 622 were from platinum-based chemotherapy groups and 607 from non-platinum-based chemotherapy groups. Overall, 517 participants experienced granulocytopenia toxicity, 244 from platinum-based groups and 273 from non-platinum-based groups. There was no statistically significant difference between interventions (RR 0.89, 95% CI 0.79 to 1.00). There was no heterogeneity (I<SUP>2 </SUP>= 0%).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Data about quality of life (QOL) were available from four studies. It was not possible to combine these in a meta-analysis because none of the studies reported enough data to calculate standardised mean differences. Results from these studies are discussed individually.</P>
<P>
<LINK REF="STD-Souhami-1997" TYPE="STUDY">Souhami 1997</LINK> measured QOL via two scales: the Rotterdam Symptom Checklist and the daily diary card. The Rotterdam Symptom Checklist measured physical symptoms, lung cancer symptoms, treatment symptoms, physical activity, psychological well-being and general QOL. It was completed by participants at each treatment cycle and at the first two follow-up visits. The study reported that there was no significant difference in physical symptoms, psychological well-being or physical activity, between interventions. Treatment-related symptoms were significantly worse, but lung cancer symptoms and general QOL were significantly better in the platinum treatment arm. <LINK REF="STD-Souhami-1997" TYPE="STUDY">Souhami 1997</LINK> was a unique study in that it was the only study to have a non-intravenous form of delivery: its non-platinum treatment arm (oral etoposide).</P>
<P>A daily diary card was used to measure acute chemotherapy-related symptoms. It measured nausea, vomiting, appetite, pain, sleep, mood, general well-being and physical activity on a daily basis. The findings from this study showed that there was no significant difference in vomiting or physical activity between the two treatment arms. Nausea was found to be worse in the platinum-based treatment arm. But in all other categories, the non-platinum-based treatment arms were significantly worse (<LINK REF="STD-Souhami-1997" TYPE="STUDY">Souhami 1997</LINK>).</P>
<P>
<LINK REF="STD-Sundstrom-2002" TYPE="STUDY">Sundstrom 2002</LINK> measured QOL via the European Organisation for the Research and Treatment of Cancer (EORTC) quality of life questionnaire C30 (QLQ-C30). The QLQ-C30 questionnaire reports five functional scales (physical, role, emotional, cognitive and social functioning), three symptom scales (fatigue, nausea/vomiting and pain), a global health and overall QOL scale and five single item scales (dyspnoea, appetite loss, sleep disturbance, constipation and diarrhoea, and the financial impact of disease and treatment). Results from the questionnaire showed no statistically significant difference between the platinum group and the non-platinum group for most of the scales.</P>
<P>
<LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK> measured QOL using the functional assessment of cancer therapy-lung (FACT-L) QOL questionnaire and a separate symptom questionnaire. The questionnaires were completed by participants at baseline and prior to each course of treatment.</P>
<P>The FACT-L questionnaire assessed physical well-being, social/family well-being, emotional well-being and additional concerns on a five-point scale. These were used to determine a FACT-L score, and the scores for physical and functional well-being were summed to give a trial outcome index (TOI) score. Both the platinum and non-platinum arm had improvements in FACT-L and TOI scores compared to baseline scores following six cycles of treatments. However there was no significant difference in FACT-L or TOI scores between treatment arms (<LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK>).</P>
<P>The symptom questionnaire employed by <LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK> assessed shortness of breath, cough, chest pain, haemoptysis, anorexia, insomnia, hoarseness, fatigue and interference with daily activity. The results found both interventions improved all symptoms except haemoptysis, in more than 20% of participants when compared to baseline. However, there was no significant difference between treatments (<LINK REF="STD-Quoix-2005" TYPE="STUDY">Quoix 2005</LINK>).</P>
<P>
<LINK REF="STD-Sekine-2014" TYPE="STUDY">Sekine 2014</LINK> used two scales to assess QOL - lung cancer subscale (LCS) of FACT-L questionnaire and Euro-QOL 5-dimension (EQ-5D) utility index. Assessments were performed at 3 weeks, 3 months, 6 months and 12 months after the commencement of chemotherapy. The LCS measured a number of symptoms including breathlessness, weight loss, cognitive function, appetite and chest discomfort (<LINK REF="REF-Cella-2002" TYPE="REFERENCE">Cella 2002</LINK>). For both the platinum group and the non-platinum group, there were no significant differences in LCS scores at all of the time points (P values: 0.171 at 3 weeks; 0.08 at 3 months; 0.112 at 6 months; 0.371 at 12 months). The EQ-5D measured five socially relevant domains - mobility, self-care, usual activities, pain/discomfort and anxiety/depression (<LINK REF="REF-Gusi-2010" TYPE="REFERENCE">Gusi 2010</LINK>). For both the platinum group and the non-platinum group, there were no significant differences in LCS scores at all of the time points (P values: 0.171 at 3 weeks; 0.08 at 3 months; 0.112 at 6 months; 0.371 at 12 months). For both the platinum group and the non-platinum group, there were no significant differences in EQ-5D utility index scores at all of the time points (P values: 0.171 at 3 weeks; 0.08 at 3 months; 0.112 at 6 months; 0.371 at 12 months).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Quality of studies</HEADING>
<P>The effect of the quality of studies was examined by including all studies that were deemed to be of high quality using the GRADE assessment approach as discussed in the Methods. As such, the included studies for the sensitivity analysis of quality were: <LINK REF="STD-Baka-2008" TYPE="STUDY">Baka 2008</LINK>; <LINK REF="STD-de-Jong-2007" TYPE="STUDY">de Jong 2007</LINK>; <LINK REF="STD-Evans-1987" TYPE="STUDY">Evans 1987</LINK>; <LINK REF="STD-Fukuoka-1991" TYPE="STUDY">Fukuoka 1991</LINK>; <LINK REF="STD-Havemann-1987" TYPE="STUDY">Havemann 1987</LINK>; <LINK REF="STD-Kanitz-1992" TYPE="STUDY">Kanitz 1992</LINK>; <LINK REF="STD-Lyss-2002" TYPE="STUDY">Lyss 2002</LINK>; <LINK REF="STD-Postmus-1996" TYPE="STUDY">Postmus 1996</LINK>; <LINK REF="STD-Roth-1992" TYPE="STUDY">Roth 1992</LINK>; <LINK REF="STD-Sculier-1990" TYPE="STUDY">Sculier 1990</LINK>; <LINK REF="STD-Sculier-1993" TYPE="STUDY">Sculier 1993</LINK>; <LINK REF="STD-Smith-1991" TYPE="STUDY">Smith 1991</LINK>; <LINK REF="STD-Sundstrom-2002" TYPE="STUDY">Sundstrom 2002</LINK>; <LINK REF="STD-Urban-1999a" TYPE="STUDY">Urban 1999a</LINK>; <LINK REF="STD-Veronesi-1994" TYPE="STUDY">Veronesi 1994</LINK> and <LINK REF="STD-White-2001" TYPE="STUDY">White 2001</LINK>, . The results are presented in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
<P>It can be seen from this table that there were five differences in outcomes between the sensitivity analysis of quality and the overall analysis. The outcomes affected were overall response, alopecia, infection, leukopenia and thrombocytopenia toxicities. For overall response and infection, there was no significant difference between the two treatment groups, however, when only the higher quality studies were included there was a significant difference favouring the platinum group. There was no significant difference between the two treatment groups in terms of alopecia toxicity. However, in the sensitivity analysis for quality, the platinum-based treatment group had a significantly higher level of alopecia toxicity. The reverse was true for thrombocytopenia toxicity. There was a significantly higher rate of thrombocytopenia toxicity in the platinum-based treatment group in the overall analysis, but this difference was not statistically significant in the sensitivity analysis for quality. Finally, for leukopenia toxicity, there was no significant difference between the treatment groups in the overall analysis. However, in the sensitivity analysis for quality, the rate of leukopenia toxicity was significantly higher in the non-platinum-based treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Full article versus abstract publication</HEADING>
<P>Full articles for all studies were available, hence this sensitivity analysis was not conducted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Use of radiotherapy</HEADING>
<P>The effect of radiotherapy was explored by including all studies that used radiotherapy. Hence, the following studies were included in the analysis: <LINK REF="STD-Baka-2008" TYPE="STUDY">Baka 2008</LINK>; <LINK REF="STD-Chahinian-1989" TYPE="STUDY">Chahinian 1989</LINK>; <LINK REF="STD-Eagan-1981" TYPE="STUDY">Eagan 1981</LINK>; <LINK REF="STD-Evans-1987" TYPE="STUDY">Evans 1987</LINK>; <LINK REF="STD-Farris-1993" TYPE="STUDY">Farris 1993</LINK>; <LINK REF="STD-Fukuoka-1986" TYPE="STUDY">Fukuoka 1986</LINK>; <LINK REF="STD-Fukuoka-1991" TYPE="STUDY">Fukuoka 1991</LINK>; <LINK REF="STD-Goodman-1990" TYPE="STUDY">Goodman 1990</LINK>; <LINK REF="STD-Greco-2005" TYPE="STUDY">Greco 2005</LINK>; <LINK REF="STD-Havemann-1987" TYPE="STUDY">Havemann 1987</LINK>; <LINK REF="STD-Jones-1993" TYPE="STUDY">Jones 1993</LINK>; <LINK REF="STD-Lyss-2002" TYPE="STUDY">Lyss 2002</LINK>; <LINK REF="STD-Postmus-1992" TYPE="STUDY">Postmus 1992</LINK>; <LINK REF="STD-Roth-1992" TYPE="STUDY">Roth 1992</LINK>; <LINK REF="STD-Sculier-1990" TYPE="STUDY">Sculier 1990</LINK>; <LINK REF="STD-Sculier-1993" TYPE="STUDY">Sculier 1993</LINK>; <LINK REF="STD-Smith-1991" TYPE="STUDY">Smith 1991</LINK>; <LINK REF="STD-Sundstrom-2002" TYPE="STUDY">Sundstrom 2002</LINK>; <LINK REF="STD-Urban-1999a" TYPE="STUDY">Urban 1999a</LINK>; <LINK REF="STD-Urban-1999b" TYPE="STUDY">Urban 1999b</LINK>; <LINK REF="STD-Veronesi-1994" TYPE="STUDY">Veronesi 1994</LINK>; <LINK REF="STD-White-2001" TYPE="STUDY">White 2001</LINK> and <LINK REF="STD-Wolf-1987" TYPE="STUDY">Wolf 1987</LINK>. The results are presented in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>It can be seen from this table that there is no significant difference between the outcomes of all studies compared with the outcomes of only studies that used radiotherapy.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Heterogeneity analysis</HEADING>
<P>It can be seen from the results that there was substantial heterogeneity associated with a number of outcomes, including overall response, nausea and vomiting, alopecia, leukopenia and thrombocytopenia toxicity. For all of these outcomes, possible reasons for the heterogeneity were explored. No specific causes of heterogeneity were found for any of the outcomes, except for thrombocytopenia toxicity (discussed below). Possible reasons for heterogeneity are mentioned in the Tumour Response and Toxicity sections in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>. It is important to note that the results of all outcomes with substantial heterogeneity must be treated with caution.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>This systematic review included 32 trials and 6075 patients, which provides adequate data to undertake meaningful meta-analyses.</P>
<P>Cisplatin and carboplatin are the only platinum-based agents used in SCLC, with cisplatin more widely used than carboplatin. Of the non-platinum agents, etoposide (E) and cyclophosphamide (C) are the most commonly used, followed by doxorubicin (D), adriamycin (A) and vincristine (V) usually in the triplet combination of either CEV, CDE or CAV (<LINK REF="REF-Abeloff-2004" TYPE="REFERENCE">Abeloff 2004</LINK>).</P>
<P>Co-intervention with radiotherapy occurred in approximately 72% of studies indicating that this plays a major role in the treatment of SCLC. It should be noted that the sensitivity analysis to exclude any confounding effects of radiotherapy did not find any statistically significant differences in any of the outcomes, including toxicity, from the overall analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Survival</HEADING>
<P>No statistically significant difference between platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens was found for survival at 6 months, 12 months or 24 months.</P>
<P>Subgroup analyses demonstrated that survival for the 'undifferentiated' subgroup was similar to that of extensive disease. This is explained by the high proportion of extensive disease-stage patients in the studies in the 'undifferentiated' group. For example, <LINK REF="STD-Urban-1999a" TYPE="STUDY">Urban 1999a</LINK> had 360 extensive disease-stage patients and 97 limited disease-stage patients. The high proportion of extensive disease-stage participants reflects the fact that SCLC is an aggressive disease that metastasises early and usually presents with extensive disease (<LINK REF="REF-Abeloff-2004" TYPE="REFERENCE">Abeloff 2004</LINK>).</P>
<P>Despite survival being better in limited disease, the slopes of the survival curves (in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>) for all three subgroups are relatively similar. This implies that the effect of chemotherapy does not differ depending on the stage of the disease and survival can be attributed to the disease extent at diagnosis (<LINK REF="REF-ACN-2004" TYPE="REFERENCE">ACN 2004</LINK>).</P>
<P>The outcomes show that even with treatment, long-term survival with SCLC is uncommon; the highest proportions of survivors at 24 months are recorded in the limited disease group (21.09%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Tumour response</HEADING>
<P>There was no statistically significant difference between platinum-based chemotherapy regimens and non-platinum-based chemotherapy regimens in terms of overall response when the results of all studies were considered. However, the sensitivity analysis revealed that, when only studies of higher quality were included, there was a statistically significant difference in response rates favouring platinum-based chemotherapy regimens. In addition, platinum-based chemotherapy regimens did demonstrate a significantly higher complete response than non-platinum-based chemotherapy regimens. However this does not translate into improved survival in the short, intermediate or long-term. These findings are consistent with the knowledge that SCLC is initially responsive to chemotherapy, but relapse is common and further response to chemotherapy is poor (<LINK REF="REF-Abeloff-2004" TYPE="REFERENCE">Abeloff 2004</LINK>; <LINK REF="REF-Peckham-1995" TYPE="REFERENCE">Peckham 1995</LINK>). This is thought to be due to resistant subpopulations of tumour cells developing over time (<LINK REF="REF-Evans-1986" TYPE="REFERENCE">Evans 1986</LINK>).</P>
<P>It should be noted that there was substantial heterogeneity in the overall response analysis. A definite reason for this could not be identified. However, a possible explanation for this is the variation in staging and response assessment methods used. Since this review involved some studies that were conducted decades apart, earlier studies may have used less sensitive staging and response assessment methods than later studies. Similarly, some study centres may not have had the sophisticated resources available for staging and response assessment as other study centres. So while the definition of overall response has remained constant, the assessment methods used may have varied. As such, this variation may have contributed to the heterogeneity in the overall response analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicity</HEADING>
<P>"Given that there was no significant difference in survival between the two types of regimen, the balance between the benefits and risks of treatment is more important. However the adverse events were not well-reported. This systematic review has shown that platinum-based regimens result in higher rates of nausea and vomiting, and thrombocytopenia than non-platinum-based regimens. There was no statistically significant difference between the two groups with respect to toxic death, alopecia, infection, anaemia, leukopenia and granulocytopenia. Therefore platinum-based chemotherapy regimens did not result in statistically significant <I>lower</I> rates of toxicity in any of the toxicity analyses.</P>
<P>It should also be noted that there was substantial heterogeneity in many of the toxicity analyses. The cause of this heterogeneity was difficult to identify. This is surprising considering the fact that all studies adhered to the grade 3/4 WHO definitions for each of the toxicity outcomes. One possible reason for the heterogeneity may be differences in the therapies used to prevent or treat toxicities, including antiemetics, antibiotics, cytokines, blood and platelet transfusions and granulocyte-colony stimulating factor (G-CSF). In particular, it should be noted that 5-HT3 antagonists, which are powerful anti-emetic agents, were only discovered in 1988 and did not come into widespread use until a decade later (<LINK REF="REF-Stubblefield-2009" TYPE="REFERENCE">Stubblefield 2009</LINK>) &#8211; after the publication date of the majority of studies in this review. This could have resulted in higher grade 3/4 nausea and vomiting toxicity with platinum-based chemotherapy regimens, than would be seen today with the availability of a wider range of more effective anti-emetic agents, including 5-HT3 antagonists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>A major limitation of this systematic review was the insufficient data to conduct a meta-analysis on quality of life (QOL). A qualitative description of the results from four studies that reported QOL did not indicate substantial differences between platinum- and non-platinum-based treatment regimens.</P>
<P>While it has been shown by a number of studies that tumour progression is associated with a poorer QOL (<LINK REF="REF-Gralla-2004" TYPE="REFERENCE">Gralla 2004</LINK>), it is not reasonable to infer that a treatment that produces a tumour response will necessarily improve QOL. While platinum-based regimens, with the better tumour response may improve QOL through tumour control, this is offset by the higher incidence of some toxicities. Therefore, the only reliable method of determining which treatment regimen is associated with a better QOL is for more RCTs to include QOL in their outcome assessment. This systematic review highlights the current lack of QOL data and the need for future studies to incorporate QOL as an outcome measure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Limitations</HEADING>
<P>There are a number of limitations associated with this systematic review. Firstly, a systematic review should ideally be conducted using individual patient data (IPD). However, this is rarely done in practice, as it is not considered practical to do so in a large number of cases, largely because IPD from studies are not always easily obtainable (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>. For this systematic review, IPD were not available for the studies, despite written requests to the authors. While this is understandable, considering a significant number of the included studies were conducted more than a decade earlier, it does limit the quality and reliability of this systematic review.</P>
<P>Secondly, the effect of including studies spanning a large time period is not known, and some chemotherapy regimens used in earlier studies may now be considered out of date. This is particularly the case with some non-platinum-based regimens. Hence, it should be kept in mind that the results from these studies may have affected the overall results. Thirdly, the effect of co-intervention with radiotherapy in limited disease is unclear as none of the studies in this subgroup included radiotherapy and thus all were excluded in the sensitivity analysis for this variable.</P>
<P>Finally, although survival graphs were given by a majority of studies, the associated log hazard ratio (HR) and summary statistics were rarely provided. As a result, the survival data from studies could not be combined to obtain an overall HR. Instead, data on survival at pre-defined time points (6 months, 12 months and 24 months) were used. Because of the lack of HR and summary statistic data, calculating the survival at these pre-defined time points was considered a reasonable procedure to determine short, intermediate and long-term survival. In addition, this method of using predefined time intervals has been used in other published systematic reviews exploring survival in SCLC (<LINK REF="REF-Pujol-2000" TYPE="REFERENCE">Pujol 2000</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<IMPLICATIONS_PRACTICE MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>This systematic review has shown that, despite the fact that the lack of individual patient data precluded calculation of a hazard ratio, platinum-based chemotherapy regimens do not offer significant survival benefit over non-platinum-based regimens. There is also no significant difference in terms of overall tumour response, although platinum-based regimens do have a significantly higher rate of complete response. Platinum-based regimens are associated with greater nausea and vomiting, and thrombocytopenia toxicity. The effect on quality of life could not be adequately assessed. These data suggest non-platinum chemotherapy regimens have a more advantageous risk-benefit profile.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>This systematic review has highlighted the lack of quality of life data in trials involving chemotherapy treatment for small cell lung cancer. With poor long-term survival despite treatment, the issue of the quality of the survival period takes on even more significance. Future trials in this area should focus of quality of life assessments, given there is no long-term survival benefit.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-05-15 23:04:22 +0200" MODIFIED_BY="[Empty name]">
<P>Thanks to Matthew Beech for his assistance with identifying studies for inclusion.</P>
<P>Thanks to Wayne Chou and Melanie Sung for their assistance with data extraction.</P>
<P>Thanks to the Australian Lung Foundation for their support of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>
<BR/>IUA: none known<BR/>SC: none known<BR/>JAEW: none known<BR/>RWB: none known<BR/>KMF: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>IUA: protocol writing, data extraction, analysis, review writing - 1st version and update<BR/>SC: protocol writing, data extraction, analysis, review writing - update<BR/>JAEW: protocol writing, data extraction, analysis, review writing - 1st version and update<BR/>RWB: supervisor, protocol writing, review writing - 1st version<BR/>KMF: supervisor, review writing - 1st version and update</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>We conducted a new search in August 2014 (search strategy outlined in Appendix 2). This yielded a further 3 studies bringing the total number of studies included in the review to 32 (29 studies were included in the original review). This is illustrated in the study flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). A meta-analysis was carried out and the conclusions not changed.</P>
<P>A new author joined the team for this update : Saion Chatterjee</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baka-2008" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Baka 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baka S, Califano R, Ferraldeschi R, Ashcroft L, Thatcher N, Taylor P, et al</AU>
<TI>Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>2008</YR>
<VL>99</VL>
<NO>3</NO>
<PG>442-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chahinian-1989" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Chahinian 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al</AU>
<TI>A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1989 Aug</YR>
<VL>7</VL>
<NO>8</NO>
<PG>993-1002</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creech-1982" MODIFIED="2008-07-31 10:45:35 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Creech 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-07-31 10:45:35 +0200" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;&amp;#239;&amp;#187;&amp;#191;Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treat Rep. 1982 Jun;66(6):1417-9.&lt;/p&gt;" NOTES_MODIFIED="2008-07-31 10:45:35 +0200" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O</AU>
<TI>Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578)</TI>
<SO>Cancer Treatment Reports</SO>
<YR>1982 Jun</YR>
<VL>66</VL>
<NO>6</NO>
<PG>1417-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-de-Jong-2007" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="de Jong 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al</AU>
<TI>Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer</TI>
<SO>European Journal of Cancer</SO>
<YR>2007</YR>
<VL>43</VL>
<PG>2345&#8211;2350</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eagan-1981" MODIFIED="2008-07-31 10:45:58 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Eagan 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-07-31 10:45:58 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eagan RT, Lee RE, Frytak S, Fleming TR, Ingle JN, Creagan ET, et al</AU>
<TI>An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer</TI>
<SO>Cancer Clinical Trials</SO>
<YR>1981</YR>
<VL>4</VL>
<NO>3</NO>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-1987" MODIFIED="2008-07-31 10:46:24 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Evans 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-07-31 10:46:24 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al</AU>
<TI>Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1987 Oct</YR>
<VL>107</VL>
<NO>4</NO>
<PG>451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farris-1993" MODIFIED="2015-04-20 04:39:55 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Farris 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-04-20 04:39:55 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, et al</AU>
<TI>Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1993 Oct</YR>
<VL>5</VL>
<NO>5</NO>
<PG>344-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuoka-1986" MODIFIED="2008-07-31 10:47:21 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Fukuoka 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-07-31 10:47:21 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuoka M, Takada M, Negoro S, Kusunoki Y, Matsui K, Ryu S, et al</AU>
<TI>Alternating non-cross resistant chemotherapy for small cell lung cancer</TI>
<SO>Japanese Journal of Clinical Oncology</SO>
<YR>1986 Sep</YR>
<VL>16</VL>
<NO>3</NO>
<PG>261-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukuoka-1991" MODIFIED="2008-07-31 10:48:03 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Fukuoka 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-07-31 10:48:03 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al</AU>
<TI>Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1991 Jun 19</YR>
<VL>83</VL>
<NO>12</NO>
<PG>855-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gatzemeier-1994" MODIFIED="2008-07-31 10:48:25 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Gatzemeier 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-07-31 10:48:25 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R</AU>
<TI>Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial</TI>
<SO>Seminars in Oncology</SO>
<YR>1994 Jun</YR>
<VL>21</VL>
<NO>3 Suppl 6</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-1990" MODIFIED="2008-07-31 10:48:42 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Goodman 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-07-31 10:48:42 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, et al</AU>
<TI>Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1990 Jan</YR>
<VL>8</VL>
<NO>1</NO>
<PG>39-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greco-2005" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Greco 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, et al</AU>
<TI>Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial</TI>
<SO>Oncologist</SO>
<YR>2005 Oct</YR>
<VL>10</VL>
<NO>9</NO>
<PG>728-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Havemann-1987" MODIFIED="2008-05-15 16:34:13 +0200" MODIFIED_BY="[Empty name]" NAME="Havemann 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-05-15 16:34:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, et al</AU>
<TI>Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial</TI>
<SO>Cancer</SO>
<YR>1987 Mar 15</YR>
<VL>59</VL>
<NO>6</NO>
<PG>1072-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1993" MODIFIED="2008-05-15 16:34:37 +0200" MODIFIED_BY="[Empty name]" NAME="Jones 1993" YEAR="1993~">
<REFERENCE MODIFIED="2008-05-15 16:34:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones AL, Holborn J, Ashley S, Smith IE</AU>
<TI>CVM versus ACE in the treatment of small cell lung cancer</TI>
<SO>Oncology</SO>
<YR>1993 Nov</YR>
<VL>50 Suppl 2</VL>
<PG>10-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kanitz-1992" MODIFIED="2008-05-15 16:34:54 +0200" MODIFIED_BY="[Empty name]" NAME="Kanitz 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-15 16:34:54 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kanitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, et al</AU>
<TI>Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer</TI>
<SO>Oncology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>5</NO>
<PG>327-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyss-2002" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Lyss 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lyss AP, Herndon JE, 2nd, Lynch TJ, Jr., Turrisi AT, Watson DM, Grethlein SJ, et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer. 2002 Feb;3(3):205-10; discussion 11-2.&lt;/p&gt;" NOTES_MODIFIED="2015-07-31 11:05:47 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyss AP, Herndon JE, Lynch TJ, Turrisi AT, Watson DM, Grethlein SJ, et al</AU>
<TI>Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430)</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2002 Feb</YR>
<VL>3</VL>
<NO>3</NO>
<PG>205-10; discussion 11-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Postmus-1992" MODIFIED="2008-07-31 10:50:23 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Postmus 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-07-31 10:50:23 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Postmus PE, Splinter TA, Palmen FM, Carney DN, Festen J, Burghouts JT, et al</AU>
<TI>Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group</TI>
<SO>European Journal of Cancer</SO>
<YR>1992</YR>
<VL>28</VL>
<NO>1</NO>
<PG>96-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Postmus-1996" MODIFIED="2008-07-31 10:50:52 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Postmus 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-07-31 10:50:52 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al</AU>
<TI>Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial</TI>
<SO>European Journal Cancer</SO>
<YR>1996 Aug</YR>
<VL>32A</VL>
<NO>9</NO>
<PG>1498-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quoix-2005" MODIFIED="2008-07-31 10:51:02 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Quoix 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-31 10:51:02 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, et al</AU>
<TI>A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer</TI>
<SO>Lung Cancer</SO>
<YR>2005 Aug</YR>
<VL>49</VL>
<NO>2</NO>
<PG>253-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roth-1992" MODIFIED="2008-07-31 10:51:21 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Roth 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-07-31 10:51:21 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al</AU>
<TI>Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1992 Feb</YR>
<VL>10</VL>
<NO>2</NO>
<PG>282-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sculier-1990" MODIFIED="2008-07-31 10:51:45 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Sculier 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-07-31 10:51:45 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, et al</AU>
<TI>A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party</TI>
<SO>Annals of Oncology</SO>
<YR>1990</YR>
<VL>1</VL>
<NO>2</NO>
<PG>128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sculier-1993" MODIFIED="2008-07-31 10:52:12 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Sculier 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-07-31 10:52:12 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, et al</AU>
<TI>Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993 Oct</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1858-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sekine-2014" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Sekine 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, et al</AU>
<TI>A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>2</NO>
<PG>96-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1991" MODIFIED="2008-05-15 16:38:50 +0200" MODIFIED_BY="[Empty name]" NAME="Smith 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-15 16:38:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith AP, Anderson G, Chappell G, Bowen DR</AU>
<TI>Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens</TI>
<SO>Thorax</SO>
<YR>1991 Mar</YR>
<VL>46</VL>
<NO>3</NO>
<PG>172-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souhami-1997" MODIFIED="2008-07-31 10:52:33 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Souhami 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-07-31 10:52:33 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al</AU>
<TI>Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1997 Apr 16</YR>
<VL>89</VL>
<NO>8</NO>
<PG>577-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundstrom-2002" MODIFIED="2008-07-31 10:52:48 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Sundstrom 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-07-31 10:52:48 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al</AU>
<TI>Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002 Dec 15</YR>
<VL>20</VL>
<NO>24</NO>
<PG>4665-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urban-1999a" MODIFIED="2008-07-31 10:52:59 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Urban 1999a" YEAR="1999">
<REFERENCE MODIFIED="2008-07-31 10:52:59 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, et al</AU>
<TI>Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group</TI>
<SO>Lung Cancer</SO>
<YR>1999 Aug</YR>
<VL>25</VL>
<NO>2</NO>
<PG>105-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urban-1999b" MODIFIED="2008-07-31 10:53:25 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Urban 1999b" YEAR="1999">
<REFERENCE MODIFIED="2008-07-31 10:53:25 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, et al</AU>
<TI>The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. 'Petites Cellules' Group</TI>
<SO>Cancer</SO>
<YR>1999 Dec 1</YR>
<VL>86</VL>
<NO>11</NO>
<PG>2238-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veronesi-1994" MODIFIED="2008-07-31 10:53:41 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Veronesi 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-07-31 10:53:41 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, et al</AU>
<TI>Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study</TI>
<SO>European Journal of Cancer</SO>
<YR>1994</YR>
<VL>30A</VL>
<NO>10</NO>
<PG>1474-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wampler-1991" MODIFIED="2008-07-31 10:53:57 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Wampler 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-07-31 10:53:57 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG</AU>
<TI>Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1991 Aug</YR>
<VL>9</VL>
<NO>8</NO>
<PG>1438-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-2001" MODIFIED="2008-07-31 10:54:05 +0200" MODIFIED_BY="Jenny Bellorini" NAME="White 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-07-31 10:54:05 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, et al</AU>
<TI>Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma</TI>
<SO>Cancer</SO>
<YR>2001 Aug 1</YR>
<VL>92</VL>
<NO>3</NO>
<PG>601-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1987" MODIFIED="2008-07-31 10:54:20 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Wolf 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-07-31 10:54:20 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, et al</AU>
<TI>Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1987 Dec</YR>
<VL>5</VL>
<NO>12</NO>
<PG>1880-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Artel_x002d_Cortes-2004" MODIFIED="2008-07-31 10:54:32 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Artel-Cortes 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-31 10:54:32 +0200" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;&amp;#239;&amp;#187;&amp;#191;Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, et al. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer. 2004 Nov;6(3):175-83.&lt;/p&gt;" NOTES_MODIFIED="2008-07-31 10:54:32 +0200" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, et al</AU>
<TI>Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2004 Nov</YR>
<VL>6</VL>
<NO>3</NO>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blackstock-2005" MODIFIED="2008-07-31 10:54:55 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Blackstock 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-31 10:54:55 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al</AU>
<TI>Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2005 Mar</YR>
<VL>6</VL>
<NO>5</NO>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Marinis-2005" MODIFIED="2008-05-15 16:16:05 +0200" MODIFIED_BY="[Empty name]" NAME="De Marinis 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-15 16:16:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O, et al</AU>
<TI>A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma</TI>
<SO>Cancer</SO>
<YR>2005 Feb 15</YR>
<VL>103</VL>
<NO>4</NO>
<PG>772-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eckardt-2006" MODIFIED="2008-07-31 10:55:10 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Eckardt 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-31 10:55:10 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al</AU>
<TI>Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006 May 1</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2044-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanna-2006" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Hanna 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Hanna N, Bunn PA, Jr., Langer C, Einhorn L, Guthrie T, Jr., Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006 May 1;24(13):2038-43.&lt;/p&gt;" NOTES_MODIFIED="2015-07-31 11:05:47 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al</AU>
<TI>Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006 May 1</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2038-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lara-2006" MODIFIED="2008-07-31 10:56:05 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Lara 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-31 10:56:05 +0200" MODIFIED_BY="Jenny Bellorini" NOTES="&lt;p&gt;Lara PN, Jr., Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar;7(5):353-6.&lt;/p&gt;" NOTES_MODIFIED="2008-07-31 10:56:05 +0200" NOTES_MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lara PN Jr, Gandara DR, Natale RB</AU>
<TI>Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer</TI>
<SO>Clinical Lung Cancer</SO>
<YR>2006 Mar</YR>
<VL>7</VL>
<NO>5</NO>
<PG>353-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClay-2005" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="McClay 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClay EF, Bogart J, Herndon JE, Watson D, Evans L, Seagren SL, et al</AU>
<TI>A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235)</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2005 Feb</YR>
<VL>28</VL>
<NO>1</NO>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niell-2005" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Niell 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al</AU>
<TI>Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005 Jun 1</YR>
<VL>23</VL>
<NO>16</NO>
<PG>3752-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paccagnella-2004" MODIFIED="2008-05-15 16:22:18 +0200" MODIFIED_BY="[Empty name]" NAME="Paccagnella 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-15 16:22:18 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al</AU>
<TI>Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial</TI>
<SO>Lung Cancer</SO>
<YR>2004 Jan</YR>
<VL>43</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pathak-2005" MODIFIED="2008-07-31 10:57:38 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Pathak 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-07-31 10:57:38 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti BK, et al</AU>
<TI>Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer</TI>
<SO>Journal of the American College of Nutrition</SO>
<YR>2005 Feb</YR>
<VL>24</VL>
<NO>1</NO>
<PG>16-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schild-2004" MODIFIED="2008-07-31 10:58:23 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Schild 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-07-31 10:58:23 +0200" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al</AU>
<TI>Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer</TI>
<SO>International Journal of Radiation, Oncology, Biology, Physics</SO>
<YR>2004 Jul 15</YR>
<VL>59</VL>
<NO>4</NO>
<PG>943-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seifart-2005" MODIFIED="2008-05-15 16:27:50 +0200" MODIFIED_BY="[Empty name]" NAME="Seifart 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-15 16:27:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seifart U, Jensen K, Ukena J, Mueller C, Schroder M, Fuhr HG, et al</AU>
<TI>Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC)</TI>
<SO>Lung Cancer</SO>
<YR>2005 Jun</YR>
<VL>48</VL>
<NO>3</NO>
<PG>415-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abeloff-2004" MODIFIED="2015-07-28 14:59:11 +0200" MODIFIED_BY="[Empty name]" NAME="Abeloff 2004" TYPE="BOOK">
<AU>Abeloff MD</AU>
<SO>Clinical oncology</SO>
<YR>2004</YR>
<EN>3rd</EN>
<PB>Elsevier Churchill Livingstone</PB>
<CY>Philadelphia, Pa</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ACN-2004" MODIFIED="2015-07-28 14:59:14 +0200" MODIFIED_BY="[Empty name]" NAME="ACN 2004" TYPE="BOOK">
<AU>ACN</AU>
<TI>Clinical practice guidelines for the prevention, diagnosis and management of lung cancer</TI>
<SO>Clinical practice guidelines for the prevention, diagnosis and management of lung cancer</SO>
<YR>2004</YR>
<PB>Cancer Council Australia</PB>
<CY>Sidney</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alberg-2003" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Alberg 2003" TYPE="JOURNAL_ARTICLE">
<AU>Alberg AJ, Samet JM</AU>
<TI>Epidemiology of lung cancer</TI>
<SO>Chest</SO>
<YR>Jan 2003</YR>
<VL>123</VL>
<NO>1 Suppl</NO>
<PG>21S-49S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cella-2002" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Cella 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, et al</AU>
<TI>What is a clinically meaningful change on the FACT-L Questionnaire? Results of ECOG study 5592</TI>
<SO>J Clin Epidemiology</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>3</NO>
<PG>285-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chabner-2010" MODIFIED="2015-06-15 11:26:42 +0200" MODIFIED_BY="[Empty name]" NAME="Chabner 2010" TYPE="BOOK">
<AU>Chabner BA, Longo DL</AU>
<SO>Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, Cancer Chemotherapy and Biotherapy)</SO>
<YR>December 2010</YR>
<EN>5</EN>
<PB>LWW</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Chan 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chan BA, Coward JI</AU>
<TI>Chemotherapy advances in small-cell lung cancer</TI>
<SO>Journal of Thoracic Disease</SO>
<YR>October 2013</YR>
<VL>5</VL>
<NO>Supplement 5</NO>
<PG>S565-S578</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dela-Cruz-2011" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Dela Cruz 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dela Cruz CS, Tanoue LT, Matthay RA</AU>
<TI>Lung cancer: epidemiology, etiology, and prevention</TI>
<SO>Clinics in Chest Medicine</SO>
<YR>December 2011</YR>
<VL>32</VL>
<NO>4</NO>
<PG>605-644</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-1986" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Evans 1986" TYPE="JOURNAL_ARTICLE">
<AU>Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, et al</AU>
<TI>The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer</TI>
<SO>Seminars in Oncology</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>3 (Suppl 3)</NO>
<PG>10-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glisson-2014" MODIFIED="2015-06-15 12:18:13 +0200" MODIFIED_BY="[Empty name]" NAME="Glisson 2014" TYPE="BOOK_SECTION">
<AU>Glisson BS, Byers LA</AU>
<TI>Pathobiology and staging of small cell carcinoma of the lung</TI>
<SO>UpToDate</SO>
<YR>Nov 2014</YR>
<PB>UpToDate</PB>
<CY>Waltham, MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gralla-2004" MODIFIED="2008-05-27 04:07:08 +0200" MODIFIED_BY="[Empty name]" NAME="Gralla 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gralla RJ</AU>
<TI>Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life</TI>
<SO>Oncologist</SO>
<YR>2004</YR>
<VL>9 Suppl 6</VL>
<PG>14-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gusi-2010" MODIFIED="2015-03-11 07:22:57 +0100" MODIFIED_BY="[Empty name]" NAME="Gusi 2010" TYPE="BOOK_SECTION">
<AU>Gusi N, Olivares PR, Rajendram R</AU>
<TI>The EQ-5D Health-Related Quality of Life Questionnaire</TI>
<SO>Handbook of Disease Burdens and Quality of Life Measures</SO>
<YR>2010</YR>
<PG>87-99</PG>
<PB>Springer New York</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heintz-2010" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Heintz 2010" TYPE="JOURNAL_ARTICLE">
<AU>Heintz NH, Janssen-Heininger YM, Mossman BT</AU>
<TI>Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways</TI>
<SO>American Journal of Respiratory Cell and Molecular Biology</SO>
<YR>Feb 2010</YR>
<VL>42</VL>
<NO>2</NO>
<PG>133-139</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors). Chapter 7</AU>
<TI>Selecting studies and collecting data. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>John Wiley &amp; Sons for The Cochrane Collaboration.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2015-05-01 14:48:24 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-05-01 14:48:24 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors).<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Le-Pechoux-2004" MODIFIED="2008-07-31 11:05:31 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Le Pechoux 2004" TYPE="JOURNAL_ARTICLE">
<AU>Le Pechoux C, Dhermain F, Bretel JJ, Laplanche A, Dunant A, Tarayre M, et al</AU>
<TI>Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation</TI>
<SO>Revue de Pneumologie Clinique</SO>
<YR>2004</YR>
<VL>3S</VL>
<PG>91-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors)</AU>
<TI>
<I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Micke-2002" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Micke 2002" TYPE="JOURNAL_ARTICLE">
<AU>Micke P, Faldum A, Metz T, Beeh K-M, Bittinger F, Hengstler J-G, Buhl R</AU>
<TI>Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer - what limits limited disease?</TI>
<SO>Lung Cancer</SO>
<YR>September 2002</YR>
<VL>37</VL>
<NO>3</NO>
<PG>271-276</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2003" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Park 2003" TYPE="JOURNAL_ARTICLE">
<AU>Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, et al</AU>
<TI>Measuring response in solid tumors: comparison of RECIST and WHO response criteria</TI>
<SO>Japanese Journal of Clinical Oncology</SO>
<YR>September 2003</YR>
<VL>33</VL>
<NO>10</NO>
<PG>533-537</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peckham-1995" MODIFIED="2008-07-31 11:05:53 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Peckham 1995" TYPE="BOOK">
<AU>Peckham MJ, Pinedo HM, Veronesi U</AU>
<SO>Oxford Textbook of Oncology</SO>
<YR>1995</YR>
<PB>Oxford University Press</PB>
<IDENTIFIERS MODIFIED="2008-07-31 11:05:44 +0200" MODIFIED_BY="Jenny Bellorini"/>
</REFERENCE>
<REFERENCE ID="REF-Pujol-2000" MODIFIED="2008-07-31 11:06:40 +0200" MODIFIED_BY="Jenny Bellorini" NAME="Pujol 2000" TYPE="JOURNAL_ARTICLE">
<AU>Pujol JL, Carestia L, Daures JP</AU>
<TI>Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent</TI>
<SO>British Journal of Cancer</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>1</NO>
<PG>8-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stinchcombe-2010" MODIFIED="2015-06-15 11:37:57 +0200" MODIFIED_BY="[Empty name]" NAME="Stinchcombe 2010" TYPE="JOURNAL_ARTICLE">
<AU>Stinchcombe TE, Gore EM</AU>
<TI>Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms</TI>
<SO>The Oncologist</SO>
<YR>Feb 2010</YR>
<VL>15</VL>
<NO>2</NO>
<PG>187-195</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stubblefield-2009" MODIFIED="2015-06-28 10:55:02 +0200" MODIFIED_BY="[Empty name]" NAME="Stubblefield 2009" TYPE="BOOK">
<AU>Stubblefield M, O'Dell M</AU>
<SO>Cancer Rehabilitation: Principles and Practice</SO>
<YR>Apr 22, 2009</YR>
<PB>Demos Medical Publishing</PB>
<CY>New York City</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1979" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NAME="WHO 1979" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>WHO handbook for reporting results of cancer treatment</SO>
<YR>1979</YR>
<EN>WHO offset publication no 48.</EN>
<PB>World Health Organization</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-06-15 14:25:32 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amarasena-2008" MODIFIED="2015-06-15 14:25:32 +0200" MODIFIED_BY="[Empty name]" NAME="Amarasena 2008" TYPE="COCHRANE_REVIEW">
<AU>Amarasena IU, Walters JA, Wood-Baker R, Fong K</AU>
<TI>Platinum versus non-platinum chemotherapy regimens for small cell lung cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>Oct 8;(4):CD006849</NO>
<IDENTIFIERS MODIFIED="2015-06-15 14:24:40 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-15 14:24:40 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006849.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-31 10:57:11 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-07-31 10:57:11 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-07-31 10:47:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baka-2008">
<CHAR_METHODS MODIFIED="2015-07-31 10:47:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>STUDY DESIGN: </B>Parallel group</P>
<P>
<B>LOCATION, NUMBER OF CENTRES: </B>United Kingdom, 2 
</P>
<P>
<B>DURATION OF STUDY: </B>April 1999 &#8211; February 2005</P>
<P>
<B>CONCEALMENT OF ALLOCATION: </B>B</P>
<P>
<B>DESCRIBED AS RANDOMISED: </B>Yes 
</P>
<P>
<B>DESCRIBED AS DOUBLE BLIND: </B>No 
</P>
<P>
<B>METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: </B>Appropriate</P>
<P>
<B>METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: </B>N/A<BR/>
<B>DESCRIPTION OF WITHDRAWALS/DROPOUTS: </B>Adequate 
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High</P>
<P>
<B>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): </B>ITT</P>
<P>
<B>COMPLIANCE: </B>
</P>
<P>
<B>CONFOUNDERS: </B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-15 12:26:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<P>Previously untreated patients with histologically or cytologically proven SCLC and a maximum of two adverse prognostic factors (extensive stage disease, PS &gt;2, raised LDH, serum sodium &lt;130mmol/l:, Alk Phos &gt;1.25 ULN) were eligible. Other eligibility criteria included age <U>&gt;</U>18 years, normal blood count, serum bilirubin &lt;35 mmol/l and creatinine clearance &gt;50 ml/min. In patients with impaired renal function, that is, creatinine clearance &gt;30 ml/min but &lt;50 ml/min and/or patients with significant cardiovascular disease, carboplatin could be substituted for cisplatin in the first or subsequent cycles.</P>
<P>
<B>EXCLUSION CRITERIA: </B>A CT brain scan was not routinely performed, but patients with known brain metastases were not eligible.</P>
<P>
<B>N SCREENED: </B>Unknown 
</P>
<P>
<B>N RANDOMISED: </B>280 (ACE &#8211; 139; PE &#8211; 141) 
</P>
<P>
<B>N COMPLETED: </B>143 (ACE &#8211; 52; PE &#8211; 91)</P>
<P>
<B>ASSESS STAGE: </B>Yes</P>
<P>
<B>(N LIMITED): </B>165 (ACE &#8211; 84; PE 81) 
</P>
<P>
<B>(N EXTENSIVE): </B>114 (ACE &#8211; 54; PE &#8211; 60)</P>
<P>
<B>M: </B>142 (ACE &#8211; 67; PE &#8211; 75)</P>
<P>
<B>F: </B>138 (ACE &#8211; 72; PE &#8211; 66)</P>
<P>
<B>MEAN AGE: </B>Median &#8211; ACE &#8211; 66 (38-81); PE &#8211; 65 (39-89)</P>
<P>
<B>BASELINE DETAILS: </B>Physical examination, Histological diagnosis, CT scan of thorax and abdomen, blood tests</P>
<P>Tumour stage was assessed with CT scan of thorax and abdomen. Disease measurement was performed within 4 weeks before the start of treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-08 02:18:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TYPE: </B>Chemotherapy</P>
<P>
<B>REGIMENS, DOSE, DELIVERY:</B>
</P>
<P>ACE - (doxorubicin 50 mg/m2 i.v., cyclophosphamide 1 g/m2 i.v. and etoposide 120 mg/m2 i.v. on day 1, followed by etoposide 240 mg/m2 orally for 2 days)</P>
<P>PE - (cisplatin 80 mg/m2 and etoposide 120 mg/m2 i.v. on day 1, followed by etoposide 240 mg/m2 orally for 2 days every 3 weeks). For patients where cisplatin was not suitable, carboplatin was substituted at an AUC of 6, calculated according to the Calvert formula (ie, carboplatin dose 1&#8260;4 target AUC of 6 (glomerular filtration rate þ 25 mg), where glomerular filtration rate was based on EDTA or measured creatinine clearance).</P>
<P>
<B>CYCLES: </B>6 cycles every 3 weeks</P>
<P>
<B>CO-INTERVENTIONS PERMITTED: </B>Thoracic radiotherapy</P>
<P>
<B>CO-INTERVENTIONS: </B>
</P>
<P>Thoracic radiotherapy was given to patients with limited stage disease achieving a complete or partial response to chemotherapy, beginning 3 weeks after the last cycle of chemotherapy (30 Gy in 10 daily fractions). Patients with ED SCLC received thoracic irradiation only if they had thoracic symptoms amenable to palliation with radiotherapy after completion of chemotherapy. Prophylactic cranial irradiation was considered for all LD patients achieving a complete response; suitable patients received 25 Gy in 10 daily fractions after completion of chemotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>
<B>OUTCOMES MEASURED: </B>
</P>
<P>Primary &#8211; 1 year survival</P>
<P>Secondary &#8211; 2 year survival, median survival, response rate, toxicity</P>
<P>
<B>FOLLOW-UP ASSESSMENT POINTS: </B>
</P>
<P>During chemotherapy, patients were assessed on days 1 and 15 with physical examination, and weekly, with blood count, biochemistry and WHO Performance Status. A chest X-ray (CXR) was carried out after every second cycle of treatment, but assessment of response was made according to the WHO criteria by CT scanning at the end of chemotherapy unless progressive disease was detected in the interim by CXR. Toxicities were graded according to the National Cancer Institute Common Toxicity Grading Criteria version December 1994 (revised).</P>
<P>
<B>OUTCOMES INCLUDED IN ANALYSES:</B>
</P>
<P>Survival</P>
<P>Response Rate</P>
<P>Toxicity</P>
<P>
<B>TYPE: </B>Chemotherapy</P>
<P>
<B>REGIMENS:</B>
</P>
<P>ACE - (doxorubicin 50 mg/m2 i.v., cyclophosphamide 1 g/m2 i.v. and etoposide 120 mg/m2 i.v. on day 1, followed by etoposide 240 mg/m2 orally for 2 days)</P>
<P>PE - (cisplatin 80 mg/m2 and etoposide 120 mg/m2 i.v. on day 1, followed by etoposide 240 mg/m2 orally for 2 days every 3 weeks). For patients where cisplatin was not suitable, carboplatin was substituted at an AUC of 6, calculated according to the Calvert formula (ie, carboplatin dose 1&#8260;4 target AUC of 6 (glomerular filtration rate þ 25 mg), where glomerular filtration rate was based on EDTA or measured creatinine clearance).</P>
<P>
<B>CYCLES: </B>6 cycles every 3 weeks</P>
<P>
<B>DOSE: </B>
</P>
<P>
<B>DELIVERY: </B>IV</P>
<P>
<B>CO-INTERVENTIONS PERMITTED: </B>Thoracic radiotherapy</P>
<P>
<B>CO-INTERVENTIONS: </B>
</P>
<P>Thoracic radiotherapy was given to patients with limited stage disease achieving a complete or partial response to chemotherapy, beginning 3 weeks after the last cycle of chemotherapy (30 Gy in 10 daily fractions). Patients with ED SCLC received thoracic irradiation only if they had thoracic symptoms amenable to palliation with radiotherapy after completion of chemotherapy. Prophylactic cranial irradiation was considered for all LD patients achieving a complete response; suitable patients received 25 Gy in 10 daily fractions after completion of chemotherapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-09 05:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>SUB-GROUPS INDENTIFIED:</B>
</P>
<P>Limited disease stage</P>
<P>Extensive disease stage</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:46:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chahinian-1989">
<CHAR_METHODS MODIFIED="2015-07-31 10:46:49 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: 20 Cancer and Leukaemia Group B (CALGB) main member institutions<BR/>DURATION OF STUDY: February 1981 to May 1984<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND:<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>CALGB performance status of 0 to 3<BR/>Informed consent<BR/>One measurable tumour</P>
<P>EXCLUSION CRITERIA:<BR/>Prior chemotherapy<BR/>Myocardial infarction within 6 months<BR/>Cardiac failure<BR/>Serious arrhythmia not directly attributable to metastatic small cell lung cancer<BR/>Patients with any contraindications to the use of warfarin<BR/>Patients already on warfarin</P>
<P>N RANDOMISED: 294<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 0<BR/>(N EXTENSIVE): 294<BR/>M: 199 (MACC - 62; MACC + W - 70; MEPH/MACC - 67)<BR/>F: 95 (MACC - 24; MACC + W - 33; MEPH/MACC - 38<BR/>AGE:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:07:18 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>MACC - methotrexate (30 mg/m<SUP>2</SUP> intravenously [IV]), doxorubicin (40mg/m2 IV), cyclophosphamide (400 mg/m<SUP>2</SUP> IV) and lomustine (30 mg/m<SUP>2</SUP> orally) given once every 3 weeks. Doxorubicin was discontinued after a total cumulative dose of 450 mg/m<SUP>2</SUP>
</P>
<P>MACC + W - methotrexate (30 mg/m<SUP>2</SUP> intravenously [IV]), doxorubicin (40 mg/m<SUP>2 </SUP>IV), cyclophosphamide (400 mg/m<SUP>2</SUP> IV), lomustine (30 mg/m<SUP>2</SUP> orally) and warfarin sodium (single oral daily dose of 10 mg starting on day 1) given once every 3 weeks. Doxorubicin was discontinued after a total cumulative dose of 450 mg/m<SUP>2</SUP>.</P>
<P>MEPH/MACC - Mitomycin (7 mg/m<SUP>2</SUP> IV on day 1), etoposide (40 mg/m<SUP>2</SUP> IV on days 1 to 3), cisplatin (50 mg/m<SUP>2</SUP> IV on day 1) and hexamethylmelamine (100 mg/m<SUP>2</SUP> orally from day 3 to 17). This was the MEPH regimen. On day 35 (week 6) of each cycle, patients received MACC chemotherapy as described above. On day 56 (week 9), MEPH component was given again 3 weeks after MACC. The two regimens were alternated in this fashion (MEPH/MACC)</P>
<P>CO-INTERVENTIONS: Radiotherapy</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-30 16:59:10 +0200" MODIFIED_BY="Jenny Bellorini">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Overall survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Overall survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only data from arms MACC + W and MEPH/MACC were considered for this systematic review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:47:24 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Creech-1982">
<CHAR_METHODS MODIFIED="2015-07-31 10:47:24 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: September 1978 to October 1979<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Moderate<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 19:55:31 +0200" MODIFIED_BY="[Empty name]">
<P>INCLUSION CRITERIA: Each patient had to be refractory to standard chemotherapy; have measurable or evaluable disease; an Eastern Cooperative Oncology Group performance status of 0 to 2; a white blood cell count &gt;= 4000/mm<SUP>3</SUP>, a platelet count &gt;= 100,000/mm<SUP>3</SUP>, a BUN &lt;= 25 mg/100 mL, a creatinine &lt; 1.5 mg/100 mL, and a bilirubin &lt;= 2.0 mg/100 mL. All patients gave informed written consent prior to participation in this study.<BR/>EXCLUSION CRITERIA:<BR/>N SCREENED: 73 (58 evaluable)<BR/>N RANDOMISED: 58 (cisplatin - 21; maytansine - 19; chlorozotocin - 18)<BR/>N COMPLETED:<BR/>ASSESS STAGE: No<BR/>(N LIMITED):<BR/>(N EXTENSIVE):<BR/>M:<BR/>F:<BR/>AGE:<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 15:59:37 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Cisplatin - 75 mg/m<SUP>2</SUP> intravenous (IV) Cisplatin every 21 days after adequate hydration and diuresis.<BR/>Maytansine - maytansine 1.5 mg/m<SUP>2</SUP> IV every 21 days.<BR/>Chlorozotocin - chlorozotocin 120 mg/m<SUP>2</SUP> IV every 42 days.</P>
<P>Each drug was given until there was clinical evidence of progressive disease, after which patients were not eligible for treatment with the other study drugs.</P>
<P>CO-INTERVENTIONS:<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:48:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Jong-2007">
<CHAR_METHODS MODIFIED="2015-07-31 10:48:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>STUDY DESIGN: </B>Parallel group</P>
<P>
<B>LOCATION, NUMBER OF CENTRES: </B>Not described 
</P>
<P>
<B>DURATION OF STUDY: </B>Feb 1999 &#8211; Feb 2005</P>
<P>
<B>CONCEALMENT OF ALLOCATION: </B>B</P>
<P>
<B>DESCRIBED AS RANDOMISED: </B>Yes 
</P>
<P>
<B>DESCRIBED AS DOUBLE BLIND: </B>Not described 
</P>
<P>
<B>METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: </B>Yes</P>
<P>
<B>METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: </B>N/A<B>
<BR/>DESCRIPTION OF WITHDRAWALS/DROPOUTS: </B>Appropriate 
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High</P>
<P>
<B>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): </B>ITT</P>
<P>
<B>COMPLIANCE: </B>
</P>
<P>
<B>CONFOUNDERS: </B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>
<B>ELIGIBILITY</B>
</P>
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<P>Patients were included if they met all the following criteria: age over 18 years, histologically or cytologically proven ED SCLC with measurable or evaluable lesions, no prior chemotherapy or radiotherapy except for symptomatic brain metastases, Eastern Cooperative Oncology Group (ECOG) performance score 0&#8211;2, adequate haematological, renal and hepatic functions (absolute neutrophil count (ANC) P2.0 x 10^9/L, platelet count P100 · 109/L, bilirubin 61.25 · upper normal limit, creatinine clearance according to Cockroft formula P60 ml/min).</P>
<P>
<B>EXCLUSION CRITERIA:</B>
</P>
<P>
<B>N SCREENED: </B>Unknown 
</P>
<P>
<B>N RANDOMISED: </B>203 
</P>
<P>
<B>N COMPLETED: </B>203 (CDE - 102; CP &#8211; 101)</P>
<P>
<B>ASSESS STAGE: </B>Yes 
</P>
<P>
<B>(N LIMITED): </B>N/A 
</P>
<P>
<B>(N EXTENSIVE): </B>203</P>
<P>
<B>M: </B>118 (CDE &#8211; 52; CP &#8211; 63)</P>
<P>
<B>F: </B>85 (CDE &#8211; 47; CP &#8211; 38)</P>
<P>
<B>MEDIAN AGE: </B>CDE &#8211; 61.7; CP &#8211; 62.7</P>
<P>
<B>BASELINE DETAILS: </B>History, physical examination, ECOG performance status, complete blood cell count (CBC), electrolytes, liver enzymes, serum creatinine and electrocardiography (ECG)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-08 02:18:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TYPE: </B>Chemotherapy</P>
<P>
<B>REGIMENS, DOSE, DELIVERY: </B>
</P>
<P>CDE - Cyclophosphamide (1000 mg/m2 i.v) on day 1, doxorubicin (45 mg/m2 i.v) on day 1, and etoposide (100 mg/m2 i.v) on days 1, 2, and 3.</P>
<P>Carboplatin (AUC 7 using the Calvert formula, i.v) followed by paclitaxel (175 mg/m2 i.v) as a 3-hour infusion both on day 1</P>
<P>
<B>CYCLES: </B>Maximum of 5 cycles every 3 weeks</P>
<P>
<B>CO-INTERVENTIONS PERMITTED: </B>Nil</P>
<P>
<B>CO-INTERVENTIONS:</B>
</P>
<P>Nil</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>
<B>OUTCOMES MEASURED: </B>
</P>
<P>Primary &#8211; Progression free survival,</P>
<P>Secondary &#8211; Overall survival, tumour response rates, toxicities</P>
<P>
<B>FOLLOW-UP ASSESSMENT POINTS: </B>
</P>
<P>On day 14 of each cycle and on clinical indications, a CBC was performed in a similar way in both arms. Tumour evaluations were performed with a computed tomography (CT) scan of the chest and repeated after two cycles and at the end of treatment. Tumour response was defined according to the WHO criteria. Follow-up after treatment was every 4&#8211;6 weeks with a CBC, liver enzymes, chest X-ray, or additional tests if clinically indicated. Toxicity was scored before each cycle according to the National Cancer Institute Common Toxicity Criteria (CTC), version 2.0.</P>
<P>
<B>OUTCOMES INCLUDED IN ANALYSES:</B>
</P>
<P>Progression-free survival</P>
<P>Overall survival</P>
<P>Tumour response rates</P>
<P>Toxicities</P>
<P>
<B>SUB-GROUPS INDENTIFIED:</B>
</P>
<P>Nil</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-03-10 05:09:21 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:49:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eagan-1981">
<CHAR_METHODS MODIFIED="2015-07-31 10:49:27 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel group<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: July 1976 to July 1978<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Previously untreated limited stage small cell lung cancer</P>
<P>EXCLUSION CRITERIA: Patients with significant cardiac disease or serum creatinines &gt; 1.5 mg/dl</P>
<P>N RANDOMISED: 62<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 62 (VOCA - 31; VOCAP - 31)<BR/>(N EXTENSIVE): 0<BR/>M: 45 (VOCA - 22; VOCAP - 23)<BR/>F: 17 (VOCA - 9; VOCAP - 8)<BR/>AGE: Median VOCA - 58 (39 to 74); VOCAP - 59 (38 to 77)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 15:59:43 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>VOCA - VP-16 50 mg/m<SUP>2</SUP> IV on days 1, 2 and 3; vincristine (Oncovin) 1.4 mg/m<SUP>2</SUP> IV on day 1; cyclophosphamide 150 mg/m<SUP>2</SUP> IV on days 1, 2 and 3; and Adriamycin 15 mg/m<SUP>2</SUP> IV on days 1, 2 and 3.</P>
<P>VOCAP - VP-16 50 mg/m<SUP>2</SUP> IV on days 1, 2 and 3; vincristine (Oncovin) 1.4 mg/m<SUP>2</SUP> IV on day 1; cyclophosphamide 150 mg/m<SUP>2</SUP> IV on days 1, 2 and 3; Adriamycin 15 mg/m<SUP>2</SUP> IV on days 1, 2 and 3; and cisplatin 40 mg/m<SUP>2</SUP> IV on day 1.</P>
<P>Both treatment arms were administered for 8 cycles</P>
<P>CO-INTERVENTIONS: Thoracic radiation therapy was administered concomitantly with the third and fourth courses of chemotherapy<BR/>CLASSIFICATION OF INTERVENTION: (ADJUVANT/NEO-ADJUVANT/PALLIATIVE): Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Regression rates<BR/>Time to progression<BR/>Survival<BR/>Tumour response<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:49:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-1987">
<CHAR_METHODS MODIFIED="2015-07-31 10:49:50 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Canada, multicentric<BR/>DURATION OF STUDY: November 1982 to April 1985<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Adequate<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-15 12:27:11 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: histologically/cytologically proven SCLC; no prior chemotherapy or radiotherapy; evidence of extensive disease (ED); evidence of good bone marrow function (leukocyte count &gt; 3.0 × 10<SUP>9</SUP>/L, granulocytes &gt; 1.5 × 10<SUP>9</SUP>/L, platelet count &gt; 75 × 10<SUP>9</SUP>/L) and satisfactory liver function (bilirubin &lt; 35 µmol/L) and renal function (serum creatinine &lt; 120 µmol/L, creatinine clearance &gt; 3.3 mL/S, blood urea nitrogen &lt; 10 mmol/L); measurable or evaluable disease; patients with malignant pleural effusions were eligible if, in addition to the effusion, they had other measurable or evaluable disease; patients had to give written and informed consent and be available for follow up.<BR/>EXCLUSION CRITERIA: patients were ineligible if central nervous system metastases were present; they had prior radiotherapy or chemotherapy or had a performance status lower than 3 on the Eastern Cooperative Oncology Group scale. Patients with a prior history of malignant disease, except for nonmelanoma skin tumours, were excluded unless they had been without evidence of disease for at least 5 years. Patients with a recent myocardial infarction (less than 3 months from the date of diagnosis) or congestive cardiac failure or arrhythmia requiring medical treatment were excluded, as were patients over 80 years of age, or those who lived too far from the treatment centre.<BR/>N RANDOMISED: 289 (standard - 144; alternating - 145)<BR/>ASSESS STAGE: No<BR/>(N LIMITED):<BR/>(N EXTENSIVE):<BR/>M: 193<BR/>F: 96<BR/>AGE: Mean: standard - 61.1; alternating - 61.5 (range: standard - 34 to 79; alternating - 41 to 79)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 15:59:47 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: chemotherapy<BR/>REGIMENS:<BR/>Standard - cyclophosphamide (1000 mg/m<SUP>2</SUP> body surface area), doxorubicin 50 mg/m<SUP>2</SUP> and vincristine 2 mg by intravenous (IV) bolus every 3 weeks for 6 cycles.<BR/>Alternating - same doses as the standard regimen alternating with etoposide 100 mg/m<SUP>2</SUP> infused over 30 to 60 minutes, and cisplatin 25 mg/m<SUP>2</SUP> in an IV bolus, daily for 3 consecutive days.<BR/>Treatment cycles were repeated at 3-week intervals in the alternating study arm.</P>
<P>The duration of treatment was 18 weeks for both arms of the study.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (best response to chemotherapy)<BR/>Survival<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (best response to chemotherapy)<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>At the end of the 6 cycles, patients were seen every 6 weeks for 6 months and every 3 months thereafter or as judged appropriate by their physician.</P>
<P>Patients receiving the etoposide and cisplatin regimen had to drink 6 to 8 glasses of water on the mornings of treatment. The etoposide was diluted in normal saline in a volume sufficient to achieve a concentration of 0.4 mg/mL or less. Blood pressure was measured every 15 minutes during the etoposide infusion, at least during the first treatment. Cisplatin was given at the end of the etoposide infusion.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:50:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farris-1993">
<CHAR_METHODS MODIFIED="2015-07-31 10:50:07 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically confirmed undifferentiated small oat cell carcinoma</P>
<P>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 113 (CEV - 57, CDDP-VP16/C-E - 57)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 52 (CEV - 27; CDDP-VP16/C-E - 25)<BR/>(N EXTENSIVE): 61 (CEV - 30; CDDP-VP16/C-E - 31)<BR/>M: 100 (CEV - 50; CDDP-VP16/C-E - 50)<BR/>F: 13 (CEV - 7; CDDP-VP16/C-E - 6)<BR/>AGE: Overall: median 61 (range: 43 to 74); CEV: 62 (45 to 74), CDDP-VP16/C-E: 60 (43 to 69)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 15:59:50 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CEV - cyclophosphamide 1000 mg/m<SUP>2</SUP>, epirubicin 60 mg/m<SUP>2</SUP> and vincristine 1 mg/m<SUP>2</SUP> all administered on day 1 and cycles repeated every 21 days (all given IV)</P>
<P>CDDP-VP16/C-E - cisplatin 50 mg/m<SUP>2</SUP> on days 1 and 2, etoposide 200 mg/m<SUP>2</SUP> on days 3, 4 and 5 alternating every 28 days with cyclophosphamide 1000 mg/m<SUP>2</SUP> on day 1 and epirubicin 60 mg/m<SUP>2</SUP> on day 1 (all given IV, except for etoposide, which was given orally)</P>
<P>CO-INTERVENTIONS: Patients with limited disease experiencing complete remission received chest irradiation (45 Gy in 15 fractions over 3 weeks) and prophylactic irradiation of the skull.</P>
<P>CLASSIFICATION OF INTERVENTION: (ADJUVANT/NEO-ADJUVANT/PALLIATIVE): Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS: After the end of chemotherapy, assessable patients were re-checked monthly for the first 3 months and then every 3 months thereafter. At each re-check visit, each patient received a complete physical examination, a chest X-ray and routine haematological and biochemistry tests</P>
<P>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:50:27 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukuoka-1986">
<CHAR_METHODS MODIFIED="2015-07-31 10:50:27 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Osaka Prefectural Habikino Hospital, single centre.<BR/>DURATION OF STUDY: August 1982 to April 1985<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:02:45 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically or cytologically confirmed SCLC, age &lt;= 79 years, a performance status (ECOG scale) of 0 to 3, with no prior therapy, with measurable or evaluable disease, with adequate bone marrow function (white blood cells [WBC] &gt;= 4000/mm<SUP>3</SUP>, platelets &gt;= 10 x 104/mm<SUP>3</SUP>), serum creatinine &lt;1.5 mg/dl, serum glutamine oxaloacetic transaminase and glutamine pyruvic transaminase &lt; 2 x normal, with normal cardiac function and no other malignant disease.</P>
<P>EXCLUSION CRITERIA:<BR/>N SCREENED: 71 (69 eligible)<BR/>N RANDOMISED: 69 (continuous - 34; alternating - 35)<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 21<BR/>(N EXTENSIVE): 48<BR/>M: 55<BR/>F: 14<BR/>AGE: mean: continuous - 61.5; alternating - 62.1 (range: continuous - 40 to 77, alternating - 36 to 74)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 18:57:56 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>The continuous regimen (CONP) consisted of nimustine hydrochloride (ACNU: 70 mg/m<SUP>2</SUP> IV on day 1), cyclophosphamide (700 mg/m<SUP>2</SUP> IV on day 2), oncovin (0.7 mg/m<SUP>2</SUP> IV on day 2) and procarbazine (100 mg/m<SUP>2 </SUP>body surface-area orally on days 1 to 7). This regimen was repeated every 4 weeks.<BR/>The alternating regimen (CONPVAD) consisted of CONP treatment as described above, followed by treatment with VAD, which contained etoposide (VP-16) (60 mg/m<SUP>2</SUP> IV on days 1 to 4), Adriamycin (30 mg/m<SUP>2</SUP> IV on day 1), and cisplatin (DDP: 60 mg/m<SUP>2</SUP> IV with 2600 ml hydration and diuresis on day 1). Thus, CONP was alternated with VAD at 4-week intervals.</P>
<P>CO-INTERVENTIONS:<BR/>Radiation therapy was performed on primary lesions and the mediastinum at the time of expected maximum response to all patients with LD<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Response duration<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other:<BR/>Patients with pleural effusion were excluded from LD (limited disease)<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:50:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukuoka-1991">
<CHAR_METHODS MODIFIED="2015-07-31 10:50:38 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel group<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: April 1985 to May 1988<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Adequate<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:04:09 +0200" MODIFIED_BY="[Empty name]">
<P>INCLUSION CRITERIA: Histologically or cytologically proven SCLC; no prior therapy; signs of measurable or evaluable disease; a performance status of 0 to 3 on the Eastern Cooperative Oncology Group (ECOG) scale; age less than 75 years; adequate bone marrow reserve (leukocyte count &gt;= 4000/mm<SUP>3</SUP> and platelet count &gt;= 100,000/mm<SUP>3</SUP>); adequate liver function (bilirubin &lt;= 1.5 mg/dL and alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase no greater than twice the upper limit of normal); adequate renal function (serum creatinine &lt;= 1.5 mg/dL and blood urea nitrogen &lt;= 25 mg/dL) and informed consent.</P>
<P>EXCLUSION CRITERIA: Ineligible if patients had another active malignant disease, a history of myocardial infarction within the previous 3 months or other cardiac disease requiring medical treatment.</P>
<P>N SCREENED: 300 (288 eligible)<BR/>N RANDOMISED: 288 (CAV - 97; PE - 97; CAV/PE - 94)<BR/>N COMPLETED: 279<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): CAV - 49; PE - 47; CAV/PE - 50<BR/>(N EXTENSIVE): CAV - 48; PE - 50; CAV/PE - 44<BR/>M: CAV - 81; PE - 78; CAV/PE - 76<BR/>F: CAV - 16; PE - 19; CAV/PE - 18<BR/>AGE: median: CAV - 63; PE - 64; CAV/PE - 64 (range: CAV - 40 to 74; PE - 37to 74; CAV/PE - 31 to 74)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:00 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CAV - cyclophosphamide at a dose of 800 mg/m<SUP>2</SUP> given intravenously (IV) on day 1, doxorubicin at 50 mg/m<SUP>2</SUP> IV on day 1 and vincristine at 1.4 mg/m<SUP>2</SUP> (maximum 2.0 mg) IV on day 1.<BR/>PE - cisplatin at 80 mg/m<SUP>2</SUP> IV on day 1 and etoposide at 100 mg/m<SUP>2</SUP> IV on days 1, 3 and 5.<BR/>(Cisplastin was given with adequate prehydration, posthydration, diuretics and antiemetic agents)</P>
<P>CAV/PE - CAV alternating with PE</P>
<P>Treatments were repeated every 3 to 4 weeks</P>
<P>CO-INTERVENTIONS: All patients with limited disease received thoracic irradiation after restaging. Thoracic irradiation consisted of 200-cGy fractions given daily 5 days per week for 4 to 5 weeks.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (classified according to World Health Organization criteria)<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (classified according to World Health Organization criteria)<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>Other: There were 3 cancellations due to patient refusal before therapy started; 9 patients were considered ineligible: 4 had histologies other than SCLC, 3 were 75 years of age or older, one had congestive heart failure and one had a simultaneous squamous cell carcinoma of the lung.</P>
<P>If patients on the CAV arm or PE arm did not respond after 2 cycles of chemotherapy, they were crossed over to the other regimen (restaging). Restaging was carried out at the completion of 4 cycles of chemotherapy to evaluate the response.</P>
<P>Cisplastin was discontinued if renal failure occurred.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:51:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gatzemeier-1994">
<CHAR_METHODS MODIFIED="2015-07-31 10:51:38 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: <BR/>DURATION OF STUDY: <BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologic diagnosis of SCLC; good performance status [Eastern Coorperative Oncology Group (ECOG) 0 to 2]; no evidence of central nervous system metastases; age between 18 and 75 years; life expectancy of at least 3 months; adequate bone marrow, renal and hepatic functions; and extensive disease (ED).<BR/>EXCLUSION CRITERIA:<BR/>N SCREENED: 344<BR/>N RANDOMISED: 317 (CEV - 156; EV - 161)<BR/>ASSESS STAGE: Yes ED only<BR/>(N LIMITED):<BR/>(N EXTENSIVE): 317<BR/>M: 235 (CEV - 117; EV - 118)<BR/>F: 82 (CEV - 39; EV - 43)<BR/>AGE: median: CEV - 58.5; EV - 62 (range: CEV - 33 to 76; EV - 18 to 75)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:05 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CEV - carboplatin 300 mg/m<SUP>2</SUP> on day 1, etoposide 140 mg/m<SUP>2</SUP> on days 1 to 3 and vincristine 1.4 mg/m<SUP>2</SUP> on days 1, 8 and 15<BR/>EV - etoposide 200 mg/m<SUP>2</SUP> on days 1 to 3, and vincristine 1.4 mg/m<SUP>2</SUP> on days 1 and 8.</P>
<P>Chemotherapy cycles in each treatment arm were repeated every 4 weeks.</P>
<P>CO-INTERVENTIONS:<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:51:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodman-1990">
<CHAR_METHODS MODIFIED="2015-07-31 10:51:54 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: September 1982 to September 1984<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Patients with previously untreated limited disease SCLC</P>
<P>EXCLUSION CRITERIA:<BR/>Patients with extensive disease SCLC<BR/>N RANDOMISED: 388<BR/>ASSESS STAGE: Yes (LD only)<BR/>(N LIMITED): 388<BR/>(N EXTENSIVE):<BR/>M: 247<BR/>F: 141<BR/>AGE: Median 61 in both arms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:08 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>EVAC - VP-16, 75 mg/m<SUP>2</SUP> IV on days 1, 2 and 3, vincristine 1.0 mg/m<SUP>2</SUP> IV on days 1 and 8, Adriamycin 40 mg/m<SUP>2</SUP> IV on day 1, cyclophosphamide 750 mg/m<SUP>2</SUP> IV on day 1<BR/>Treatment was repeated every 3 weeks for 6 cycles</P>
<P>VP-16/CDDP alternating with VAC - VP-16 100 mg/m<SUP>2</SUP> IV on days 1, 2 and 3, CDDP 100 mg/m<SUP>2</SUP> IV on day 1, vincristine 1.0 mg/m<SUP>2</SUP> IV on days 22 and 29, Adriamycin 50 mg/m<SUP>2</SUP> IV on day 22, cyclophosphamide, 750 mg/m<SUP>2</SUP> on day 22<BR/>Treatment was repeated every 6 weeks for a total of 6 cycles</P>
<P>CO-INTERVENTIONS:<BR/>Chest irradiation<BR/>Prophylactic cranial irradiation</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Survival<BR/>Tumour response<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:52:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greco-2005">
<CHAR_METHODS MODIFIED="2015-07-31 10:52:07 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel group<BR/>LOCATION, NUMBER OF CENTRES: 29 affiliate Minnie Pearl Cancer Research Network participating sites</P>
<P>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:39:49 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Patients with previously untreated histologically confirmed SCLC; age &gt; 18 years; Easter Cooperative Oncology Group (ECOG) performance status score of 0 or 1; ANC &gt; 1500/µl; platelet count &gt; 100,000/µl; serum bilirubin &lt;= 1.5 mg/dl, for those without known hepatic metastases, and &lt; 2.5 mg/dl for those with known hepatic metastases; serum creatinine &lt;= 1.5 mg/dl; no previous treatment for small cell lung cancer; no history of prior malignancy within 5 years, with the exception of nonmelanoma skin cancer or cervical carcinoma in situ; and no history of congestive heart failure or myocardial infarction within 3 months.</P>
<P>EXCLUSION CRITERIA: Patients with mixed histology lung cancer.<BR/>N SCREENED:<BR/>N RANDOMISED: 120 (PCE - 60; PT - 60)<BR/>N COMPLETED: 120<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 0<BR/>(N EXTENSIVE): 120<BR/>M: PCE - 39; PT - 29<BR/>F: PCE - 21; PT - 31</P>
<P>AGE: median age (range): PCE - 60 (42 to 78); PT 62 (38 to 79)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:10 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>PCE - paclitaxel, carboplatin, etoposide<BR/>PT - paclitaxel, topotecan</P>
<P>Up to 8 cycles<BR/>After the completion of 4 courses of chemotherapy, patients responding well to treatment and tolerating treatment with no grade 4 toxicity could continue on treatment for a maximum of 8 courses at the discretion of the treating physician</P>
<P>PCE - paclitaxel at a dose of 200 mg/m<SUP>2</SUP> IV over 1 hour on day 1; carboplatin dosing was based on the Calvert formula with a target area under the concentration-time curve of 6 given IV over 1 hour on day 1; etoposide given orally with a total dose of 50 mg, alternating with 100 mg, on a daily basis on days 1 to 10. Repeated every 21 days.</P>
<P>PT - paclitaxel was administered at a dose of 175 mg/m<SUP>2</SUP> IV over 1 hour on day 1, and topotecan was given at a dose of 1.5 mg/m<SUP>2</SUP> IV over 1 hour on days 1, 2 and 3. Repeated every 21 days.</P>
<P>CO-INTERVENTIONS: Patients with brain metastases were treated with whole-brain radiotherapy concurrently with the beginning of chemotherapy.<BR/>Cytokines were used at the discretion of each investigator; however, they were not used during the first course of therapy. All patients received standard supportive care, including blood and platelet transfusions, antiemetics and antibiotics.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Primary: tumour response rate; time to progression<BR/>Secondary: overall survival; toxicity (haematologic and non-haematologic)</P>
<P>FOLLOW UP ASSESSMENT POINTS: Tumour status was assessed after 2 courses of chemotherapy (6 weeks), and thereafter every 2 courses until the completion of treatment (4 to 8 courses).</P>
<P>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response rate<BR/>Overall survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:52:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Havemann-1987">
<CHAR_METHODS MODIFIED="2015-07-31 10:52:25 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Germany, multicentre<BR/>DURATION OF STUDY: July 1981 to November 1983.<BR/>CONCEALMENT OF ALLOCATION: C<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-06-15 12:27:36 +0200" MODIFIED_BY="[Empty name]">
<P>INCLUSION CRITERIA: Histologic proof of SCLC - positive cytologic findings were not considered histologic confirmation; signs of measurable or evaluable disease; performance status of 50% or more according to the Karnofsky scale; age of 70 years or younger; and informed patient consent.<BR/>EXCLUSION CRITERIA: prior radiotherapy, chemotherapy or surgical treatment received; existence of an accessory malignant disease; evidence of renal dysfunction (creatinine &gt; 1.5 mg/dL), chronic haptic disease (bilirubin &gt; 2.0 mg/dL); or advanced respiratory or cardiac insufficiency.<BR/>N RANDOMISED: 306 (302 evaluable) (sequential - 155, alternating - 151)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 104<BR/>(N EXTENSIVE): 198<BR/>M: 254<BR/>F: 48<BR/>AGE:<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:13 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Sequential chemotherapy consisted of 8 cycles of CAV - cyclophosphamide 1000 mg/m<SUP>2</SUP> intravenously (IV) on day 1, Adriamycin 50 mg/m<SUP>2</SUP> IV on day 1, and vincristine 2 mg IV on day 1, all administered in 3-week intervals.</P>
<P>Alternating chemotherapy consisted of 3 cycles of EVI (cycles 1, 3 and 5) - etoposide 80 mg/m<SUP>2</SUP> IV on days 1 to 3, vindesine 3 mg/m<SUP>2</SUP> IV on day 1, and iphosphamide 1500 mg/m<SUP>2</SUP> IV on days 1 to 5 alternating with 3 cycles (cycles 2, 4 and 6) of PAV - cisplatin 90 mg/m<SUP>2</SUP> IV on day 1, Adriamycin 60 mg/m<SUP>2</SUP> IV on day 1, and vincristine 2 mg IV on day 1, all administered in 3-week intervals and followed by application of CMC - cyclophosphamide 1000 mg/m<SUP>2</SUP> IV on days 1 and 22, methotrexate 15 mg/m<SUP>2</SUP> orally on days 1, 4, 8 and 11; and CCNU 100 mg/m<SUP>2</SUP> orally on day 1 in a 6-week cycle.</P>
<P>CO-INTERVENTIONS:<BR/>Responsive patients received prophylactic cranial irradiation after 3 cycles. Patients without distant metastases after 8 cycles of chemotherapy received chest irradiation.<BR/>Patients with brain metastases received cranial irradiation immediately. Accessory painful metastatic sites were irradiated as necessary.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (defined as best response at any time during treatment)<BR/>Survival<BR/>Progression-free survival<BR/>Tumour progression or relapse<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (defined as best response at any time during treatment)<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-08 08:43:20 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:52:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1993">
<CHAR_METHODS MODIFIED="2015-07-31 10:52:37 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: August 1987 to April 1990<BR/>CONCEALMENT OF ALLOCATION:D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Previously untreated patients; histologically or cytologically confirmed SCLC; World Health Organization performance status<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 104 (CVM - 54; ACE - 50)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 32 (CVM - 17; ACE - 15)<BR/>(N EXTENSIVE): 72 (CVM - 37; ACE - 35)<BR/>M: 61<BR/>F: 43<BR/>AGE: median: CVM - 67; ACE - 64 (range: CVM - 33 to 79; ACE - 47 to 75)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 21:00:43 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CVM - carboplatin 300 mg/m<SUP>2</SUP> in 500 ml (Dextrose 5% in Water solution) delivered intravenously (IV) over 60 minutes, on day 1, vinblastine 6 to 10 mg/m<SUP>2</SUP> IV on day 1, and methotrexate 30 to 50 mg/m<SUP>2</SUP> IV on day 1.<BR/>The course was repeated every 28 days. Leucovorin was administered orally 24 hours after methotrexate to reverse the latter agent's toxic effects (15 mg every 6 hours × 6 doses)</P>
<P>ACE - doxorubicin 40 mg/m<SUP>2</SUP> IV on day 1, cyclophosphamide 600 mg/m<SUP>2</SUP> IV on day 1 and etoposide 100 mg/m<SUP>2</SUP> days 1 to 3 (outpatient treatment: 200 mg/m<SUP>2</SUP> orally. days 2 and 3).<BR/>The course was repeated every 21 days</P>
<P>CO-INTERVENTIONS:<BR/>Some limited disease (LD) patients who did not respond to chemotherapy were given thoracic radiotherapy<BR/>Prophylactic cranial radiotherapy was also given to some patients<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 20:59:12 +0200" MODIFIED_BY="[Empty name]">
<P>To prevent vomiting dexamethasone and metoclopramide (8 and 20 mg respectively) were administered IV prior to the first chemotherapy course and orally after chemotherapy (4 and 10 to 20 mg respectively, every 4 hours over 48 hours). Thereafter the doses of the antiemetics were modified as needed.</P>
<P>If platelet and leukocyte counts had not returned to at least 3 × 10<SUP>9</SUP>/L and 100 × 10<SUP>9</SUP>/L, respectively, by the time of the next treatment cycle, an additional week of no treatment was added before the cycle began to allow blood count recovery. Doses of all chemotherapy agents were reduced by 25% for the duration of the study if 2 treatment cycle delays occurred.</P>
<P>During part of the selection period, patients with limited disease and a good performance status (grade 1 to 2) had the option of undergoing intensive therapy with other protocols.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:52:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kanitz-1992">
<CHAR_METHODS MODIFIED="2015-07-31 10:52:55 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Czechoslovakia, Hungary, Poland and Yugoslavia; multicentric<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Adequate<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically or cytologically confirmed SCLC; measurable and/or evaluable extensive disease; no prior chemotherapy and no prior radiotherapy except for brain metastases; adequate bone marrow, renal, liver and cardiac function; age up to 70 years; any infection controlled; and informed patient's consent.<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 111 (HD - EDX + CPA: 52; HD - EDX + DDP: 59)<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE): 111<BR/>M: 94 (HD - EDX + CPA: 42; HD - EDX + DDP: 52)<BR/>F: 17 (HD - EDX + CPA: 10; HD - EDX + DDP: 7)<BR/>AGE: median: HD - EDX + CPA: 55; HD - EDX + DDP: 56 (range: HD - EDX + CPA: 33 to 69; HD - EDX + DDP: 33 to 70)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:20 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>HD - EDX + CPA: High dose epirubicin 120 mg/m<SUP>2</SUP> intravenously (IV) on day 1, as a bolus injected into a running infusion in combination with cyclophosphamide 800 mg/m<SUP>2</SUP> IV in 500 mL infusion.<BR/>HD - EDX + DDP: High dose epirubicin 120 mg/m<SUP>2</SUP> IV on day 1, as a bolus injected into a running infusion, in combination with cisplatin 60 mg/m<SUP>2</SUP> IV in infusion of at least 1.5 L of saline followed by 500 mL of 10% mannitol if needed.</P>
<P>Both regimens were repeated every 4 weeks</P>
<P>CO-INTERVENTIONS:<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (judged according to World Health Organization criteria)<BR/>Survival<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (judged according to World Health Organization criteria)<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-08 08:44:00 +0200" MODIFIED_BY="[Empty name]">
<P>Other:<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:53:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyss-2002">
<CHAR_METHODS MODIFIED="2015-07-31 10:53:23 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: April 1995 to [not reported]<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:09:44 +0200" MODIFIED_BY="[Empty name]">
<P>INCLUSION CRITERIA: Extensive stage histologically or cytologically documented small cell carcinoma of the bronchus; included patients with disease that was not considered to be limited stage. Patients were allowed to have evaluable or measurable disease. Patients had to have a CALGB performance status of 0 to 2 (except for patients in Arm 4); have a life expectancy &gt;= 2 months and lack other serious comorbidity. Patients were also required to be at least 2 weeks since major surgery; at least 3 weeks from cranial irradiation; and were not allowed to have received prior pelvic or mediastinal radiotherapy, systemic chemotherapy or to have ongoing need for corticosteroid administration. Each patient had to be aware of the nature of his/her disease and willingly give written consent to participate in the study after being informed of the experimental nature of the therapy, alternatives, potential benefits, side effects, risks and discomfort.<BR/>EXCLUSION CRITERIA: patients with a prior or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin or other primary cancer that had been completely resected more than 5 years ago (without radiotherapy or chemotherapy). Pregnant people and patients who were &lt; 16 years of age were excluded. Patients could not have had serious medical or psychiatric illness that would prevent informed consent or intensive treatment or would limit survival to less than 2 years.<BR/>
<BR/>N RANDOMISED: 95<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE):<BR/>M: 66<BR/>F: 24<BR/>AGE: mean: Arm 1 - 60.8; Arm 2 - 64.7; Arm 3 - 58.0; Arm 4 - 61.1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 19:04:01 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Chemotherapy was given every 21 days for 6 cycles in patients with CR, PR or stable disease.<BR/>Arm 1 - consisted of cisplatin 75 mg/m<SUP>2</SUP> intravenously (IV) on day 1 prior to topotecan 1 mg/m<SUP>2</SUP> IV on days 1 to 5.<BR/>Arm 2 - cisplatin 75 mg/m<SUP>2</SUP> IV on day 1 prior to paclitaxel 230 mg/m<SUP>2</SUP> IV over 3 hours on day 1.<BR/>Arm 3 - paclitaxel 230 mg/m<SUP>2</SUP> IV over 3 hours on day 1 prior to topotecan 1 mg/m<SUP>2</SUP> IV on days 1 to 5.<BR/>Arm 4 - paclitaxel 175 mg/m<SUP>2</SUP> IV over 3 hours on day 1 prior to topotecan 1 mg/m<SUP>2</SUP> IV on days 1 to 5.</P>
<P>CO-INTERVENTIONS:<BR/>G-CSF was given for all patients until white blood cell count was 10,000/L after day 15<BR/>Dexamethasone for patients who received paclitaxel. Thirty minutes prior to paclitaxel administration they also received cimetidine, diphenhydramine and dexamethasone.<BR/>For patients who attained a CR from chemotherapy, prophylactic cranial irradiation was allowed at the discretion of the investigator.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]">
<P>Other:<BR/>Only Arm 1 and Arm 3 were considered for this meta-analysis<BR/>Arm 3 was added in October 1997 after early termination of Arms 1 and 3 due to toxicity and after completion of accrual to Arm 2<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:53:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Postmus-1992">
<CHAR_METHODS MODIFIED="2015-07-31 10:53:35 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Multicentre<BR/>DURATION OF STUDY: April 1986 to June 1987<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:46:51 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Newly diagnosed patients with histologically or cytologically proven SCLC; no previous chemotherapy; normal renal function (creatinine clearance &gt; 60 ml/min); normal bilirubin (&lt; 25 µmol/L); ECOG performance score &lt;= 3; age &lt;= 70 years; normal number of leukocytes (&gt; 3.0 x 10<SUP>9</SUP>/L) and platelets (&gt; 100 x 10<SUP>9</SUP>/L). In the case of bone marrow metastases, all values of leukocytes and platelets were acceptable. Informed consent was obtained from all patients.<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 178 (CDE - 63; IMP - 55; VP - 60)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 78<BR/>(N EXTENSIVE): 100<BR/>M: 142<BR/>F: 36<BR/>AGE: median: CDE - 59; IMP - 59; VP - 57 (range: CDE - 39 to 70; IMP - 38 to 69; VP - 39 to 70)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:24 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CDE - cyclophosphamide 1 g/m<SUP>2</SUP> IV on day 1, doxorubicin 45 mg/m<SUP>2</SUP> IV on day 1, and etoposide 100 mg/m<SUP>2</SUP> IV on days 1, 3 and 5. Maximally 5 courses were given at 3-week intervals between courses.</P>
<P>IMP - carboplatin 400 mg/m<SUP>2</SUP> dissolved in 250 ml dextrose 5% and given as a 30 min IV infusion, and ifosfamide 5 g/m<SUP>2</SUP> given as a 24-hour infusion. Mesna 0.6 g/m<SUP>2</SUP> was given as an IV bolus with 200 ml mannitol (20%) before the ifosfamide infusion. During the ifosfamide infusion and the following 12 hours 3.75 g/m<SUP>2</SUP> mesna was given as a continuous infusion. Forced diuresis was established by giving 6 L of dextrose/saline in 38 hours. Maximally 5 courses were given at 4-week intervals.</P>
<P>VP - carboplatin 400 mg/m<SUP>2</SUP> dissolved in 250 ml dextrose 5% and given as a 30 min IV infusion, and vincristine 2 mg IV bolus on day 1 and 8. Maximally 5 courses were given at 4-week intervals.</P>
<P>CO-INTERVENTIONS:<BR/>Patients with a complete response after chemotherapy received prophylactic cranial irradiation 12 x 2.5 Gy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (defined according to standard criteria)<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (defined according to standard criteria)<BR/>Survival<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-08 08:45:23 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:53:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Postmus-1996">
<CHAR_METHODS MODIFIED="2015-07-31 10:53:43 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: September 1988 to February 1992<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:47:09 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically or cytologically proven SCLC; no previous chemotherapy, normal renal function (creatinine clearance &gt; 60 ml/min); normal bilirubin levels (&lt; 25 µmol/L); an ECOG (Easter Cooperative Oncology Group) performance score &lt;= 3; age &lt; 75 years; normal numbers of leukocytes (&gt; 3 × 10<SUP>9</SUP>/L) and platelets (&gt; 100 × 10<SUP>9</SUP>/L); extensive disease; and informed consent obtained from all patients.<BR/>EXCLUSION CRITERIA:<BR/>N SCREENED: 148 (143 eligible)<BR/>N RANDOMISED: 143 (CDE - 73; CDE + VIMP - 70)<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE):<BR/>M: 117<BR/>F: 26<BR/>AGE: median: CDE - 61; CDE + VIMP - 61 (range: CDE - 41 to 73; CDE + VIMP - 29 to 74)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:27 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Standard therapy (CDE) - 1 g/m<SUP>2</SUP> cyclophosphamide intravenously (IV) on day 1, 45 mg/m<SUP>2</SUP> doxorubicin IV on day 1 and 100 mg/m<SUP>2</SUP> etoposide IV on days 1, 3 and 5. A maximum of 5 courses were given at 3-week intervals between courses.<BR/>Alternating therapy (CDE + VIMP) - 2 mg vincristine IV as a bolus dose on days 1 and 8, 400 mg/m<SUP>2</SUP> carboplatin dissolved in 250 ml 5% dextrose and given as a 30 min IV infusion, 5 g/m<SUP>2</SUP> ifosfamide given as a 24-hour infusion and 0.6 g/m<SUP>2</SUP> mesna given as an IV bolus with 200 ml mannitol (20%) before infusion with ifosfamide. During the ifosfamide infusion and over the following 12 hours, 3.75 g/m<SUP>2</SUP> of mesna was given as a continuous infusion. Forced diuresis was established by giving 6 L of dextrose/saline in 38 hours. CDE was given during courses 1, 3 and 5 and VIMP during courses 2 and 4. The interval between CDE and VIMP was 3 weeks and between VIMP and CDE was 4 weeks.</P>
<P>CO-INTERVENTIONS:<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (defined according to standard criteria of the World Health Organization)<BR/>Toxicity<BR/>Survival<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Toxicity<BR/>Survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:53:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quoix-2005">
<CHAR_METHODS MODIFIED="2015-07-31 10:53:52 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Canada and Europe; multicentric<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:19:18 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Aged at least 18 years; histologically proven ED SCLC; no prior chemotherapy or immunotherapy; written informed consent from patients, in accordance with local and national guidelines for the centre; at least one non- CNS indicator lesion, which was bi-dimensionally measurable; an Eastern Cooperative Oncology Group performance status score ? 2; life expectancy of at least 3 months; adequate bone marrow reserves (haemoglobin &gt;= 9.0 g/dL, white blood cells &gt;= 3.5 x 10<SUP>9</SUP>/L, neutrophils &gt;= 1.5 x 10<SUP>9</SUP>/L, platelets &gt;= 100 x 10<SUP>9</SUP>/L) and adequate renal and hepatic function (creatinine &lt;= 1.5 mg/dL, creatinine clearance &gt;= 60 mL/min, serum bilirubin &lt;= 2.0 mg/ dL, aspartate transaminase [AST], alanine transaminase [ALT] and alkaline phosphatase &lt;= 2 times the upper limit of normal, or &lt;= 5 times the upper limit of normal if liver metastases were present.) Patients with brain and/or leptomeningeal metastases scan were included, provided they were asymptomatic on neurological examination and were not receiving corticosteroid therapy.<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 82 (T/C - 41; T/E - 41)<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE): 82<BR/>M: 57<BR/>F: 25<BR/>AGE: median: 61 (range: T/C - 33 to 78; T/E - 25 to 78)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:29 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>T/C- topotecan 1.25 mg/m<SUP>2</SUP> as a 30 min intravenous (IV) infusion daily for 5 consecutive days, followed by cisplatin 50 mg/m<SUP>2</SUP> as a 3-hour infusion after the 5th dose of topotecan. Patients also received fluids for hydration (before and for 24 hours after cisplatin) and antiemetic prophylaxis.<BR/>T/E - topotecan 0.75 mg/m<SUP>2</SUP> as a 30-minute IV infusion daily for 5 consecutive days and etoposide 60 mg/m<SUP>2</SUP> as a 30 to 60-minute IV infusion, daily before each topotecan infusion.</P>
<P>Treatment was repeated every 21 days</P>
<P>CO-INTERVENTIONS:<BR/>Use of therapeutic G-CSF was allowed but not prophylactically<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (evaluated according by strict radiological criteria)<BR/>Disease progression<BR/>Survival<BR/>Toxicity<BR/>Quality of life</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (evaluated according by strict radiological criteria)<BR/>Survival<BR/>Toxicity<BR/>Quality of life<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>Patients who required delays in treatment of more than 2 weeks were considered for alternative cytotoxic therapy off-protocol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:53:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roth-1992">
<CHAR_METHODS MODIFIED="2015-07-31 10:53:59 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: United States of America; multicentric<BR/>DURATION OF STUDY: February 1985 to April 1989<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Adequate<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:21:04 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Age &gt;= 18 years; histologic or cytologic confirmation of SCLC of the lung; no prior chemotherapy or radiotherapy; patients had extensive disease (ED) which is defined as disease spread beyond the primary site, mediastinum and ipsilateral supraclavicular lymph nodes; patients with brain metastases were eligible; adequate bone marrow reserve was required (total leukocyte count &gt;= 4000 / µL and platelet count &gt;= 100 000/ µL) although patients with documented bone marrow involvement were eligible if their leukocyte and platelet count were greater than 3000 /µL and greater than 50 000 /µL, respectively; adequate hepatic function, defined as serum total bilirubin level less than 2.9 mg/dL; adequate renal function with a serum creatinine level &lt;= 1.8 mg/dL for men or &lt;= 1.5 mg/dL for women; a Zubrod performance status of 0 to 3 was required; all patients gave written consent before entry.<BR/>EXCLUSION CRITERIA: Patients with malignant pleural effusions as their only site of metastatic disease; patients with previous or concomitant malignancy other than adequately treated squamous cell or basal cell carcinoma or in situ carcinoma of the uterine cervix; patients with clinical congestive cardiac failure, cardiac arrhythmias requiring medical therapy or who had myocardial infarction within 3 months of diagnosis.<BR/>N RANDOMISED: 437 (EP - 148; CAV - 146; CAV/EP - 143)<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE): 437<BR/>M: 370<BR/>F: 107<BR/>AGE: median EP - 62.2; CAV - 61.7; CAV/EP - 62.6<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:32 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Regimen A: EP - cisplatin 20 mg/m<SUP>2</SUP>/d IV for 5 days in combination with etoposide 80 mg/m<SUP>2</SUP>/d IV for 5 days, repeated every 3 weeks for 4 cycles (12 weeks)</P>
<P>Regimen B: CAV - cyclophosphamide 1000 mg/m<SUP>2</SUP>, doxorubicin 40 mg/m<SUP>2</SUP> and vincristine 1 mg/m<SUP>2</SUP> (maximum 2.0 mg), all given IV on day 1 and repeated every 3 weeks for 6 cycles (18 weeks)</P>
<P>CAV/EP - CAV in the same dosages as in regimen B was given on day 1 and EP given in the same dosages as in regimen A on days 22 to 26, with cycles repeated every 6 weeks for 3 cycles (18 weeks)<BR/>CO-INTERVENTIONS:<BR/>Patients with brain metastases were required to have concomitant whole brain radiotherapy and chemotherapy at the initiation of the study<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>In the cisplatin containing arms, sufficient hydration to ensure a urinary output of at least 100 cc/h before and for 4 hours after the infusion of cisplatin was required</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:54:13 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculier-1990">
<CHAR_METHODS MODIFIED="2015-07-31 10:54:13 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:28:49 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Patients with pathologically proven SCLC (histology was checked by 2 independent pathologists according to the WHO classification) had to have received no prior therapy (radiotherapy, chemotherapy or surgery), have an evaluable or measurable lesion, a Kamofsky performance status of at least 50, no history of prior malignant tumour except non-melanoma skin cancer or in situ carcinoma of the cervix, and no demonstrated brain metastasis. In addition, they had to have adequate haematological (white blood cells &gt;= 3000/mm<SUP>3</SUP> and platelets &gt;= 100,000/mm<SUP>3</SUP>), renal (serum creatinine &lt; 1.5 mg/dl) and hepatic (serum bilirubin &lt; 1.5 mg/dl) functions, be aged &lt;= 75 years, have no uncontrolled infectious disease, be accessible for follow up and provide informed consent.</P>
<P>EXCLUSION CRITERIA:<BR/>N SCREENED: 221 (201 eligible)<BR/>N RANDOMISED: 201 (CEV - 95; EV - 106)<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 99<BR/>(N EXTENSIVE): 102<BR/>M: 181<BR/>F: 20<BR/>AGE: median: CEV - 61; EV - 62 (range: CEV - 37 to 75; EV - 35 to 74)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-15 12:28:06 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CEV - cisplatin 60 mg/m<SUP>2</SUP> on day 1; etoposide 120 mg/m<SUP>2</SUP> on days 1, 2 and 3; vindesine 3 mg/m<SUP>2</SUP> on day 1<BR/>EV - etoposide 120 mg/m<SUP>2</SUP> on days 1, 2 and 3; vindesine 3 mg/m<SUP>2</SUP> on day 1</P>
<P>All drugs were IV administered. Cisplatin was given by IV drip over 15 minutes, after prehydration with 1000 ml of 5% dextrose in half normal saline for 1½ hours. Another litre of the same solution was then infused over 2 hours. Patients received 40 mg IV of furosemide during prehydration and immediately after cisplatin administration. Vindesine was given by IV bolus also after the cisplatin administration and prior to the infusion of etoposide. Etoposide was diluted in 500 ml of saline and given over 1 hour. Administration of high doses of metoclopamide was recommended for control of emesis. Courses were repeated every 3 weeks, according to haematologic status, for a total of 8 courses.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Toxicity<BR/>Survival<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Toxicity<BR/>Survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-31 15:45:50 +0200" MODIFIED_BY="[Empty name]">
<P>Other:<BR/>20 patients were ineligible because of having: non-small cell lung cancer (6), brain metastases initially (5), no brain CT scan at initial workup (5), a history of prior malignant disease (2), thrombocytopenia (1), an incomplete initial workup (1). Of the 201 eligible patients, 18 were not evaluable for response to chemotherapy for the following reasons: loss to follow up (4), treatment refusal (2), workup refusal at evaluation (1), death prior to receiving chemotherapy (1), drug dosage violation (2), and early death considered not due to SCLC or toxicity (8).<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:54:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sculier-1993">
<CHAR_METHODS MODIFIED="2015-07-31 10:54:35 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:30:42 +0200" MODIFIED_BY="[Empty name]">
<P>INCLUSION CRITERIA: Patients with pathologically proven SCLC (using World Health Organization (WHO) classification); no prior therapy (radiotherapy, chemotherapy or surgery); Karnofsky performance status of at least 60; no history of prior malignant tumour except non melanoma skin cancer or in situ carcinoma of the cervix adequate hematologic (WBC count &gt;= 3000/µL and platelet count &gt;= 100,000/ µL), renal (serum creatinine &lt; 1.5 mg/dL) and hepatic (serum bilirubin &lt; 1.5 mg/dL) functions; age less than 75 years; no recent myocardial infarction (&lt; 3 months before date of diagnosis); no congestive cardiac failure or cardiac arrhythmia requiring medical treatment and no uncontrolled hypertension; no uncontrolled infectious disease; patients had to be accessible for follow up and provide informed consent.<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 215 (MDC - 107; SC - 108)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 95<BR/>(N EXTENSIVE): 120<BR/>M: 193<BR/>F: 22<BR/>AGE: median- 61 (range: MDC - 35 to 74; SC - 33 to 74)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-06-15 12:28:14 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>MDC - Adriamycin 25 mg/m<SUP>2</SUP> on day 1, cyclophosphamide 500 mg/m<SUP>2</SUP> on day 1, etoposide 120 mg/m<SUP>2</SUP> on day 1, cisplatin 60 mg/m<SUP>2</SUP> on day 8, vindesine 3 mg/m<SUP>2</SUP> on day 8, vincristine 2 mg total dose on day 15, methotrexate 100 mg/m<SUP>2</SUP> on day 15 with leucovorin.<BR/>SC - Adriamycin 50 mg/m<SUP>2</SUP> on day 1, cyclophosphamide 1 g/m<SUP>2</SUP> on day 1, etoposide 80 mg/m<SUP>2</SUP> on days 1 to 3.<BR/>All drugs were IV administered. Adriamycin, cyclophosphamide, vindesine, vincristine and methotrexate were administered by bolus. Etoposide was diluted in 250 mL of saline and administered over 1 hour. Cisplastin 60 mg/m<SUP>2</SUP> was administered by IV drip over 15 minutes in 250 mL of saline, after prehydration with 1000 mL of 5% dextrose in half normal saline for 1 hour. Another 1 L of the same solution was infused after cisplatin injection over 1 hour.<BR/>Patients received 40 mg of IV furosemide during prehydration. Leucovorin (factor citrovorum) was administered 24 hours after methotrexate infusion at 15 mg oral total dose every 6 hours for 2 days.<BR/>Administration of high dose metoclopramide was recommended for control of emesis.<BR/>Courses were repeated every 3 weeks, according to haematologic status, for a total of 6 courses.<BR/>CO-INTERVENTIONS:<BR/>Those with complete response (CR) received prophylactic cranial irradiation in a dosage of 30 Gy delivered in 10 fractions over 2 weeks, as soon as CR was documented.<BR/>Chest irradiation was performed, but not for patients with limited disease (LD).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (evaluated during regular meetings of the group by at least 3 independent observers)<BR/>Dose-intensity<BR/>Survival<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (evaluated during regular meetings of the group by at least 3 independent observers)<BR/>Survival<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:54:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sekine-2014">
<CHAR_METHODS MODIFIED="2015-07-31 10:54:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>STUDY DESIGN: </B>Parallel group</P>
<P>
<B>LOCATION, NUMBER OF CENTRES: </B>Japan 
</P>
<P>
<B>DURATION OF STUDY: </B>July 2006 &#8211; September 2007; December 2007 &#8211; April 2008</P>
<P>
<B>CONCEALMENT OF ALLOCATION: </B>Not described</P>
<P>
<B>DESCRIBED AS RANDOMISED: </B>Yes 
</P>
<P>
<B>DESCRIBED AS DOUBLE BLIND: </B>No 
</P>
<P>
<B>METHOD OF RANDOMISATION WELL DESCRIBED/APPROPRIATE: </B>Yes</P>
<P>
<B>METHOD OF BLINDING WELL DESCRIBED/APPROPRIATE: </B>N/A<BR/>
<B>DESCRIPTION OF WITHDRAWALS/DROPOUTS: </B>Yes 
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low</P>
<P>
<B>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT):</B> ITT</P>
<P>
<B>COMPLIANCE: </B>
</P>
<P>
<B>CONFOUNDERS: </B>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>
<B>INCLUSION CRITERIA: </B>
</P>
<P>The eligibility criteria were histologically or cytologically proven SCLC; no previous chemotherapy; measurable disease; age &gt;= 70 years; Eastern Cooperative Oncology Group performance status (PS) of 0 to 2; life expectancy of &gt;= 2 months; adequate bone marrow function (white blood cell count of 4.0 x 10^9 to 12 x 10^9/L, neutrophil count &gt;= 2.0x10^9/L, hemoglobin &gt;=9.5 g/dL, and platelet count &gt;=100x10^9/L); adequate liver function (aspartate aminotransferase and alanine aminotransferase &lt;= 2.5 times the upper limit of the normal range and total bilirubin &lt; 1.5 mg/dL); adequate renal function (serum creatinine &lt;= 1.5 mg/dL and glomerular filtration rate [GFR] calculated using the Cockcroft-Gault method &gt;= 30 mL/min); adequate pulmonary function (PaO2 &gt;= 60 Torr under room air); adequate cardiac function (electrocardiogram without abnormal findings requiring treatment and left ventricular ejection fraction measured using echocardiography &gt;= 60%); and written informed consent. Patients who received radiation or surgery for metastatic sites other than the primary site were eligible if they received these treatments two weeks or more before registration for this study.</P>
<P>
<B>EXCLUSION CRITERIA:</B>
</P>
<P>Patients were excluded if they had symptomatic brain metastases; pleural or pericardial effusion or ascites that required drainage; superior vena cava syndrome; abnormal cardiac function that required treatment or a history of this condition; interstitial pneumonitis or lung fibrosis identified on chest radiograph; severe infection; serious syndrome of inappropriate secretion of antidiuretic hormone or uncontrolled diabetes mellitus; gastric or duodenal ulcer; or active prior malignancies with a disease-free interval of less than five years, except for carcinoma in situ. Pregnant or lactating women, men who had no intention of using contraception, and patients who had participated in registration-directed clinical trials in the previous six months were also ineligible.</P>
<P>
<B>N SCREENED: </B>62</P>
<P>
<B>N RANDOMISED: </B>62 (32 in Arm A - non-platinum (amrubicin) and 30 in Arm B - platinum (carboplatin/etoposide)</P>
<P>
<B>N COMPLETED: </B>61 (31 for amrubicin and 30 carboplatin/etoposide)</P>
<P>
<B>ASSESS STAGE: </B>Yes 
</P>
<P>
<B>(N LIMITED): </B>NA 
</P>
<P>
<B>(N EXTENSIVE): </B>62</P>
<P>
<B>M: </B>24 (amrubicin), 24 carboplatin/etoposide</P>
<P>
<B>F: </B>8 (amrubicin), 6 (carboplatin/etoposide)</P>
<P>
<B>MEAN AGE: </B>Median Age: [Amrubicin &#8211;76years (70-88); EP - 75 years (70-82)]</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-08 02:18:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>TYPE: </B>Chemotherapy</P>
<P>
<B>REGIMENS AND DOSE:</B>
</P>
<P>The patients were randomly assigned to receive amrubicin monotherapy (arm A) or carboplatin/etoposide (arm B). In arm A, amrubicin dissolved in 20 mL normal saline was administered once intravenously as a 5-minute infusion on days 1 to 3, every 3 weeks. At the start of the study, the dose of amrubicin was set at 45 mg/m2/ d for 3 days in patients aged &lt; 75 years and at 40 mg/m2/d for 3 days in patients aged &gt;= 75 years. However, 2 of the first 21 patients in arm A who received amrubicin at 45 mg/m2/d died of severe infection associated with serious myelosuppression, and dose reduction was also required in subsequent cycles in 4 of 8 patients who started at 45 mg/m2/d.</P>
<P>
<B>CYCLES: </B>In both arms chemotherapy was repeated every 3 weeks for a total of 4-6 cycles</P>
<P>
<B>DELIVERY: IV</B>
</P>
<P>
<B>CO-INTERVENTIONS PERMITTED: </B>Nil</P>
<P>
<B>CO-INTERVENTIONS: </B>Nil</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-03-10 11:26:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>OUTCOMES MEASURED: </B>
</P>
<P>Primary endpoint: overall survival</P>
<P>Secondary endpoints: objective response rate, toxicity, time to progression and quality of life.</P>
<P>
<B>FOLLOW-UP ASSESSMENT POINTS: </B>
</P>
<P>Objective tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, using CT or MRI for target and nontarget lesions performed every 4 weeks, and every 2 months after the best tumor response was established.</P>
<P>
<B>OUTCOMES INCLUDED IN ANALYSES:</B>
</P>
<P>Survival</P>
<P>Response rate</P>
<P>Toxicity</P>
<P>Quality of Life</P>
<P>
<B>SUB-GROUPS INDENTIFIED:</B>
</P>
<P>Nil &#8211; Extensive Stage SCLC (ED-SCLC) only</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<P>Trial terminated early due to treatment-related deaths in non-platinum (amrubicin) arm</P>
<P>Between July 4, 2006, and September 5, 2007, 21 and 22 patients were enrolled in arms A and B, respectively. Two patients in arm A treated with amrubicin at 45 mg/m2/d died from severe infection associated with grade 4 neutropenia (sepsis in the first cycle in one patient and pneumonia in the third cycle in the other). There were no treatment-related deaths in arm B. The dose of amrubicin was reduced to 40 mg/m2/d in subsequent cycles in 4 of 8 patients who started at 45 mg/m2/d. After a recommendation from the Data Monitoring Committee (DMC), the protocol was amended and amrubicin was administered at 40 mg/m2/d in all patients registered in arm A thereafter. From December 2007 to April 2008, 11 and 8 patients were added to arms A and B, respectively. Of these patients, one in arm A died of amrubicin- induced pneumonitis. Enrollment of patients was then terminated early after a DMC recommendation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:55:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1991">
<CHAR_METHODS MODIFIED="2015-07-31 10:55:14 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY:<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically confirmed small cell lung cancer.<BR/>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 95 (VACE - 48; CVACE - 47)<BR/>N COMPLETED: 78<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 60<BR/>(N EXTENSIVE): 35<BR/>M: 62<BR/>F: 33<BR/>AGE: median: VACE - 61; CVACE - 60 (range: 37 to 75; CVACE - 46 to 72)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:40 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>VACE - 6 cycles of the VACE combination; vincristine 1.2 mg/m2, doxorubicin 40 mg/m<SUP>2</SUP> and cyclophosphamide 700 mg/m<SUP>2</SUP> on day 1, plus etoposide 110 mg/m<SUP>2</SUP> daily for 3 days. This cycle was repeated at 3-weekly intervals.<BR/>CVACE - etoposide 110 mg/m<SUP>2</SUP> for 3 days plus cisplatin 100 mg/m<SUP>2</SUP> with mannitol diuresis on the second day for the first 2 3-weekly cycles.<BR/>VACE in the above doses was administered for the next 2 cycles; cycles 5 and 6, if given, consisted of etoposide and cisplatin in the same doses as before.</P>
<P>The effects of the treatments were assessed formally at the end of cycle 4.</P>
<P>CO-INTERVENTIONS:<BR/>12 complete responders after cycle 6 received prophylactic cranial irradiation.<BR/>Partial responders received further chemotherapy (with mitomycin C and procarbazine) or radiotherapy or no further treatment depending on individual circumstances.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>OUTCOMES MEASURED: <BR/>Tumour response<BR/>Survival<BR/>Cause of death<BR/>Effect of prophylactic cranial irradiation<BR/>FOLLOW-UP ASSESSMENT POINTS: <BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response<BR/>Survival<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 04:24:10 +0200" MODIFIED_BY="[Empty name]">
<P>Patient withdrawal: of the VACE regimen - 4 withdrew due to leukopenia; 1 due to severe vomiting, and of the CVACE regimen - 1 due to renal failure, 4 due to nausea and vomiting or leukopenia and 1 due to cerebral metastases developed after 2 cycles of treatment.</P>
<P>Patients who had not responded were withdrawn 3 weeks after cycle 4.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:55:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Souhami-1997">
<CHAR_METHODS MODIFIED="2015-07-31 10:55:29 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: United Kingdom<BR/>DURATION OF STUDY: February 1993 to December, 1995<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Untreated SCLC based on biopsy findings or on cytologic criteria<BR/>WHO performance status grade 2 or 3 or serum alkaline phosphatase levels greater than 1.5 times the upper limit of normal according to the participating institution.<BR/>Patients over the age of 75 with any stage SCLC</P>
<P>EXCLUSION CRITERIA:<BR/>Patients who were less than 75 years of age with limited SCLC and performance status 0 or 1<BR/>Patients with a medical contraindication to chemotherapy</P>
<P>N RANDOMISED: 155<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 11<BR/>(N EXTENSIVE): 144<BR/>M: 84<BR/>F: 71<BR/>AGE: IV group - 67 (49 to 80); oral group - 66 (50 to 86)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:43 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Intravenous chemotherapy group - alternating cycles of:<BR/>1) PE - cisplatin (60 mg/m<SUP>2</SUP> on day 1) and etopside (120 mg/m<SUP>2</SUP> IV on day 1, 100 mg given orally twice a day on days 2 and 3)<BR/>2) CAV - cyclophosphamide (750 mg/m<SUP>2</SUP>), doxorubicin (50 mg/m<SUP>2</SUP>) and vincristine (2 mg/m<SUP>2</SUP>) all given on day 1</P>
<P>3 alternating cycles of PE and CAV were given at 21-day intervals</P>
<P>Oral etoposide group<BR/>100 mg of oral etopside was given twice daily for 5 days every 212 days for 6 cycles</P>
<P>CO-INTERVENTIONS:<BR/>Palliative therapy was permitted to control symptoms associated with disease progression or for persisting symptoms such as pain</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Survival<BR/>Progression-free survival<BR/>Tumour response<BR/>Toxicity<BR/>Quality of life</P>
<P>FOLLOW-UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:55:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundstrom-2002">
<CHAR_METHODS MODIFIED="2015-07-31 10:55:42 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Norway, multicentric<BR/>DURATION OF STUDY: January 1989 to August 1994<BR/>CONCEALMENT OF ALLOCATION:D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Adequate<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Adequate<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:35:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Histologically/cytologically confirmed SCLC; age of 18 to 75 years; and Eastern Cooperative Oncology Group (ECOG) performance status &lt;= 2; adequate bone marrow and renal function (WBC count &gt;= 3000/µL, platelet count &gt;= 125,000/ µL, serum creatinine level &lt; 125 µmol/L); no serious cardiovascular disease, and no previous or other concomitant malignant disease with the exception of basal cell carcinoma or in situ carcinoma of the cervix. Patients with evidence of brain metastases were eligible.<BR/>EXCLUSION CRITERIA:<BR/>N SCREENED: 440<BR/>N RANDOMISED: 436 (EP - 218; CEV - 218)<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 214<BR/>(N EXTENSIVE): 222<BR/>M: 281<BR/>F: 155<BR/>AGE: median - 64, range (EP - 43 to 75; CEV - 44 to 75)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:46 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>EP - etoposide 100 mg/m<SUP>2</SUP> followed by cisplatin 75 mg/m<SUP>2</SUP>, both administered intravenously (IV) on day 1. Daily oral etoposide 200 mg/m<SUP>2</SUP> was given on days 2 to 4 (on an empty stomach). Standard prehydration and posthydration procedures were followed in conjunction with cisplatin administration.</P>
<P>CEV - epirubicin 50 mg/m<SUP>2</SUP>, cyclophosphamide 1000 mg/m<SUP>2</SUP>, and vincristine 2 mg, all IV on day 1.</P>
<P>For both, chemotherapy was administered every 3 weeks to a maximum of 5 courses. Before the third course, all patients were evaluated for a response.</P>
<P>CO-INTERVENTIONS: Patients who achieved complete remission during the treatment period received prophylactic cranial irradiation.<BR/>ED - SCLC patients did not receive radiotherapy as part of routine therapy. But chest or cranial irradiation was optional if severe symptoms could not be palliated by chemotherapy.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response (according to World Health Organization response criteria)<BR/>Relapse pattern and palliative treatment<BR/>Survival<BR/>Toxicity<BR/>Quality of life</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Tumour response (according to World Health Organization response criteria)<BR/>Relapse pattern and palliative treatment<BR/>Survival<BR/>Toxicity<BR/>Quality of life<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:56:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Urban-1999a">
<CHAR_METHODS MODIFIED="2015-07-31 10:56:05 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: France<BR/>DURATION OF STUDY: October 1 1985 to April 30 1988<BR/>CONCEALMENT OF ALLOCATION: C<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Yes<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Patients with proven small cell lung cancer. There were no eligibility restrictions in terms of age, sex, performance status or extent of disease.<BR/>EXCLUSION CRITERIA: Patients with associated neoplasia, heart failure or renal failure and patients previously treated by surgery, chemotherapy or radiation were eligible for this trial.<BR/>N RANDOMISED: 394 (standard - 203; alternating - 191)<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 169<BR/>(N EXTENSIVE): 225<BR/>M: 361<BR/>F: 33<BR/>AGE: median: standard - 59 ± 11, alternating - 60 ± 19 (range: standard - 28 to 79; alternating - 29 to 81)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:10:10 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>Standard regimen - (CCVAP 16) consisted of CCNU 80 mg orally, cyclophosphamide 1000 mg/m<SUP>2</SUP> IV d1, doxorubicin 45 mg/m<SUP>2</SUP> IV d1, and VP 16 225 mg/m<SUP>2</SUP> IV d1.<BR/>Alternating regimen - consisted of sequence B with CCNU 80 mg orally d1, cyclophosphamide 1000 mg/m<SUP>2</SUP> IV d1, and doxorubicin 45 mg/m<SUP>2</SUP> IV d1 alternating at 4-weekly intervals with sequence C, consisting of cisplatin 80 mg/m2 IV d1, vindesine 3 mg/m<SUP>2</SUP> IV d1, and VP 16 225 mg/m<SUP>2</SUP> IV d1.</P>
<P>Courses of therapy were administered every 28 days in the 2 groups.</P>
<P>CO-INTERVENTIONS:<BR/>Thoracic irradiation was scheduled for patients with limited forms of disease after 2 cycles of chemotherapy in the case of no response. Thoracic irradiation delivered 45 to 50 Grays equivalent.<BR/>Cephalic irradiation was administered to patients with cerebral metastases - 40 Grays equivalent or recommended prophylactically - 24 to 30 Grays equivalent in the case of complete response.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Survival<BR/>Tumour response (defined as best response for at least 1 month at any time during treatment)<BR/>Toxicity<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response (defined as best response for at least 1 month at any time during treatment)<BR/>Toxicity<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:56:17 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Urban-1999b">
<CHAR_METHODS MODIFIED="2015-07-31 10:56:17 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Multicentre, 39 French centres<BR/>DURATION OF STUDY: May 1988 to May 1994<BR/>CONCEALMENT OF ALLOCATION: C<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Appropriate<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Moderate<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Biopsy confirmed limited or extensive disease SCLC</P>
<P>EXCLUSION CRITERIA:<BR/>Patients who had undergone thoracic surgery to remove the tumour<BR/>Patients who had been treated previously with chemotherapy and radiotherapy<BR/>Patients for whom close follow up would be unlikely<BR/>Age &gt;70 years, renal or hepatic disease, serious cardiac disease, history of prior malignant tumour in the past 5 years<BR/>Patients who did not meet the standard criteria for haematological status</P>
<P>N RANDOMISED: 457<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 97<BR/>(N EXTENSIVE): 360<BR/>M:37<BR/>F: 420<BR/>AGE: Mean CDE - 57 +/- 9 years; PCDE - 56 +/- 10 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:51 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CDE - Cyclophosphamide (1000 mg/m<SUP>2</SUP> on day 1), doxorubicin (45 mg/m<SUP>2</SUP> on day 1) and etoposide (150 mg/m<SUP>2</SUP> on days 1 and 2)</P>
<P>PCDE - Cisplatin (100 mg/mm<SUP>2</SUP> on day 1), cyclophosphamide (1000 mg/m<SUP>2</SUP> on day 1), doxorubicin (45 mg/m<SUP>2</SUP> on day 1) and etoposide (150 mg/m<SUP>2</SUP> on days 1 and 2)</P>
<P>Chemotherapy was administered every 4 weeks for a total of 6 courses</P>
<P>CO-INTERVENTIONS:<BR/>Thoracic radiotherapy<BR/>Prophylactic brain irradiation<BR/>Brain irradiation</P>
<P>CLASSIFICATION OF INTERVENTION: (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Survival<BR/>Tumour response<BR/>Haematologic toxicity<BR/>Mortality related to toxic events</P>
<P>
<BR/>FOLLOW UP ASSESSMENT POINTS:<BR/>Monthly during treatment<BR/>2-monthly after treatment up to 1 year<BR/>3-monthly from 1 year after treatment</P>
<P>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response<BR/>Haematologic toxicity<BR/>Mortality related to toxic events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:56:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Veronesi-1994">
<CHAR_METHODS MODIFIED="2015-07-31 10:56:30 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: Italy, multicentric<BR/>DURATION OF STUDY: September 1986 to December 1991<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Adequate<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Histologically-proven small cell lung cancer<BR/>Age &lt; 75 years<BR/>Karnofsky Performance status &gt; 40<BR/>Normal serum creatinine values<BR/>Adequate cardiac function<BR/>Adequate liver function</P>
<P>EXCLUSION CRITERIA:<BR/>Brain metastases<BR/>Previous treatment<BR/>N SCREENED: 139<BR/>N RANDOMISED: 136<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 55 (CEV - 33; PE 22)<BR/>(N EXTENSIVE): 81 (CEV - 33; PE - 48)<BR/>M: 119 (CEV - 59; PE - 60)<BR/>F: 17 (CEV - 7; PE - 10)<BR/>AGE: Median: CEV - 60 (41 to 70); PE - 61 (41 to 70)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:53 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CEV - cyclophosphamide 1000 mg/m<SUP>2</SUP> IV, epirubicin 70 mg/m<SUP>2</SUP> IV, vincristine 1.2 mg/m<SUP>2</SUP> IV every 3 weeks. This was repeated for 6 cycles.</P>
<P>PE - cisplatin 20 mg/m<SUP>2</SUP> IV for 5 consecutive days, every 3 weeks, and etoposide 75 mg/m<SUP>2</SUP> IV given as a 45-min IV infusion on the same days, plus 1000ml of IV fluids with 100 g of mannitol daily. This was repeated for 6 cycles.</P>
<P>CO-INTERVENTIONS:<BR/>After 3 cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions - only in patients with limited disease achieving complete remission).</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE): Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Overall survival<BR/>Tumour response<BR/>Duration of response<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Overall survival<BR/>Tumour response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:56:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wampler-1991">
<CHAR_METHODS MODIFIED="2015-07-31 10:56:43 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: November 1983 to November 1987<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Patients with histologically or cytologically documented extensive disease SCLC without prior treatment<BR/>A performance status of 0, 1, 2 or 3<BR/>Adequate marrow, renal and hepatic function</P>
<P>EXCLUSION CRITERIA:<BR/>N RANDOMISED: 167<BR/>ASSESS STAGE: Yes (ED only)<BR/>(N LIMITED):<BR/>(N EXTENSIVE): 167<BR/>M: 113<BR/>F: 54<BR/>AGE:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:00:57 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>CAV - 3-week cycle of cyclophosphamide (1200 mg/m<SUP>2</SUP>), doxorubicin (45 mg/m<SUP>2</SUP>), vincristine (1.4 mg/m<SUP>2</SUP>, maximum dose 2 mg) all on day 1</P>
<P>MEP/CAV - 3-weekly alternating cycles of<BR/>MEP - methotrexate (40 mg/m<SUP>2</SUP> on day 1), etopside (100 mg/m<SUP>2</SUP> on days 1, 2, 3) and cisplatin (100 mg/m<SUP>2</SUP> on day 3)<BR/>CAV - cyclophosphamide (1200 mg/m<SUP>2</SUP>), doxorubicin (45 mg/m<SUP>2</SUP>), vincristine (1.4 mg/m<SUP>2</SUP>, maximum dose 2 mg) all on day 1</P>
<P>CO-INTERVENTIONS:</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Survival<BR/>Time to progression<BR/>Tumour response<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response<BR/>Toxicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:56:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-White-2001">
<CHAR_METHODS MODIFIED="2015-07-31 10:56:58 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel group<BR/>LOCATION, NUMBER OF CENTRES:<BR/>DURATION OF STUDY: June 1996 to January 1999<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Adequate<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>High<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 20:52:31 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA: Patients with histologically or cytologically proven SCLC were eligible for inclusion in the study. They were required to have either a Karnofsky Performance status &lt;= 50 and/or at least 2 of the following adverse prognostic indicators: Karnofsky Performance status &lt; 60; extensive disease; and elevated alkaline phosphatase, lactic dehydrogenase, or low sodium.</P>
<P>Patients had received no previous chemotherapy, surgery, or radiotherapy for SCLC, and no prior malignancy was permitted except basal cell carcinoma of the skin or in situ carcinoma of the cervix. A creatinine clearance of at least 30 mL per minute was required, and patients with liver derangement were only eligible if their plasma bilirubin was &lt; 35 mol/L.</P>
<P>EXCLUSION CRITERIA:<BR/>N SCREENED:<BR/>N RANDOMISED: 119 (CAV - 59; Carboplatin - 60)<BR/>N COMPLETED:<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): (CAV - 17; Carbo - 21)<BR/>(N EXTENSIVE): (CAV - 42; Carbo - 39)<BR/>M: (CAV - 34; Carbo - 29)<BR/>F: (CAV - 25; Carbo - 31)<BR/>MEAN AGE: CAV - median 70 (46 to 85); Carbo 70 (54 to 76)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:01:00 +0200" MODIFIED_BY="[Empty name]">
<P>REGIMENS:<BR/>Control arm - in the control arm, CAV was administered on day 1 of a 3-week cycle for 4 cycles. This consisted of cyclophosphamide 750 mg/m<SUP>2</SUP> IV, vincristine 1.3 mg/m<SUP>2</SUP> IV (to a maximum of 2 mg), and doxorubicin 40 mg/m<SUP>2</SUP> IV, all given as a bolus on day 1.</P>
<P>Experimental arm - patients who were allocated to the experimental arm received 4 courses of single-agent carboplatin IV infused over 1 hour and administered at 4-week intervals. The dosage was derived from the formula of Calvert giving an AUC of 7.</P>
<P>Dose reductions were not performed. Chemotherapy was delayed if there was evidence of sepsis or persisting myelosuppression (white blood cells &lt; 3000/mm<SUP>3</SUP>, neutrophils &lt; 1500/mm<SUP>3</SUP>, and platelets &lt; 100,000/mm<SUP>3</SUP>) at the time of scheduled retreatment.</P>
<P>Control arm - In the event of significant peripheral neuropathy, vincristine was omitted.</P>
<P>CO-INTERVENTIONS:<BR/>Patients who had limited disease and an objective response to treatment could be considered for consolidation thoracic and prophylactic cranial irradiation.</P>
<P>Erythropoietin and growth factors were permitted at the individual physician's discretion.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Primary: toxicity<BR/>Secondary: objective response rate; survival; quality of life</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Toxicity<BR/>Objective response rate<BR/>Survival<BR/>Quality of life<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-31 10:57:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolf-1987">
<CHAR_METHODS MODIFIED="2015-07-31 10:57:11 +0200" MODIFIED_BY="[Empty name]">
<P>STUDY DESIGN: Parallel study<BR/>LOCATION, NUMBER OF CENTRES: 14 German hospitals<BR/>DURATION OF STUDY: December 1983 to December 1984<BR/>CONCEALMENT OF ALLOCATION: D<BR/>DESCRIBED AS RANDOMISED: Yes<BR/>DESCRIBED AS DOUBLE BLIND: No<BR/>METHOD OF RANDOMISATION WELL-DESCRIBED/APPROPRIATE: Not described<BR/>METHOD OF BLINDING WELL-DESCRIBED/APPROPRIATE: Not described<BR/>DESCRIPTION OF WITHDRAWALS/DROP-OUTS: Not described<BR/>
</P>
<P>
<B>GRADE ASSESSMENT QUALITY RATING: </B>Low<BR/>TYPE OF ANALYSIS (AVAILABLE CASE/TREATMENT RECEIVED/ ITT): ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>ELIGIBILITY<BR/>INCLUSION CRITERIA:<BR/>Histologic proof of small cell lung cancer<BR/>Signs of measurable or evaluable disease<BR/>Karnofsky Performance Status of 50% of more<BR/>Informed patient's consent</P>
<P>EXCLUSION CRITERIA:<BR/>Age &gt; 70 years<BR/>Prior treatment (chemotherapy, radiotherapy or surgery)<BR/>Existence of accessory malignant disease<BR/>Evidence of renal dysfunction<BR/>Chronic hepatic disease<BR/>Advanced respiratory or cardiac insufficiency</P>
<P>N RANDOMISED: 141<BR/>ASSESS STAGE: Yes<BR/>(N LIMITED): 54 (PE - 27; IE - 27)<BR/>(N EXTENSIVE): 87 (PE - 46; IE - 41)<BR/>M: 127 (PE - 65; IE - 62)<BR/>F: 14 (PE - 8; IE - 6)<BR/>AGE:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-07-31 16:01:03 +0200" MODIFIED_BY="[Empty name]">
<P>TYPE: Chemotherapy<BR/>REGIMENS:<BR/>PE - cisplatin 80 mg/m<SUP>2</SUP>, IV on day 1 and etoposide 150 mg/m<SUP>2</SUP>, IV on days 3 through 5.</P>
<P>IE - ifosfamide, 1500 mg/m<SUP>2</SUP> IV on days 1 through 5 and etoposide 120 mg/m<SUP>2</SUP> IV on days 3 through 5.</P>
<P>A maximum of 6 cycles as administered in 3-week intervals</P>
<P>CO-INTERVENTIONS:<BR/>In both arms, second-line therapy consisted of CAV - cyclophosphamide 600 mg/m<SUP>2</SUP> IV on days 1 and 2, Adriamycin 50 mg/m<SUP>2</SUP> IV on day 1 and vincristine 2 mg IV on day 1.</P>
<P>Chest irradiation was applied to patients in both arms. In limited stage, 45 Gy was administered.</P>
<P>Patients achieving a complete response received prophylactic cranial irradiation after the third cycle of chemotherapy respectively after the onset of complete response.</P>
<P>Patients with cranial metastases received brain irradiation immediately.<BR/>Painful metastases were irradiated as necessary.</P>
<P>CLASSIFICATION OF INTERVENTION (ADJUVANT/NEO-ADJUVANT/PALLIATIVE):<BR/>Palliative</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]">
<P>OUTCOMES MEASURED:<BR/>Tumour response<BR/>Survival<BR/>Toxicity</P>
<P>FOLLOW UP ASSESSMENT POINTS:<BR/>OUTCOMES INCLUDED IN ANALYSES:<BR/>Survival<BR/>Tumour response</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ED = extensive disease<BR/>IV = intravenous<BR/>LD = limited disease<BR/>SCLC = small cell lung cancer<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-07-31 16:01:11 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Artel_x002d_Cortes-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-31 16:01:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blackstock-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-31 16:01:10 +0200" MODIFIED_BY="[Empty name]">
<P>Does not compare chemotherapy regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Marinis-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eckardt-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanna-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lara-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McClay-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Niell-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paccagnella-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pathak-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study disease is non-small cell lung cancer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-07-31 16:01:11 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schild-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-07-31 16:01:11 +0200" MODIFIED_BY="[Empty name]">
<P>Does not compare chemotherapy regimens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seifart-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Platinum agents used in all treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 06:03:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Described and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:50:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:51:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:51:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:24:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:27:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:29:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:32:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:33:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 21:02:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:05:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:08:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Sequence generation reported and adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:13:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:28:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:34:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:32:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:33:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:44:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:46:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:58:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:00:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 11:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Described and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:01:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-29 22:56:49 +0200" MODIFIED_BY="Denise M Mitchell" RESULT="YES" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Described as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:07:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:41:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Sequence generation reported and adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:42:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Sequence generation reported and adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:13:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:45:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:47:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:49:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 05:11:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Described and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-03-10 11:26:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 06:20:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:50:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:51:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:51:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:24:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:27:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:29:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:32:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:33:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 21:02:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:05:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:08:38 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Allocation concealment not adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:13:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:28:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:34:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:32:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:33:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:44:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:55:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:58:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:00:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 11:26:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Described and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:01:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:04:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:07:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:41:52 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Allocation concealment not adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:42:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Allocation concealment not adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:13:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:45:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:47:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:49:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 05:11:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Described and appropriate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-03-10 11:27:07 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.05" NO="5" REF_IDS="CMP-001.13 CMP-001.12 CMP-001.11 CMP-001.10 CMP-001.09 CMP-001.08 CMP-001.07 CMP-001.06">
<NAME>Toxicity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Participants</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03">
<NAME>Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Investigators</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4" REF_IDS="CMP-001.04 CMP-001.05">
<NAME>Tumour Response</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.06" NO="6">
<NAME>Quality of Life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-03-09 06:04:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2015-03-09 06:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2015-03-09 06:04:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2015-03-09 06:04:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2015-03-09 06:04:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2015-03-09 06:04:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:50:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:50:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:51:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:51:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 19:46:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 19:46:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:51:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:51:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:11:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:51:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:11:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:12:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:51:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:51:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:52:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:52:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:52:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:15:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 20:24:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 20:24:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:24:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 20:24:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:24:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:24:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 20:27:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 20:27:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:27:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 20:27:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:27:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:27:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 20:29:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 20:29:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:29:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 20:29:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:29:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:29:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 20:32:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 20:32:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:32:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 20:32:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:32:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:32:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 20:33:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 20:33:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 20:33:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 20:33:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 20:33:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 20:33:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-13 21:02:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-13 21:02:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-13 21:02:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-13 21:02:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-13 21:02:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-13 21:03:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 11:05:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 11:05:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 11:05:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 11:05:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 11:05:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 11:05:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 11:08:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 11:08:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 11:08:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 11:08:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 11:09:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 11:09:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 11:13:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 11:13:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 11:13:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 11:13:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 11:14:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 11:14:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 11:28:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 11:28:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 11:28:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 11:28:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 11:28:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 11:28:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 11:34:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 11:34:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 11:34:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 11:34:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 11:35:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 11:35:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 12:32:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 12:32:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 12:32:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 12:32:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 12:32:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 12:32:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 12:33:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 12:33:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 12:33:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 12:33:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 12:33:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 12:33:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 12:44:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 12:44:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 12:44:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 12:44:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 12:44:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 12:45:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 12:55:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 12:55:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 12:55:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 12:55:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 12:55:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 12:55:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 12:58:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 12:58:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 12:58:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 12:58:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 12:58:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 12:58:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 13:00:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 13:00:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 13:00:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 13:00:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 13:00:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 13:00:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-03-10 11:26:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2015-03-10 11:27:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2015-03-10 11:27:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2015-03-10 11:27:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2015-03-10 11:27:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2015-03-10 11:27:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 13:02:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 13:02:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 13:02:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 13:02:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 13:02:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 13:02:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 13:04:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 13:04:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 13:04:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 13:04:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 13:04:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 13:04:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 13:07:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 13:07:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 13:07:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 13:07:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 13:07:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 13:07:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:42:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:42:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:42:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:42:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:42:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 14:42:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:43:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:43:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:43:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:43:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:44:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 14:44:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 13:13:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 13:13:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 13:13:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 13:13:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 13:13:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 13:13:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:45:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:45:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:45:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:45:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:45:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 14:45:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:47:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:47:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:47:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:47:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:47:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 14:47:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-05-15 14:49:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2008-05-15 14:49:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2008-05-15 14:49:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2008-05-15 14:49:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2008-05-15 14:49:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2008-05-15 14:49:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-03-10 05:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2015-03-10 10:35:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2015-03-10 10:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2015-03-10 10:35:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2015-03-10 10:35:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.06" MODIFIED="2015-03-10 10:35:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-06-15 12:28:30 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.03">
<NAME>Survival</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2" REF_IDS="CMP-001.04 CMP-001.05">
<NAME>Tumour Response</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.04" NO="4">
<NAME>Quality of Life</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3" REF_IDS="CMP-001.06 CMP-001.07 CMP-001.08 CMP-001.08 CMP-001.09 CMP-001.10 CMP-001.10 CMP-001.11 CMP-001.12 CMP-001.13">
<NAME>Toxicity</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-15 12:26:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-06-15 12:26:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-06-15 12:26:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-03-09 06:06:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION>
<P>Not assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-05-13 19:47:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 19:47:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-05-13 20:13:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-05-13 20:13:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:13:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:16:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:25:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:28:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:30:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:32:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 20:34:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-13 21:03:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 11:07:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-05-15 11:10:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 11:10:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 11:14:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 11:29:23 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 11:35:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 12:32:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 12:34:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 12:56:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 12:59:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-05-15 13:01:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, dropouts and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 13:01:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-15 12:28:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-06-15 12:28:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-06-15 12:28:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-06-15 12:28:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-05-15 13:02:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 13:03:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 13:09:58 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Data incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-05-15 13:08:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-05-15 13:08:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 13:09:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Data incomplete</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 14:43:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 14:44:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 13:13:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 14:46:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 14:48:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2008-07-31 15:34:05 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Reasons for withdrawals, drop-outs and exclusions not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2008-05-15 14:49:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>N/A</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-06-15 12:26:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2015-06-15 12:26:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2015-06-15 12:27:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>All randomised patients accounted for; withdrawals and dropouts adequately described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.04" MODIFIED="2015-03-10 10:37:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Not assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-03-10 11:29:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 06:15:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 19:32:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:13:18 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>No mention of survival - an expected outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:23:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:26:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:28:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:30:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:33:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:35:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 21:03:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:07:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:10:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:15:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:29:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:35:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:33:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:34:34 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:45:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:56:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:59:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:01:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 11:29:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:03:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:06:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:09:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:43:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:44:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:14:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:46:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:48:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:50:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-10 10:39:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-05-01 15:05:35 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Baka-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 19:32:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chahinian-1989">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:12:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Creech-1982">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:23:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eagan-1981">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:26:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Evans-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:28:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Farris-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:30:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1986">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:33:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fukuoka-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 20:35:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gatzemeier-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-13 21:03:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:07:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greco-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:10:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Havemann-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:15:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:29:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kanitz-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 11:35:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lyss-2002">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:33:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Postmus-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-31 15:34:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Postmus-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:46:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Quoix-2005">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:56:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roth-1992">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 12:59:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1990">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:01:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sculier-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-01 15:05:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sekine-2014">
<DESCRIPTION>
<P>Trial initially interrupted (to allow for a dose reduction) and then terminated early due to treatment related deaths in non-platinum (amrubicin) arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:03:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Smith-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:06:42 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Souhami-1997">
<DESCRIPTION>
<P>Compared a single oral agent versus multiple intravenous agents</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:09:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundstrom-2002">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:43:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999a">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:44:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Urban-1999b">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 13:14:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Veronesi-1994">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:46:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wampler-1991">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:48:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-White-2001">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-05-15 14:50:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wolf-1987">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-de-Jong-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2015-03-16 12:26:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-03-11 06:19:29 +0100" MODIFIED_BY="Jenny Bellorini" NO="1">
<TITLE MODIFIED="2008-07-31 10:38:37 +0200" MODIFIED_BY="Jenny Bellorini">Summary of included studies</TITLE>
<TABLE COLS="6" ROWS="35">
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study ID</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3" VALIGN="TOP">
<P>
<B>Number of Patients</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Radiotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>First Author</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Year</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Platinum group</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Non-platinum group</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Baka</P>
</TD>
<TD>
<P>2008</P>
</TD>
<TD>
<P>141</P>
</TD>
<TD>
<P>139</P>
</TD>
<TD>
<P>280</P>
</TD>
<TD>
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chahinian</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1989</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>105</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>103</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>208</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Creech</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1982</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>19</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>40</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>de Jong</P>
</TD>
<TD>
<P>2007</P>
</TD>
<TD>
<P>101</P>
</TD>
<TD>
<P>102</P>
</TD>
<TD>
<P>203</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eagan</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1981</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>31</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>62</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Evans</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>145</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>144</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>289</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Farris</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>56</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>57</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>113</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fukuoka</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1986</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>34</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>69</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fukuoka</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>97</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>194</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gatzemeier</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1994</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>171</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>173</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>344</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Goodman</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1990</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>194</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>194</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>388</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Greco</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>120</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Havemann</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>150</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>152</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>302</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Jones</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>54</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>50</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>104</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kanitz</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>52</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>111</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lyss</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>13</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>25</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Postmus</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>63</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>123</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Postmus</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1996</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>143</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Quoix</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>41</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>82</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Roth</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>148</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>146</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>294</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sculier</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1990</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>95</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>106</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>201</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sculier</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>108</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>215</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD>
<P>Sekine</P>
</TD>
<TD>
<P>2014</P>
</TD>
<TD>
<P>30</P>
</TD>
<TD>
<P>32</P>
</TD>
<TD>
<P>62</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Smith</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>47</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>48</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>95</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Souhami</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>80</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>75</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>155</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sundstrom</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>218</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>218</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>436</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urban</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999a</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>191</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>203</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>394</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urban</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999b</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>229</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>228</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>457</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Veronesi</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1994</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>70</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>66</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>136</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wampler</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>85</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>170</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>White</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>60</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>59</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>119</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wolf</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>73</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>141</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PCI, TRT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Total: 32</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3036</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>3039</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>6075</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PCI - Prophylactic Cranial Irradiation</P>
<P>TRT - Thoracic Radiotherapy</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2015-03-10 15:29:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-07-31 10:39:16 +0200" MODIFIED_BY="Jenny Bellorini">Studies by subgroup</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Undifferentiated</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>
<B>LD-SCLC</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>
<B>ED-SCLC</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Creech</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1982</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Eagan</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1981</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Chahinian</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1989</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Farris^</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fukuoka </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1986</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fukuoka</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1986</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fukuoka^</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Goodman</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1990</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gatzemeier</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1994</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Postmus </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Havemann </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Greco</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sculier </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1990</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Jones </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Havemann </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sculier</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sundstrom</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Jones </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1993</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Smith </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urban*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999a</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Kanitz</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Souhami</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1997</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wolf</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Lyss</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urban</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999b</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Baka*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2008</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Postmus </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1996</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Veronesi </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1994</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Quoix</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2005</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>White </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2001</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Roth</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1992</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sundstrom</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2002</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Urban*</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1999a</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wampler </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1991</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P> -</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Wolf </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1987</P>
</TD>
</TR>
<TR>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>de Jong</P>
</TD>
<TD>
<P>2007</P>
</TD>
</TR>
<TR>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>Sekine</P>
</TD>
<TD>
<P>2014</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Baka*</P>
</TD>
<TD>
<P>2008</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>^Presented undifferentiated survival data; response data sorted by stage.<BR/>*Presented undifferentiated response data; survival data sorted by stage.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2015-03-10 16:21:57 +0100" MODIFIED_BY="Jenny Bellorini" NO="3">
<TITLE MODIFIED="2008-07-31 10:40:18 +0200" MODIFIED_BY="Jenny Bellorini">Survival by subgroup</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Subgroup</B>
</P>
</TD>
<TD ALIGN="CENTER" COLSPAN="3" VALIGN="TOP">
<P>
<B>% Survival</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>6 months</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>12 months</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>24 months</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Undifferentiated</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>68.09%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30.92%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8.08%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>LD-SCLC</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>88.70%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>57.98%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>21.09%</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>ED-SCLC</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>65.36%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>29.37%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6.93%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2015-03-11 08:24:20 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-07-31 10:41:22 +0200" MODIFIED_BY="Jenny Bellorini">Sensitivity analysis - quality</TITLE>
<TABLE COLS="3" ROWS="14">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All studies</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Higher quality studies</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Overall response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Complete response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Toxic death</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nausea and Vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alopecia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anaemia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Leukopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Thrombocytopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Granulocytopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NSSD - No statistically significant difference between treatment groups.</P>
<P>P - Statistically significant effect favouring platinum-based regimens.</P>
<P>NP - Statistically significant effect favouring non-platinum-based regimens.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2015-03-16 12:26:37 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-07-31 10:41:58 +0200" MODIFIED_BY="Jenny Bellorini">Sensitivity analysis - radiotherapy use</TITLE>
<TABLE COLS="3" ROWS="14">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>All studies</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Only studies using radiotherapy</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>6-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>12-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>24-month survival</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Overall response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Complete response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>P</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Toxic death</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nausea and Vomiting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Alopecia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Anaemia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Leukopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Thrombocytopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NP</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Granulocytopenia</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>NSSD</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NSSD - No statistically significant difference between treatment groups.</P>
<P>P - Statistically significant effect favouring platinum-based regimens.</P>
<P>NP - Statistically significant effect favouring non-platinum-based regimens.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-06-28 10:27:23 +0200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-06-28 10:27:23 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Treatment Regimens</NAME>
<DICH_OUTCOME CHI2="62.97958130853895" CI_END="1.0882176476477814" CI_START="0.999951146901411" CI_STUDY="95" CI_TOTAL="95" DF="35" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0431512281753565" ESTIMABLE="YES" EVENTS_1="2083" EVENTS_2="1983" I2="44.42643270596878" I2_Q="44.31093982127208" ID="CMP-001.01" LOG_CI_END="0.036715764589462886" LOG_CI_START="-2.121714940706189E-5" LOG_EFFECT_SIZE="0.01834727372002796" METHOD="MH" MODIFIED="2015-06-05 14:26:56 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0025618210375224493" P_Q="0.16601378554065338" P_Z="0.050265218028040466" Q="3.5913696398919637" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.006220324270386132" TOTALS="YES" TOTAL_1="2874" TOTAL_2="2881" WEIGHT="100.0" Z="1.957700061554325">
<NAME>6-month survival</NAME>
<GROUP_LABEL_1>Platinum regime</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-platinum regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Non-Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.005165066604869" CI_END="1.096918939459273" CI_START="0.942349335522957" DF="9" EFFECT_SIZE="1.0167009558970586" ESTIMABLE="YES" EVENTS_1="624" EVENTS_2="607" I2="35.737994110041726" ID="CMP-001.01.01" LOG_CI_END="0.04017453509862131" LOG_CI_START="-0.02578807134123777" LOG_EFFECT_SIZE="0.007193231878691755" MODIFIED="2015-06-05 14:26:34 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.12214167120182184" P_Z="0.6690379660365684" STUDIES="10" TAU2="0.0049458654607533814" TOTAL_1="901" TOTAL_2="907" WEIGHT="28.07314139517598" Z="0.4274687182816364">
<NAME>Undifferentiated</NAME>
<DICH_DATA CI_END="1.356324811496129" CI_START="0.8442060306878116" EFFECT_SIZE="1.070054945054945" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" LOG_CI_END="0.1323637064544632" LOG_CI_START="-0.07355154973540864" LOG_EFFECT_SIZE="0.02940607835952726" MODIFIED="2015-03-11 08:27:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.12095564078288785" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.014630267037199003" WEIGHT="2.233385915694412"/>
<DICH_DATA CI_END="1.1731328992070276" CI_START="0.917548430128923" EFFECT_SIZE="1.0375" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="80" LOG_CI_END="0.06934721426630479" LOG_CI_START="-0.03737100349804409" LOG_EFFECT_SIZE="0.015988105384130355" ORDER="2" O_E="0.0" SE="0.06268680937847619" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.003929636070053411" WEIGHT="4.587940779899084"/>
<DICH_DATA CI_END="1.0272375321393479" CI_START="0.7125667489169201" EFFECT_SIZE="0.8555555555555555" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="54" LOG_CI_END="0.011670878815931594" LOG_CI_START="-0.1471744473496176" LOG_EFFECT_SIZE="-0.06775178426684303" MODIFIED="2015-03-11 08:27:28 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.09330653088668932" STUDY_ID="STD-Postmus-1992" TOTAL_1="60" TOTAL_2="63" VAR="0.008706108706108707" WEIGHT="3.119795401459429"/>
<DICH_DATA CI_END="1.139381484068364" CI_START="0.8062240746128718" EFFECT_SIZE="0.9584345479082321" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="78" LOG_CI_END="0.05666915751817213" LOG_CI_START="-0.09354423754563508" LOG_EFFECT_SIZE="-0.01843754001373149" ORDER="4" O_E="0.0" SE="0.08823609182877803" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.007785607901216551" WEIGHT="3.3248352476443785"/>
<DICH_DATA CI_END="1.1907157857089044" CI_START="0.8973327345497397" EFFECT_SIZE="1.0336673797995721" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="83" LOG_CI_END="0.0758081112490868" LOG_CI_START="-0.04704648896916896" LOG_EFFECT_SIZE="0.014380811139958894" ORDER="5" O_E="0.0" SE="0.07216540030828247" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.0052078450016546565" WEIGHT="4.0747923706545865"/>
<DICH_DATA CI_END="1.549656886683621" CI_START="0.8250087092956453" EFFECT_SIZE="1.1306990881458967" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.1902355506120119" LOG_CI_START="-0.08354146674816547" LOG_EFFECT_SIZE="0.05334704193192323" ORDER="6" O_E="0.0" SE="0.1608179752154608" STUDY_ID="STD-Smith-1991" TOTAL_1="47" TOTAL_2="48" VAR="0.025862421152400557" WEIGHT="1.4514785547993216"/>
<DICH_DATA CI_END="1.7722416894161306" CI_START="0.8515120570071126" EFFECT_SIZE="1.228448275862069" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="29" LOG_CI_END="0.2485229484890552" LOG_CI_START="-0.06980919825383418" LOG_EFFECT_SIZE="0.08935687511761052" MODIFIED="2015-06-05 14:26:34 +0200" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.18698987876631326" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.03496521476104053" WEIGHT="1.130673970898564"/>
<DICH_DATA CI_END="1.1884673136672776" CI_START="0.9148532874419868" EFFECT_SIZE="1.0427239466540776" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="148" LOG_CI_END="0.07498724185793738" LOG_CI_START="-0.03864854698613758" LOG_EFFECT_SIZE="0.018169347435899885" MODIFIED="2015-03-11 08:27:26 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.06675022487323638" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.004455592520627626" WEIGHT="4.361912693011824"/>
<DICH_DATA CI_END="1.0855752703240829" CI_START="0.7593657712908687" EFFECT_SIZE="0.9079365079365079" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="54" LOG_CI_END="0.035659941427547776" LOG_CI_START="-0.11954898274866284" LOG_EFFECT_SIZE="-0.04194452066055751" ORDER="9" O_E="0.0" SE="0.09117049035767173" STUDY_ID="STD-Veronesi-1994" TOTAL_1="70" TOTAL_2="66" VAR="0.008312058312058314" WEIGHT="3.204389692885997"/>
<DICH_DATA CI_END="3.346119575427057" CI_START="1.1558994502711826" EFFECT_SIZE="1.9666666666666666" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="14" LOG_CI_END="0.524541456656334" LOG_CI_START="0.06292005718862952" LOG_EFFECT_SIZE="0.29373075692248174" MODIFIED="2015-03-16 13:12:08 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.27115869511011" STUDY_ID="STD-White-2001" TOTAL_1="60" TOTAL_2="59" VAR="0.0735270379338176" WEIGHT="0.5839367682283825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.782602390475047" CI_END="1.0702580506814379" CI_START="0.9353100962074581" DF="7" EFFECT_SIZE="1.0005114493845946" ESTIMABLE="YES" EVENTS_1="459" EVENTS_2="467" I2="45.23806822610669" ID="CMP-001.01.02" LOG_CI_END="0.02948850336303827" LOG_CI_START="-0.02904437763626985" LOG_EFFECT_SIZE="2.220628633842002E-4" MODIFIED="2015-03-11 08:27:23 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0775858021752377" P_Z="0.9881347149772666" STUDIES="8" TAU2="0.0037744464697267626" TOTAL_1="516" TOTAL_2="528" WEIGHT="30.056352662361117" Z="0.01487147760733111">
<NAME>Limited Disease</NAME>
<DICH_DATA CI_END="1.0456118709163191" CI_START="0.774666032903929" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.019370505180930087" LOG_CI_START="-0.11088548630228032" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2015-03-11 08:27:18 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.07651301417479446" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.005854241338112298" WEIGHT="3.8566536031313183"/>
<DICH_DATA CI_END="1.3080360508972753" CI_START="0.7492912747532299" EFFECT_SIZE="0.99" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.11661971378182216" LOG_CI_START="-0.1253493245867223" LOG_EFFECT_SIZE="-0.004364805402450088" MODIFIED="2015-03-11 08:27:20 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.14213381090374025" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="10" TOTAL_2="11" VAR="0.020202020202020193" WEIGHT="1.7624256246031753"/>
<DICH_DATA CI_END="1.0614798072380764" CI_START="0.9420810393011204" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="178" LOG_CI_END="0.025911736901932526" LOG_CI_START="-0.02591173690193252" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-11 08:27:20 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.030441365042722893" STUDY_ID="STD-Goodman-1990" TOTAL_1="194" TOTAL_2="194" VAR="9.266767056643112E-4" WEIGHT="6.515658402217673"/>
<DICH_DATA CI_END="1.1380033427582388" CI_START="0.8292569061241575" EFFECT_SIZE="0.9714407502131287" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" LOG_CI_END="0.05614353775265981" LOG_CI_START="-0.08131090295092962" LOG_EFFECT_SIZE="-0.012583682599134881" ORDER="14" O_E="0.0" SE="0.08074141887974345" STUDY_ID="STD-Havemann-1987" TOTAL_1="51" TOTAL_2="53" VAR="0.006519176722714192" WEIGHT="3.655356437075655"/>
<DICH_DATA CI_END="1.5559205410744046" CI_START="0.8895589514018195" EFFECT_SIZE="1.1764705882352942" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.19198741434128969" LOG_CI_START="-0.05082526576987513" LOG_EFFECT_SIZE="0.07058107428570728" MODIFIED="2015-03-11 08:27:22 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.14262937023944944" STUDY_ID="STD-Jones-1993" TOTAL_1="17" TOTAL_2="15" VAR="0.020343137254901944" WEIGHT="1.7530628271443232"/>
<DICH_DATA CI_END="1.2691278707531015" CI_START="1.0124596439777795" EFFECT_SIZE="1.133552271483306" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="87" LOG_CI_END="0.10350538156258321" LOG_CI_START="0.005377721519246394" LOG_EFFECT_SIZE="0.0544415515409148" MODIFIED="2015-03-11 07:54:18 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.0576406732492072" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="105" TOTAL_2="109" VAR="0.0033224472126218707" WEIGHT="4.879862945809777"/>
<DICH_DATA CI_END="0.9987215096871578" CI_START="0.7846369145761904" EFFECT_SIZE="0.8852309099222679" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="81" LOG_CI_END="-5.555965261494312E-4" LOG_CI_START="-0.10533126360437502" LOG_EFFECT_SIZE="-0.052943430065262205" MODIFIED="2015-03-11 07:54:23 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.06154574548966637" STUDY_ID="STD-Urban-1999a" TOTAL_1="81" TOTAL_2="88" VAR="0.003787878787878788" WEIGHT="4.652924874641199"/>
<DICH_DATA CI_END="1.3144909518977888" CI_START="0.8988076170820968" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" LOG_CI_END="0.1187576010514449" LOG_CI_START="-0.04633325574255547" LOG_EFFECT_SIZE="0.03621217265444471" MODIFIED="2015-03-11 08:27:23 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.09697518649371681" STUDY_ID="STD-Wolf-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.009404186795491154" WEIGHT="2.9804079477379983"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.15230231796424" CI_END="1.1681728227927002" CI_START="1.0206515372579539" DF="17" EFFECT_SIZE="1.0919237094991265" ESTIMABLE="YES" EVENTS_1="1000" EVENTS_2="909" I2="37.39020801653115" ID="CMP-001.01.03" LOG_CI_END="0.06750709828403957" LOG_CI_START="0.008877494019375416" LOG_EFFECT_SIZE="0.03819229615170751" MODIFIED="2015-06-05 14:26:56 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.05587171694250348" P_Z="0.010664442229825986" STUDIES="18" TAU2="0.007327086802596723" TOTAL_1="1457" TOTAL_2="1446" WEIGHT="41.8705059424629" Z="2.5535060617610075">
<NAME>Extensive Disease</NAME>
<DICH_DATA CI_END="1.01557411077857" CI_START="0.6899564059431307" EFFECT_SIZE="0.8370793650793651" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="75" LOG_CI_END="0.006711621219685847" LOG_CI_START="-0.16117834876484327" LOG_EFFECT_SIZE="-0.07723336377257874" MODIFIED="2015-03-11 08:27:07 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.09861939943766714" STUDY_ID="STD-Chahinian-1989" TOTAL_1="105" TOTAL_2="103" VAR="0.009725785945446142" WEIGHT="2.920299454222133"/>
<DICH_DATA CI_END="1.3140370040336053" CI_START="0.8041251731320764" EFFECT_SIZE="1.027934936350778" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="56" LOG_CI_END="0.1186075953769747" LOG_CI_START="-0.09467634208584275" LOG_EFFECT_SIZE="0.011965626645565967" MODIFIED="2015-06-05 14:26:42 +0200" MODIFIED_BY="[Empty name]" ORDER="547" O_E="0.0" SE="0.1252840406381767" STUDY_ID="STD-de-Jong-2007" TOTAL_1="101" TOTAL_2="102" VAR="0.01569609083862831" WEIGHT="2.1247734507961265"/>
<DICH_DATA CI_END="1.3806445059847374" CI_START="1.0532922339077875" EFFECT_SIZE="1.205911330049261" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="98" LOG_CI_END="0.14008186904652362" LOG_CI_START="0.02254888207409766" LOG_EFFECT_SIZE="0.08131537556031063" ORDER="20" O_E="0.0" SE="0.06903945834527166" STUDY_ID="STD-Evans-1987" TOTAL_1="145" TOTAL_2="144" VAR="0.0047664468086085" WEIGHT="4.238498884289324"/>
<DICH_DATA CI_END="1.7530559714168346" CI_START="0.8583360346988754" EFFECT_SIZE="1.2266666666666666" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.24379578243116992" LOG_CI_START="-0.06634265452345954" LOG_EFFECT_SIZE="0.08872656395385518" MODIFIED="2015-03-11 08:27:08 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.18217685307717182" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="25" TOTAL_2="23" VAR="0.033188405797101445" WEIGHT="1.1816523110618924"/>
<DICH_DATA CI_END="1.2585335067208854" CI_START="0.9467508923844823" EFFECT_SIZE="1.0915666358879654" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="114" LOG_CI_END="0.09986478253060709" LOG_CI_START="-0.023764276851473337" LOG_EFFECT_SIZE="0.03805025283956688" MODIFIED="2015-06-05 14:26:42 +0200" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.07262032145474775" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.005273711088190897" WEIGHT="4.051441944235159"/>
<DICH_DATA CI_END="1.519395452701559" CI_START="0.9876461044633351" EFFECT_SIZE="1.225" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="40" LOG_CI_END="0.18167082229889944" LOG_CI_START="-0.005398644897796828" LOG_EFFECT_SIZE="0.0881360887005513" MODIFIED="2015-03-11 08:27:10 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.10988553104013646" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.012074829931972793" WEIGHT="2.54534159401929"/>
<DICH_DATA CI_END="1.3943209149871643" CI_START="0.9007577019828504" EFFECT_SIZE="1.1206896551724137" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="58" LOG_CI_END="0.14436274188829326" LOG_CI_START="-0.04539201572845679" LOG_EFFECT_SIZE="0.04948536307991826" ORDER="24" O_E="0.0" SE="0.11146288392527805" STUDY_ID="STD-Havemann-1987" TOTAL_1="99" TOTAL_2="99" VAR="0.012423974492940007" WEIGHT="2.4976759679404195"/>
<DICH_DATA CI_END="2.036743321029577" CI_START="0.8306187607573394" EFFECT_SIZE="1.3006756756756757" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="16" LOG_CI_END="0.3089363008291243" LOG_CI_START="-0.08059826393000018" LOG_EFFECT_SIZE="0.11416901844956209" MODIFIED="2015-03-11 08:27:11 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.2288145315667033" STUDY_ID="STD-Jones-1993" TOTAL_1="37" TOTAL_2="35" VAR="0.05235608985608986" WEIGHT="0.7949857917166858"/>
<DICH_DATA CI_END="1.2977938903572337" CI_START="0.839372570551885" EFFECT_SIZE="1.0437109723461195" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.1132057252932348" LOG_CI_START="-0.07604522699085778" LOG_EFFECT_SIZE="0.018580249151188492" MODIFIED="2015-06-05 14:26:51 +0200" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.1111669461789984" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.012358089922764326" WEIGHT="2.5065334681487283"/>
<DICH_DATA CI_END="1.231913683990952" CI_START="0.34296234021141303" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09058027935464283" LOG_CI_START="-0.46475356606893165" LOG_EFFECT_SIZE="-0.18708664335714442" ORDER="27" O_E="0.0" SE="0.326205849748677" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.10641025641025642" WEIGHT="0.4134526935655262"/>
<DICH_DATA CI_END="1.5690729327682786" CI_START="0.6931169340162044" EFFECT_SIZE="1.042857142857143" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" LOG_CI_END="0.19564313068870112" LOG_CI_START="-0.15919349047630296" LOG_EFFECT_SIZE="0.0182248201061991" MODIFIED="2015-06-05 14:26:52 +0200" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.20843278774192614" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.04344422700587084" WEIGHT="0.9376389348860051"/>
<DICH_DATA CI_END="1.591621696866374" CI_START="1.0227455570817316" EFFECT_SIZE="1.2758620689655173" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" LOG_CI_END="0.20183985078417402" LOG_CI_START="0.009767601551903874" LOG_EFFECT_SIZE="0.10580372616803894" MODIFIED="2015-06-05 14:26:55 +0200" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.11282418997200305" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.012729297842838633" WEIGHT="2.4574324850394778"/>
<DICH_DATA CI_END="1.152295041707072" CI_START="0.8608559929185136" EFFECT_SIZE="0.9959719334719335" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="104" LOG_CI_END="0.06156369313200412" LOG_CI_START="-0.06506949281072924" LOG_EFFECT_SIZE="-0.0017528998393625747" MODIFIED="2015-03-11 07:56:03 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.07438496026714159" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.005533122313944233" WEIGHT="3.9620222567178223"/>
<DICH_DATA CI_END="1.1412359350377945" CI_START="0.7324676183801165" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.05737543818913353" LOG_CI_START="-0.13521157024987285" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2015-06-05 14:26:54 +0200" MODIFIED_BY="[Empty name]" ORDER="861" O_E="0.0" SE="0.11312656207813906" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.01279761904761905" WEIGHT="2.448604256600839"/>
<DICH_DATA CI_END="1.5476067782382414" CI_START="0.9861239227131906" EFFECT_SIZE="1.2353671790094707" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="57" LOG_CI_END="0.1896606231847842" LOG_CI_START="-0.006068505374447299" LOG_EFFECT_SIZE="0.09179605890516845" ORDER="31" O_E="0.0" SE="0.11497225899050478" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="113" TOTAL_2="109" VAR="0.013218620337379708" WEIGHT="2.395573314286689"/>
<DICH_DATA CI_END="1.1705263445068679" CI_START="0.7903232756933521" EFFECT_SIZE="0.9618181818181818" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="75" LOG_CI_END="0.06838119261206085" LOG_CI_START="-0.10219522753017704" LOG_EFFECT_SIZE="-0.016907017459058097" MODIFIED="2008-05-27 01:27:15 +0200" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.10019743355844803" STUDY_ID="STD-Urban-1999a" TOTAL_1="110" TOTAL_2="115" VAR="0.010039525691699606" WEIGHT="2.8639512091959993"/>
<DICH_DATA CI_END="1.704357048776855" CI_START="1.0658771071379978" EFFECT_SIZE="1.3478260869565217" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="46" LOG_CI_END="0.2315605810821339" LOG_CI_START="0.027707134551225743" LOG_EFFECT_SIZE="0.1296338578166798" MODIFIED="2015-06-05 14:26:56 +0200" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.11974452358309019" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.014338750928141242" WEIGHT="2.2650540703113218"/>
<DICH_DATA CI_END="1.826385115826646" CI_START="0.9202679259965507" EFFECT_SIZE="1.2964426877470356" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="22" LOG_CI_END="0.2615923592023415" LOG_CI_START="-0.036085714130619145" LOG_EFFECT_SIZE="0.11275332253586118" MODIFIED="2015-03-11 08:27:16 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.17485757380600883" STUDY_ID="STD-Wolf-1987" TOTAL_1="46" TOTAL_2="41" VAR="0.030575171117323822" WEIGHT="1.2655738554294595"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="58.745730777766504" CI_END="1.1566875902818812" CI_START="0.9682444645732875" CI_STUDY="95" CI_TOTAL="95" DF="37" EFFECT_MEASURE="RR" EFFECT_SIZE="1.05827990462403" ESTIMABLE="YES" EVENTS_1="1100" EVENTS_2="1046" I2="37.01669974968906" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.06321607620530928" LOG_CI_START="-0.014014977184273676" LOG_EFFECT_SIZE="0.02460054951051781" METHOD="MH" MODIFIED="2015-03-16 13:12:41 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.012921052616295614" P_Q="0.611586744995479" P_Z="0.21180343467558282" Q="0.9833971348712143" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="31" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.024215276329919648" TOTALS="YES" TOTAL_1="3015" TOTAL_2="3019" WEIGHT="100.0" Z="1.2486218670950515">
<NAME>12-month survival</NAME>
<GROUP_LABEL_1>Platinum regime</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Non-Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.61912792976494" CI_END="1.220048730777182" CI_START="0.821052262060375" DF="9" EFFECT_SIZE="1.0008615140110517" ESTIMABLE="YES" EVENTS_1="278" EVENTS_2="281" I2="45.84553390505554" ID="CMP-001.02.01" LOG_CI_END="0.08637717746570762" LOG_CI_START="-0.08562919805467174" LOG_EFFECT_SIZE="3.739897055179578E-4" MODIFIED="2015-03-16 13:12:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05502540827701452" P_Z="0.9931997012330402" STUDIES="10" TAU2="0.0428976423728871" TOTAL_1="901" TOTAL_2="907" WEIGHT="25.802706300582113" Z="0.008523013768371394">
<NAME>Undifferentiated</NAME>
<DICH_DATA CI_END="7.469851971799161" CI_START="1.3908053828716462" EFFECT_SIZE="3.2232142857142856" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" LOG_CI_END="0.8733119955948132" LOG_CI_START="0.14326636287613945" LOG_EFFECT_SIZE="0.5082891792354763" MODIFIED="2015-03-16 12:07:13 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.4288324184431133" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.18389724310776942" WEIGHT="0.9889194393944586"/>
<DICH_DATA CI_END="1.4310190072813342" CI_START="0.6988027377077338" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.15564540224515577" LOG_CI_START="-0.15564540224515586" LOG_EFFECT_SIZE="0.0" ORDER="36" O_E="0.0" SE="0.18285375947194285" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.03343549735302313" WEIGHT="3.5698829851815175"/>
<DICH_DATA CI_END="1.0460862769225423" CI_START="0.4227423777137884" EFFECT_SIZE="0.665" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" LOG_CI_END="0.019567504843075532" LOG_CI_START="-0.3739242142368663" LOG_EFFECT_SIZE="-0.17717835469689538" MODIFIED="2015-03-16 12:07:14 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.23113898360298119" STUDY_ID="STD-Postmus-1992" TOTAL_1="60" TOTAL_2="63" VAR="0.05342522974101921" WEIGHT="2.6507621661461838"/>
<DICH_DATA CI_END="1.0843001040787659" CI_START="0.5427007546628407" EFFECT_SIZE="0.7671052631578947" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="48" LOG_CI_END="0.035149499460110006" LOG_CI_START="-0.2654395745036645" LOG_EFFECT_SIZE="-0.11514503752177727" ORDER="38" O_E="0.0" SE="0.17656750998623447" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.03117608558273901" WEIGHT="3.715498390846653"/>
<DICH_DATA CI_END="1.2499190830612223" CI_START="0.6440105946739625" EFFECT_SIZE="0.897196261682243" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="45" LOG_CI_END="0.09688189867407335" LOG_CI_START="-0.19110698796535588" LOG_EFFECT_SIZE="-0.047112544645641234" ORDER="39" O_E="0.0" SE="0.16916609757998083" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.028617168570439597" WEIGHT="3.895456976133399"/>
<DICH_DATA CI_END="1.8460080474579317" CI_START="0.5650061420112054" EFFECT_SIZE="1.0212765957446808" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.26623358995043234" LOG_CI_START="-0.2479468310706929" LOG_EFFECT_SIZE="0.009143379439869719" ORDER="40" O_E="0.0" SE="0.302032124541942" STUDY_ID="STD-Smith-1991" TOTAL_1="47" TOTAL_2="48" VAR="0.09122340425531915" WEIGHT="1.7828211047623876"/>
<DICH_DATA CI_END="5.396506447988355" CI_START="0.8867137093450067" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7321127003115122" LOG_CI_START="-0.0522165769228104" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2015-03-16 13:12:31 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.4607188999399794" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.21226190476190473" WEIGHT="0.8703017986897134"/>
<DICH_DATA CI_END="1.497078673332917" CI_START="0.8088825997931745" EFFECT_SIZE="1.1004366812227073" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="57" LOG_CI_END="0.17524462365405685" LOG_CI_START="-0.09211450677074466" LOG_EFFECT_SIZE="0.04156505844165606" MODIFIED="2015-03-16 12:07:39 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.1570480766605683" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.02466409838278374" WEIGHT="4.210498134703025"/>
<DICH_DATA CI_END="1.5369950624119195" CI_START="0.6707932526093245" EFFECT_SIZE="1.0153846153846153" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.18667247233338102" LOG_CI_START="-0.17341131453535483" LOG_EFFECT_SIZE="0.006630578899013076" ORDER="43" O_E="0.0" SE="0.21151499885018732" STUDY_ID="STD-Veronesi-1994" TOTAL_1="70" TOTAL_2="66" VAR="0.04473859473859474" WEIGHT="2.9846985073367827"/>
<DICH_DATA CI_END="1.9448962770927072" CI_START="0.4108844514995382" EFFECT_SIZE="0.8939393939393939" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2888964449998034" LOG_CI_START="-0.38628029279925247" LOG_EFFECT_SIZE="-0.048691923899724494" ORDER="44" O_E="0.0" SE="0.3966021579619195" STUDY_ID="STD-White-2001" TOTAL_1="60" TOTAL_2="59" VAR="0.15729327170005136" WEIGHT="1.1338667973879926"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="22.244334664690257" CI_END="1.3862514443123368" CI_START="0.9488384113737439" DF="8" EFFECT_SIZE="1.1468777695054848" ESTIMABLE="YES" EVENTS_1="363" EVENTS_2="338" I2="64.0357865470399" ID="CMP-001.02.02" LOG_CI_END="0.14184201164165383" LOG_CI_START="-0.022807742287155465" LOG_EFFECT_SIZE="0.059517134677249214" MODIFIED="2015-03-16 12:08:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.004482797827467744" P_Z="0.15649326316164314" STUDIES="9" TAU2="0.04526267551282561" TOTAL_1="597" TOTAL_2="612" WEIGHT="31.712878549167325" Z="1.4169646494687833">
<NAME>Limited Disease</NAME>
<DICH_DATA CI_END="1.6864811446092198" CI_START="0.9017973384477409" EFFECT_SIZE="1.2332332332332332" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="37" LOG_CI_END="0.22698149000316487" LOG_CI_START="-0.04489105079831622" LOG_EFFECT_SIZE="0.09104521960242433" MODIFIED="2015-03-10 13:22:30 +0100" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.1596992762575716" STUDY_ID="STD-Baka-2008" TOTAL_1="81" TOTAL_2="84" VAR="0.025503858837192174" WEIGHT="4.139382460325347"/>
<DICH_DATA CI_END="1.3749453725461018" CI_START="0.7273016222806118" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.13828544371313603" LOG_CI_START="-0.13828544371313603" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-16 12:07:48 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.1624591083221647" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.02639296187683285" WEIGHT="4.0666603570054285"/>
<DICH_DATA CI_END="3.270590916484755" CI_START="0.36996372548496936" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5146262262332614" LOG_CI_START="-0.43184085591681115" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2015-03-16 12:07:53 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.5559594491425693" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="10" TOTAL_2="11" VAR="0.3090909090909091" WEIGHT="0.6174698372112081"/>
<DICH_DATA CI_END="1.153698989438863" CI_START="0.892458116984615" EFFECT_SIZE="1.0147058823529411" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="136" LOG_CI_END="0.06209251221817483" LOG_CI_START="-0.049412156156136866" LOG_EFFECT_SIZE="0.006340178031018975" MODIFIED="2015-03-16 12:07:57 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.06549839416008096" STUDY_ID="STD-Goodman-1990" TOTAL_1="194" TOTAL_2="194" VAR="0.004290039637549327" WEIGHT="7.219934565474023"/>
<DICH_DATA CI_END="2.159002731500191" CI_START="0.9931988802236081" EFFECT_SIZE="1.464349376114082" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" LOG_CI_END="0.334253191789863" LOG_CI_START="-0.0029637787600247487" LOG_EFFECT_SIZE="0.16564470651491914" ORDER="48" O_E="0.0" SE="0.1980829177519296" STUDY_ID="STD-Havemann-1987" TOTAL_1="51" TOTAL_2="53" VAR="0.0392368423051177" WEIGHT="3.2434932115827633"/>
<DICH_DATA CI_END="2.843851013645817" CI_START="0.6159711234522481" EFFECT_SIZE="1.3235294117647058" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.45390684042398854" LOG_CI_START="-0.21043964695781145" LOG_EFFECT_SIZE="0.12173359673308855" MODIFIED="2015-03-16 12:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3902404152562192" STUDY_ID="STD-Jones-1993" TOTAL_1="17" TOTAL_2="15" VAR="0.15228758169934642" WEIGHT="1.16602370268227"/>
<DICH_DATA CI_END="1.8489434140882617" CI_START="1.0479714421840933" EFFECT_SIZE="1.391991341991342" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.26692362001516595" LOG_CI_START="0.020349448038118584" LOG_EFFECT_SIZE="0.14363653402664228" ORDER="50" O_E="0.0" SE="0.1448388891811539" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="105" TOTAL_2="109" VAR="0.020978303819230583" WEIGHT="4.553888303915608"/>
<DICH_DATA CI_END="0.9123857580697043" CI_START="0.50533205007491" EFFECT_SIZE="0.6790123456790124" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="56" LOG_CI_END="-0.03982150248352235" LOG_CI_START="-0.2964231562852895" LOG_EFFECT_SIZE="-0.16812232938440588" ORDER="51" O_E="0.0" SE="0.15072908164182977" STUDY_ID="STD-Urban-1999a" TOTAL_1="81" TOTAL_2="88" VAR="0.022719256052589388" WEIGHT="4.384969991306128"/>
<DICH_DATA CI_END="3.139988068568055" CI_START="1.1607139962272635" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.4969279978296163" LOG_CI_START="0.06472522132177218" LOG_EFFECT_SIZE="0.2808266095756942" MODIFIED="2015-03-16 12:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.2538780503589557" STUDY_ID="STD-Wolf-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.06445406445406446" WEIGHT="2.3210561196645507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.68400569315525" CI_END="1.1829559347116358" CI_START="0.9434064482754284" DF="18" EFFECT_SIZE="1.0564129196638234" ESTIMABLE="YES" EVENTS_1="459" EVENTS_2="427" I2="3.6609156750890426" ID="CMP-001.02.03" LOG_CI_END="0.07296856739377189" LOG_CI_START="-0.025301159634873203" LOG_EFFECT_SIZE="0.02383370387944933" MODIFIED="2015-03-16 13:12:41 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4115199012291806" P_Z="0.3417496055621032" STUDIES="19" TAU2="0.0023410020383799967" TOTAL_1="1517" TOTAL_2="1500" WEIGHT="42.484415150250555" Z="0.9507139713188909">
<NAME>Extensive Disease</NAME>
<DICH_DATA CI_END="2.1007204824358494" CI_START="0.3855819975919787" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.32236826991595013" LOG_CI_START="-0.4138832510373004" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2015-03-10 13:23:22 +0100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.43247778791174585" STUDY_ID="STD-Baka-2008" TOTAL_1="60" TOTAL_2="54" VAR="0.18703703703703703" WEIGHT="0.9742213601031237"/>
<DICH_DATA CI_END="1.2250820197292527" CI_START="0.5392505447586503" EFFECT_SIZE="0.8127891156462586" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.08816516586249777" LOG_CI_START="-0.26820940749466854" LOG_EFFECT_SIZE="-0.09002212081608539" MODIFIED="2015-03-16 12:08:15 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.20933618847258834" STUDY_ID="STD-Chahinian-1989" TOTAL_1="105" TOTAL_2="103" VAR="0.043821639804231025" WEIGHT="3.024924228598078"/>
<DICH_DATA CI_END="1.8864650314137719" CI_START="0.7358722332238435" EFFECT_SIZE="1.1782178217821782" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="24" LOG_CI_END="0.275648759282685" LOG_CI_START="-0.1331975840629087" LOG_EFFECT_SIZE="0.07122558760988816" MODIFIED="2015-03-16 13:12:35 +0100" MODIFIED_BY="[Empty name]" ORDER="548" O_E="0.0" SE="0.2401583659032411" STUDY_ID="STD-de-Jong-2007" TOTAL_1="101" TOTAL_2="102" VAR="0.05767604071331504" WEIGHT="2.5131665173321354"/>
<DICH_DATA CI_END="2.0305174656444467" CI_START="0.9437784007155754" EFFECT_SIZE="1.3843260188087774" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="33" LOG_CI_END="0.30760672945786244" LOG_CI_START="-0.025129966129939826" LOG_EFFECT_SIZE="0.14123838166396135" ORDER="54" O_E="0.0" SE="0.19545118206148188" STUDY_ID="STD-Evans-1987" TOTAL_1="145" TOTAL_2="144" VAR="0.038201164569230533" WEIGHT="3.2973125844490427"/>
<DICH_DATA CI_END="6.83911823001819" CI_START="0.9359247471267906" EFFECT_SIZE="2.53" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.835000111585153" LOG_CI_START="-0.028759069233517252" LOG_EFFECT_SIZE="0.40312052117581787" MODIFIED="2015-03-16 12:08:20 +0100" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.5073764184897892" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="25" TOTAL_2="23" VAR="0.2574308300395257" WEIGHT="0.7307273610355685"/>
<DICH_DATA CI_END="1.4294165138388488" CI_START="0.8521544418919571" EFFECT_SIZE="1.1036682615629985" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="66" LOG_CI_END="0.15515879513443548" LOG_CI_START="-0.06948168788235272" LOG_EFFECT_SIZE="0.04283855362604139" MODIFIED="2015-03-16 13:12:36 +0100" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.13195493171238626" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.017412104003220522" WEIGHT="4.944017961405134"/>
<DICH_DATA CI_END="1.7542338546885374" CI_START="0.6838007840600873" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.24408748813547257" LOG_CI_START="-0.1650704055681253" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2015-03-16 12:08:26 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.24034137212573184" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.05776397515527951" WEIGHT="2.510470787726635"/>
<DICH_DATA CI_END="2.147694104338577" CI_START="0.8803046002597534" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="24" LOG_CI_END="0.3319724249520247" LOG_CI_START="-0.0553670286194618" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="58" O_E="0.0" SE="0.22752511238910916" STUDY_ID="STD-Havemann-1987" TOTAL_1="99" TOTAL_2="99" VAR="0.051767676767676754" WEIGHT="2.7085880143265744"/>
<DICH_DATA CI_END="2.963071526334668" CI_START="0.4110399978745899" EFFECT_SIZE="1.1036036036036037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.47174213515117136" LOG_CI_START="-0.3861159153233837" LOG_EFFECT_SIZE="0.04281310991389386" MODIFIED="2015-03-16 12:08:29 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.5039100653145896" STUDY_ID="STD-Jones-1993" TOTAL_1="37" TOTAL_2="35" VAR="0.2539253539253539" WEIGHT="0.739936901215768"/>
<DICH_DATA CI_END="1.2546536479898092" CI_START="0.45486783848125956" EFFECT_SIZE="0.7554479418886199" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.0985238536841852" LOG_CI_START="-0.3421147689601016" LOG_EFFECT_SIZE="-0.12179545763795822" MODIFIED="2015-03-16 13:12:37 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.258833308137614" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.06699468140146106" WEIGHT="2.2564040283781455"/>
<DICH_DATA CI_END="1.0303484558395002" CI_START="0.07119018233950791" EFFECT_SIZE="0.2708333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.012984124565043819" LOG_CI_START="-1.1475798947025448" LOG_EFFECT_SIZE="-0.5672978850687505" MODIFIED="2015-03-16 12:08:35 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.6817210498023292" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.4647435897435897" WEIGHT="0.4209076270688733"/>
<DICH_DATA CI_END="1.9086106071461169" CI_START="0.6894736567882513" EFFECT_SIZE="1.1471428571428572" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.2807173330990058" LOG_CI_START="-0.16148232257015752" LOG_EFFECT_SIZE="0.05961750526442415" MODIFIED="2015-03-16 13:12:38 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.2597502666636646" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.06747020103184487" WEIGHT="2.244701363567477"/>
<DICH_DATA CI_END="1.2379826614854301" CI_START="0.4689071053035776" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.09271456223342668" LOG_CI_START="-0.3289131863894157" LOG_EFFECT_SIZE="-0.11809931207799451" MODIFIED="2015-03-16 13:12:38 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.24766622663207347" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.06133855981416957" WEIGHT="2.40557905207979"/>
<DICH_DATA CI_END="1.8144000951703643" CI_START="0.8476537449092026" EFFECT_SIZE="1.2401544401544402" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="35" LOG_CI_END="0.2587330599927745" LOG_CI_START="-0.07178151494199148" LOG_EFFECT_SIZE="0.09347577252539152" ORDER="64" O_E="0.0" SE="0.1941458973902137" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.037692629473451394" WEIGHT="3.324397964727813"/>
<DICH_DATA CI_END="1.4220051189939533" CI_START="0.43028790597544503" EFFECT_SIZE="0.7822222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.15290115978813942" LOG_CI_START="-0.3662408603825647" LOG_EFFECT_SIZE="-0.10666985029721264" MODIFIED="2015-03-16 13:12:39 +0100" MODIFIED_BY="[Empty name]" ORDER="557" O_E="0.0" SE="0.30494659244271655" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.09299242424242427" WEIGHT="1.7559129225153445"/>
<DICH_DATA CI_END="1.925854087494884" CI_START="0.6847218032634005" EFFECT_SIZE="1.1483354403708386" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.28462337967515605" LOG_CI_START="-0.1644858428845116" LOG_EFFECT_SIZE="0.06006876839532224" ORDER="65" O_E="0.0" SE="0.26380898045805456" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="113" TOTAL_2="109" VAR="0.06959517817031823" WEIGHT="2.1938548016816823"/>
<DICH_DATA CI_END="1.686720584958401" CI_START="0.5928664231157543" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="23" LOG_CI_END="0.22704314514916907" LOG_CI_START="-0.22704314514916904" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-05-27 01:28:13 +0200" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.2667325346846322" STUDY_ID="STD-Urban-1999a" TOTAL_1="110" TOTAL_2="115" VAR="0.07114624505928853" WEIGHT="2.158171483163632"/>
<DICH_DATA CI_END="1.3164587774101635" CI_START="0.5815791676410825" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.11940726448759453" LOG_CI_START="-0.23539115844296804" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2015-03-16 13:12:41 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.2084103499099309" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.04343487394957983" WEIGHT="3.042218165118473"/>
<DICH_DATA CI_END="2.6938701787122534" CI_START="0.6152860563124005" EFFECT_SIZE="1.28743961352657" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.4303766626462798" LOG_CI_START="-0.21092292683493316" LOG_EFFECT_SIZE="0.10972686790567329" MODIFIED="2015-03-16 12:08:58 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.37670255334542985" STUDY_ID="STD-Wolf-1987" TOTAL_1="46" TOTAL_2="41" VAR="0.14190481369696642" WEIGHT="1.2389020257572616"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.629396437642434" CI_END="1.3126405879743666" CI_START="0.8482317447381872" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0551888059260566" ESTIMABLE="YES" EVENTS_1="287" EVENTS_2="279" I2="30.715057363356674" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11814582888690554" LOG_CI_START="-0.07148547827262777" LOG_EFFECT_SIZE="0.023330175307138927" METHOD="MH" MODIFIED="2015-03-16 13:13:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04775190471920765" P_Q="0.8702189166803346" P_Z="0.6296174678379198" Q="0.2780209616858251" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10526093411868823" TOTALS="YES" TOTAL_1="2698" TOTAL_2="2700" WEIGHT="100.0" Z="0.4822653394096919">
<NAME>24-month survival</NAME>
<GROUP_LABEL_1>Platinum regime</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Non-Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.621383605081354" CI_END="1.3310332972830112" CI_START="0.7088022962947131" DF="9" EFFECT_SIZE="0.9713081166956868" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="76" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.12418891997159157" LOG_CI_START="-0.14947488414229895" LOG_EFFECT_SIZE="-0.012642982085353667" MODIFIED="2015-03-16 13:12:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6764718523971708" P_Z="0.8562917687942047" STUDIES="10" TAU2="0.0" TOTAL_1="901" TOTAL_2="907" WEIGHT="31.846250222923846" Z="0.18109658034400258">
<NAME>Undifferentiated</NAME>
<DICH_DATA CI_END="3.660384227005764" CI_START="0.5031812565208548" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5635266752605653" LOG_CI_START="-0.2982755447113833" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2015-03-16 12:09:48 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.5062268900013125" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.256265664160401" WEIGHT="3.4320612251237352"/>
<DICH_DATA CI_END="2.3916869553841695" CI_START="0.5691008633245148" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.37870433482881344" LOG_CI_START="-0.244810755567587" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="70" O_E="0.0" SE="0.3662558505483207" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.13414334806087386" WEIGHT="5.18278707677382"/>
<DICH_DATA CI_END="2.9802353011847114" CI_START="0.2367598289032775" EFFECT_SIZE="0.84" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4742505546708357" LOG_CI_START="-0.6256919825470724" LOG_EFFECT_SIZE="-0.07572071393811836" MODIFIED="2015-03-16 12:09:55 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.6461116911651711" STUDY_ID="STD-Postmus-1992" TOTAL_1="60" TOTAL_2="63" VAR="0.4174603174603175" WEIGHT="2.3736961450418694"/>
<DICH_DATA CI_END="1.8975860976657375" CI_START="0.36905029500518294" EFFECT_SIZE="0.8368421052631579" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="12" LOG_CI_END="0.27820148991289284" LOG_CI_START="-0.43291444317764777" LOG_EFFECT_SIZE="-0.07735647663237745" ORDER="72" O_E="0.0" SE="0.41771301917802345" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.1744841663908198" WEIGHT="4.435400003591396"/>
<DICH_DATA CI_END="2.855842117279689" CI_START="0.532900481765042" EFFECT_SIZE="1.233644859813084" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.45573419417923006" LOG_CI_START="-0.2733538871379496" LOG_EFFECT_SIZE="0.0911901535206402" ORDER="73" O_E="0.0" SE="0.42826994800991974" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.18341514836841938" WEIGHT="4.298178806898424"/>
<DICH_DATA CI_END="5.083687438991294" CI_START="0.4616261856081565" EFFECT_SIZE="1.5319148936170213" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7061788409192991" LOG_CI_START="-0.33570956392819723" LOG_EFFECT_SIZE="0.185234638495551" ORDER="74" O_E="0.0" SE="0.6120104064382014" STUDY_ID="STD-Smith-1991" TOTAL_1="47" TOTAL_2="48" VAR="0.3745567375886525" WEIGHT="2.585943563498736"/>
<DICH_DATA CI_END="1.904057595168093" CI_START="0.005708106229426548" EFFECT_SIZE="0.10425240054869685" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.279680081068085" LOG_CI_START="-2.2435079531424518" LOG_EFFECT_SIZE="-0.9819139360371832" MODIFIED="2015-03-16 13:12:58 +0100" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.4821331412774745" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="2.1967186484730346" WEIGHT="0.5390062662534967"/>
<DICH_DATA CI_END="2.250136312048181" CI_START="0.44054461913579046" EFFECT_SIZE="0.9956331877729258" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.3522088282345477" LOG_CI_START="-0.35601009891341606" LOG_EFFECT_SIZE="-0.0019006353394342094" MODIFIED="2015-03-16 12:10:05 +0100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.41601130354694316" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.17306540467882686" WEIGHT="4.458009346744674"/>
<DICH_DATA CI_END="1.1675603285291218" CI_START="0.15731390053235592" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.06727933006932203" LOG_CI_START="-0.8032329006585109" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="77" O_E="0.0" SE="0.5113431934345675" STUDY_ID="STD-Veronesi-1994" TOTAL_1="70" TOTAL_2="66" VAR="0.26147186147186147" WEIGHT="3.38333913607731"/>
<DICH_DATA CI_END="6.752632066903212" CI_START="0.14319519186951488" EFFECT_SIZE="0.9833333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.829473086804905" LOG_CI_START="-0.8440715642879039" LOG_EFFECT_SIZE="-0.0072992387414994656" ORDER="78" O_E="0.0" SE="0.9830484122315444" STUDY_ID="STD-White-2001" TOTAL_1="60" TOTAL_2="59" VAR="0.9663841807909604" WEIGHT="1.1578286529203827"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.769165510078658" CI_END="1.6450233255430844" CI_START="0.6995507564905292" DF="8" EFFECT_SIZE="1.0727428917630872" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="122" I2="57.37690098313554" ID="CMP-001.03.02" LOG_CI_END="0.21617206039105605" LOG_CI_START="-0.15518076942940223" LOG_EFFECT_SIZE="0.03049564548082688" MODIFIED="2015-03-16 12:10:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.016144128063966257" P_Z="0.7475238476813055" STUDIES="9" TAU2="0.20287081139215227" TOTAL_1="597" TOTAL_2="612" WEIGHT="37.250381271967896" Z="0.32190607976042745">
<NAME>Limited Disease</NAME>
<DICH_DATA CI_END="1.6386669932570639" CI_START="0.43325598185191017" EFFECT_SIZE="0.8425925925925926" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.21449070605073037" LOG_CI_START="-0.3632554323824426" LOG_EFFECT_SIZE="-0.07438236316585611" MODIFIED="2015-03-10 13:24:14 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.33937094160515474" STUDY_ID="STD-Baka-2008" TOTAL_1="81" TOTAL_2="84" VAR="0.11517263600596934" WEIGHT="5.628822411681088"/>
<DICH_DATA CI_END="2.3532235686900935" CI_START="0.5246283938596544" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3716631894097804" LOG_CI_START="-0.2801482082884301" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2015-03-16 12:10:10 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.3828772415263841" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.14659498207885305" WEIGHT="4.926552604114131"/>
<DICH_DATA CI_END="5.179278712462457" CI_START="0.058405816097928845" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7142692823304204" LOG_CI_START="-1.2335439033419326" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2015-03-16 12:10:12 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.1441551070947107" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="10" TOTAL_2="11" VAR="1.309090909090909" WEIGHT="0.8772791761552304"/>
<DICH_DATA CI_END="1.6259644777242994" CI_START="0.8743103878417832" EFFECT_SIZE="1.1923076923076923" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="52" LOG_CI_END="0.21111105337561542" LOG_CI_START="-0.05833436164870599" LOG_EFFECT_SIZE="0.0763883458634547" MODIFIED="2015-03-16 12:10:14 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.15827357056160163" STUDY_ID="STD-Goodman-1990" TOTAL_1="194" TOTAL_2="194" VAR="0.025050523138318286" WEIGHT="9.521660227906274"/>
<DICH_DATA CI_END="3.3636234107148737" CI_START="0.43701626379373393" EFFECT_SIZE="1.2124183006535947" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5268073664945876" LOG_CI_START="-0.3595024002276559" LOG_EFFECT_SIZE="0.08365248313346585" ORDER="82" O_E="0.0" SE="0.5206227442767486" STUDY_ID="STD-Havemann-1987" TOTAL_1="51" TOTAL_2="53" VAR="0.27104804185825276" WEIGHT="3.2972410944579176"/>
<DICH_DATA CI_END="1.34981441672574" CI_START="0.004837662009659878" EFFECT_SIZE="0.08080808080808081" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.1302740623229283" LOG_CI_START="-2.315364477534141" LOG_EFFECT_SIZE="-1.0925452076056064" MODIFIED="2015-03-16 12:10:17 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="1.4365801844180597" STUDY_ID="STD-Jones-1993" TOTAL_1="17" TOTAL_2="15" VAR="2.0637626262626263" WEIGHT="0.5720460775384191"/>
<DICH_DATA CI_END="6.094017327280239" CI_START="1.4758165969072063" EFFECT_SIZE="2.998941798941799" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="9" LOG_CI_END="0.7849036847293683" LOG_CI_START="0.16903239007498894" LOG_EFFECT_SIZE="0.47696803740217864" ORDER="84" O_E="0.0" SE="0.36176584709205833" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="105" TOTAL_2="109" VAR="0.13087452812223455" WEIGHT="5.25453232661264"/>
<DICH_DATA CI_END="0.9314120998986674" CI_START="0.2027558594138545" EFFECT_SIZE="0.4345679012345679" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="20" LOG_CI_END="-0.030858124482426887" LOG_CI_START="-0.6930265863186105" LOG_EFFECT_SIZE="-0.3619423554005187" ORDER="85" O_E="0.0" SE="0.3889610322693238" STUDY_ID="STD-Urban-1999a" TOTAL_1="81" TOTAL_2="88" VAR="0.15129068462401796" WEIGHT="4.836381176954951"/>
<DICH_DATA CI_END="7.187033425788754" CI_START="0.5565578679023623" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8565496646983858" LOG_CI_START="-0.25448967337042344" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-03-16 12:10:27 +0100" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="0.6526300069150406" STUDY_ID="STD-Wolf-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.42592592592592593" WEIGHT="2.335866176547241"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.621804741313436" CI_END="1.7525932087551748" CI_START="0.7060430414029482" DF="14" EFFECT_SIZE="1.112387630033549" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="81" I2="35.25054838160768" ID="CMP-001.03.03" LOG_CI_END="0.24368112448268278" LOG_CI_START="-0.15116882292267655" LOG_EFFECT_SIZE="0.04625615078000313" MODIFIED="2015-03-16 13:13:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08672657451293253" P_Z="0.6460802167755049" STUDIES="15" TAU2="0.24211448978662306" TOTAL_1="1200" TOTAL_2="1181" WEIGHT="30.903368505108265" Z="0.45921439366021793">
<NAME>Extensive Disease</NAME>
<DICH_DATA CI_END="91.8640318426425" CI_START="0.2212382503835346" EFFECT_SIZE="4.508196721311475" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9631455023554274" LOG_CI_START="-0.6551397847164361" LOG_EFFECT_SIZE="0.6540028588194956" MODIFIED="2015-03-10 13:25:42 +0100" MODIFIED_BY="[Empty name]" ORDER="539" O_E="0.0" SE="1.5379937383472115" STUDY_ID="STD-Baka-2008" TOTAL_1="60" TOTAL_2="54" VAR="2.365424739195231" WEIGHT="0.5022012444587064"/>
<DICH_DATA CI_END="2.6197933567653924" CI_START="0.09182666747466658" EFFECT_SIZE="0.49047619047619045" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.41826703652744784" LOG_CI_START="-1.037031176584942" LOG_EFFECT_SIZE="-0.30938207002874707" MODIFIED="2015-03-16 12:10:32 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.8548493742245548" STUDY_ID="STD-Chahinian-1989" TOTAL_1="105" TOTAL_2="103" VAR="0.7307674526121128" WEIGHT="1.4841379066762188"/>
<DICH_DATA CI_END="7.533035597908136" CI_START="0.25280645169509575" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8769700197276257" LOG_CI_START="-0.5972118469251526" LOG_EFFECT_SIZE="0.13987908640123647" MODIFIED="2015-03-16 12:10:34 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="1.4510094656787393"/>
<DICH_DATA CI_END="1.7099483853606543" CI_START="0.5985728083113474" EFFECT_SIZE="1.0116959064327486" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.23298300144983708" LOG_CI_START="-0.22288301597655383" LOG_EFFECT_SIZE="0.005049992736641626" MODIFIED="2015-03-16 13:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.2677779552094418" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.07170503329614981" WEIGHT="7.0114126344753425"/>
<DICH_DATA CI_END="1.5608102159044583" CI_START="0.19774471755990533" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19335009896489205" LOG_CI_START="-0.7038951091715042" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2015-03-16 12:10:40 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.5270462766947299" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.2777777777777778" WEIGHT="3.2393107570284596"/>
<DICH_DATA CI_END="7.7738402068781935" CI_START="0.5145462079939399" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8906356093613294" LOG_CI_START="-0.288575618033367" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="91" O_E="0.0" SE="0.6926745121613612" STUDY_ID="STD-Havemann-1987" TOTAL_1="99" TOTAL_2="99" VAR="0.4797979797979798" WEIGHT="2.1207803014198263"/>
<DICH_DATA CI_END="7.502975334214647" CI_START="0.013291126152980877" EFFECT_SIZE="0.3157894736842105" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8752335187236451" LOG_CI_START="-1.8764382198620155" LOG_EFFECT_SIZE="-0.5006023505691853" MODIFIED="2015-03-16 12:10:42 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="1.6163456002399996" STUDY_ID="STD-Jones-1993" TOTAL_1="37" TOTAL_2="35" VAR="2.6125730994152048" WEIGHT="0.45653318212047256"/>
<DICH_DATA CI_END="0.49834094245845345" CI_START="0.0018617727672104645" EFFECT_SIZE="0.03045977011494253" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="14" LOG_CI_END="-0.30247343080338224" LOG_CI_START="-2.7300733265602393" LOG_EFFECT_SIZE="-1.5162733786818108" MODIFIED="2015-03-16 13:13:01 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.4259841955808665" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="2.0334309260464107" WEIGHT="0.5801590415688792"/>
<DICH_DATA CI_END="4.078351010616146" CI_START="0.01137482586065346" EFFECT_SIZE="0.2153846153846154" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.610484601386554" LOG_CI_START="-1.944055243315789" LOG_EFFECT_SIZE="-0.6667853209646175" ORDER="94" O_E="0.0" SE="1.5005493499543263" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="2.251648351648351" WEIGHT="0.5264442833236765"/>
<DICH_DATA CI_END="3.446663702232171" CI_START="0.31553731792975054" EFFECT_SIZE="1.042857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5373989105068985" LOG_CI_START="-0.5009492702945002" LOG_EFFECT_SIZE="0.0182248201061991" MODIFIED="2015-03-16 13:13:02 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.6099308613091319" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.37201565557729943" WEIGHT="2.5997114599626427"/>
<DICH_DATA CI_END="5.116563634113768" CI_START="0.7607884178608574" EFFECT_SIZE="1.972972972972973" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.7089783797672154" LOG_CI_START="-0.11873610766029358" LOG_EFFECT_SIZE="0.2951211360534609" ORDER="96" O_E="0.0" SE="0.48620358716771117" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.2363939281747501" WEIGHT="3.6316808473777047"/>
<DICH_DATA CI_END="4.3722939755990415" CI_START="0.3325115844898552" EFFECT_SIZE="1.2057522123893805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.64070935448725" LOG_CI_START="-0.4781932195567294" LOG_EFFECT_SIZE="0.0812580674652603" ORDER="97" O_E="0.0" SE="0.6572489106505013" STUDY_ID="STD-Sundstrom-2002" TOTAL_1="113" TOTAL_2="109" VAR="0.4319761305512706" WEIGHT="2.3095603438433594"/>
<DICH_DATA CI_END="172.67542393052594" CI_START="0.5123001804566049" EFFECT_SIZE="9.405405405405405" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2372305309035334" LOG_CI_START="-0.2904754911443618" LOG_EFFECT_SIZE="0.9733775198795859" ORDER="98" O_E="0.0" SE="1.4847870296975392" STUDY_ID="STD-Urban-1999a" TOTAL_1="110" TOTAL_2="115" VAR="2.204592523558041" WEIGHT="0.5371688908146304"/>
<DICH_DATA CI_END="14.660946838513258" CI_START="1.280802528282136" EFFECT_SIZE="4.333333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.16616201897243" LOG_CI_START="0.1074821762019184" LOG_EFFECT_SIZE="0.6368220975871743" MODIFIED="2015-03-16 13:13:03 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.6218737801931388" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.38672699849170433" WEIGHT="2.521975311917107"/>
<DICH_DATA CI_END="2.811697795660007" CI_START="0.1589300194156547" EFFECT_SIZE="0.6684782608695652" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.448968640412428" LOG_CI_START="-0.7987940635527051" LOG_EFFECT_SIZE="-0.17491271157013855" MODIFIED="2015-03-16 12:11:00 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.7329419888341175" STUDY_ID="STD-Wolf-1987" TOTAL_1="46" TOTAL_2="41" VAR="0.5372039589961116" WEIGHT="1.9312828344424984"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="106.7467389866641" CI_END="1.1334985502444872" CI_START="0.9842523175490286" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0562426686214683" ESTIMABLE="YES" EVENTS_1="1846" EVENTS_2="1716" I2="66.27531637805114" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.05442096899608541" LOG_CI_START="-0.00689355393415681" LOG_EFFECT_SIZE="0.02376370753096436" METHOD="MH" MODIFIED="2015-03-16 13:13:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="6.238469296704352E-9" P_Q="0.8481976824398588" P_Z="0.12869985566792014" Q="0.3292831652009194" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="31" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.026882235346913076" TOTALS="YES" TOTAL_1="2824" TOTAL_2="2827" WEIGHT="100.0" Z="1.519248904629756">
<NAME>Overall response</NAME>
<GROUP_LABEL_1>Platinum regime</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Non-Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="43.53061219331464" CI_END="1.2067794029539525" CI_START="0.8920047560195408" DF="10" EFFECT_SIZE="1.0375225139250461" ESTIMABLE="YES" EVENTS_1="682" EVENTS_2="657" I2="77.02766054474239" ID="CMP-001.04.01" LOG_CI_END="0.08162788912328664" LOG_CI_START="-0.049632830032468996" LOG_EFFECT_SIZE="0.015997529545408843" MODIFIED="2015-03-16 13:13:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.996098109970703E-6" P_Z="0.6328316522195107" STUDIES="11" TAU2="0.04232356549256119" TOTAL_1="1105" TOTAL_2="1120" WEIGHT="30.220855117623337" Z="0.47774508554095296">
<NAME>Undifferentiated</NAME>
<DICH_DATA CI_END="1.245111358182577" CI_START="0.9320762507649042" EFFECT_SIZE="1.0772830299042189" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="97" LOG_CI_END="0.09520819487068914" LOG_CI_START="-0.030548557676207934" LOG_EFFECT_SIZE="0.032329818597240614" MODIFIED="2015-03-10 13:28:21 +0100" MODIFIED_BY="[Empty name]" ORDER="541" O_E="0.0" SE="0.07387013895201211" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.005456797428789576" WEIGHT="4.011205245292744"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-03-16 13:13:42 +0100" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Creech-1982" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="0.04957472201555825"/>
<DICH_DATA CI_END="0.9420273806543378" CI_START="0.5734705923566219" EFFECT_SIZE="0.735" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="50" LOG_CI_END="-0.02593647396479321" LOG_CI_START="-0.24148884786681696" LOG_EFFECT_SIZE="-0.1337126609158051" MODIFIED="2015-03-16 12:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.12661653143150794" STUDY_ID="STD-Postmus-1992" TOTAL_1="60" TOTAL_2="63" VAR="0.016031746031746036" WEIGHT="3.0227560745995183"/>
<DICH_DATA CI_END="1.6473429844696335" CI_START="1.0286652490431163" EFFECT_SIZE="1.3017543859649123" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="54" LOG_CI_END="0.21678403071484892" LOG_CI_START="0.012274068498222462" LOG_EFFECT_SIZE="0.11452904960653569" ORDER="103" O_E="0.0" SE="0.12013016414668617" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.014431256337909764" WEIGHT="3.1398580126609477"/>
<DICH_DATA CI_END="1.374961300126642" CI_START="0.8913000428466801" EFFECT_SIZE="1.107024419656316" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="62" LOG_CI_END="0.13829047461866278" LOG_CI_START="-0.049976072599217804" LOG_EFFECT_SIZE="0.0441572010097225" ORDER="104" O_E="0.0" SE="0.11058870177022186" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.012229860959223071" WEIGHT="3.3165825958871302"/>
<DICH_DATA CI_END="1.473353138297676" CI_START="0.8515582343072036" EFFECT_SIZE="1.1201098146877144" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="31" LOG_CI_END="0.16830685249973645" LOG_CI_START="-0.0697856472040321" LOG_EFFECT_SIZE="0.049260602647852175" ORDER="105" O_E="0.0" SE="0.13985671290287502" STUDY_ID="STD-Smith-1991" TOTAL_1="47" TOTAL_2="48" VAR="0.019559900143997205" WEIGHT="2.7931208702274497"/>
<DICH_DATA CI_END="2.064375321867944" CI_START="0.8453409743302032" EFFECT_SIZE="1.3210227272727273" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="22" LOG_CI_END="0.31478865874870093" LOG_CI_START="-0.07296807992505512" LOG_EFFECT_SIZE="0.12091028941182291" MODIFIED="2015-03-16 13:13:40 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.22777022772377684" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.051879276637341154" WEIGHT="1.6469782591721371"/>
<DICH_DATA CI_END="0.934107984576084" CI_START="0.7209974760418791" EFFECT_SIZE="0.8206640599111936" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="158" LOG_CI_END="-0.029602915638510186" LOG_CI_START="-0.14206625558986782" LOG_EFFECT_SIZE="-0.085834585614189" MODIFIED="2015-03-11 08:06:40 +0100" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.06606152258993861" STUDY_ID="STD-Urban-1999a" TOTAL_1="191" TOTAL_2="203" VAR="0.004364124766900969" WEIGHT="4.15147548146716"/>
<DICH_DATA CI_END="1.6008981611105881" CI_START="1.1904440513769734" EFFECT_SIZE="1.3804997981725442" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="119" LOG_CI_END="0.20436370576412288" LOG_CI_START="0.07570898919975978" LOG_EFFECT_SIZE="0.14003634748194135" MODIFIED="2015-03-16 12:11:48 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.0755724173610249" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.005711190265788937" WEIGHT="3.9798976468137717"/>
<DICH_DATA CI_END="1.2280665102983712" CI_START="0.7238855423398428" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="42" LOG_CI_END="0.08922188820040287" LOG_CI_START="-0.14033009714517924" LOG_EFFECT_SIZE="-0.025554104472388168" ORDER="109" O_E="0.0" SE="0.13483997249264842" STUDY_ID="STD-Veronesi-1994" TOTAL_1="70" TOTAL_2="66" VAR="0.01818181818181818" WEIGHT="2.8785359447278407"/>
<DICH_DATA CI_END="1.1610900819010654" CI_START="0.38714420571457697" EFFECT_SIZE="0.6704545454545454" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.06486591530695564" LOG_CI_START="-0.4121272363230046" LOG_EFFECT_SIZE="-0.17363066050802448" ORDER="110" O_E="0.0" SE="0.28018813842161944" STUDY_ID="STD-White-2001" TOTAL_1="60" TOTAL_2="59" VAR="0.07850539291217258" WEIGHT="1.2308702647590817"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.043029445598401" CI_END="1.1229099532943903" CI_START="0.9377863661393727" DF="7" EFFECT_SIZE="1.0261820718574648" ESTIMABLE="YES" EVENTS_1="312" EVENTS_2="301" I2="22.592312210072745" ID="CMP-001.04.02" LOG_CI_END="0.05034493136803454" LOG_CI_START="-0.027896085473773025" LOG_EFFECT_SIZE="0.011224422947130773" MODIFIED="2015-03-16 12:12:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2495816135092188" P_Z="0.5738767657025351" STUDIES="8" TAU2="0.003629402704826718" TOTAL_1="402" TOTAL_2="407" WEIGHT="22.576448763568095" Z="0.5623511966389989">
<NAME>Limited Disease</NAME>
<DICH_DATA CI_END="1.1192231018254355" CI_START="0.8329202121366789" EFFECT_SIZE="0.9655172413793104" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.048916665825946476" LOG_CI_START="-0.07939659893942018" LOG_EFFECT_SIZE="-0.015239966556736846" MODIFIED="2015-03-16 12:12:03 +0100" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.07537184688408069" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.005680915302717304" WEIGHT="3.983597880110685"/>
<DICH_DATA CI_END="1.2756967107164483" CI_START="0.5698694707851057" EFFECT_SIZE="0.8526315789473684" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.10574743573430075" LOG_CI_START="-0.2442246085546968" LOG_EFFECT_SIZE="-0.06923858641019802" MODIFIED="2015-03-16 12:12:08 +0100" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.20557531120491598" STUDY_ID="STD-Farris-1993" TOTAL_1="25" TOTAL_2="27" VAR="0.042261208576998055" WEIGHT="1.876078056515974"/>
<DICH_DATA CI_END="2.7322639831102826" CI_START="0.7872998818592871" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4365226572604239" LOG_CI_START="-0.10385981372737396" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2015-03-16 12:12:09 +0100" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.3174233383946047" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="10" TOTAL_2="11" VAR="0.10075757575757571" WEIGHT="1.0162855677638223"/>
<DICH_DATA CI_END="1.9650533387268962" CI_START="1.023057203651395" EFFECT_SIZE="1.417872340425532" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="25" LOG_CI_END="0.29337434321036276" LOG_CI_START="0.00989991771566474" LOG_EFFECT_SIZE="0.15163713046301375" ORDER="114" O_E="0.0" SE="0.16651428075662272" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="47" TOTAL_2="49" VAR="0.02772700569589538" WEIGHT="2.375394629562888"/>
<DICH_DATA CI_END="1.12217030674038" CI_START="0.9031319539650748" EFFECT_SIZE="1.0067114093959733" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="149" LOG_CI_END="0.050058772842385975" LOG_CI_START="-0.04424879155557148" LOG_EFFECT_SIZE="0.0029049906434072477" MODIFIED="2015-03-16 12:12:12 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.0553967301573329" STUDY_ID="STD-Goodman-1990" TOTAL_1="194" TOTAL_2="194" VAR="0.0030687977121243567" WEIGHT="4.331019155229143"/>
<DICH_DATA CI_END="1.3487335076876321" CI_START="0.8849601998903628" EFFECT_SIZE="1.0925087983911512" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="39" LOG_CI_END="0.12992614717082127" LOG_CI_START="-0.05307626077864344" LOG_EFFECT_SIZE="0.038424943196088926" ORDER="116" O_E="0.0" SE="0.10749652030604469" STUDY_ID="STD-Havemann-1987" TOTAL_1="51" TOTAL_2="53" VAR="0.011555501877907878" WEIGHT="3.3747693611326173"/>
<DICH_DATA CI_END="1.1423964287906159" CI_START="0.6815031045107233" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.05781683679996205" LOG_CI_START="-0.16653216144514746" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2015-03-16 12:12:16 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.13178371211462925" STUDY_ID="STD-Jones-1993" TOTAL_1="17" TOTAL_2="15" VAR="0.01736694677871148" WEIGHT="2.9315456617778457"/>
<DICH_DATA CI_END="1.4650616741454683" CI_START="0.825903797330417" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" LOG_CI_END="0.16585590740498937" LOG_CI_START="-0.0830705370885392" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2015-03-16 12:12:17 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.14622062570127167" STUDY_ID="STD-Wolf-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.02138047138047139" WEIGHT="2.6877584514751143"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="49.63419077265389" CI_END="1.1937773154181577" CI_START="0.9581405733655507" DF="17" EFFECT_SIZE="1.069488887957954" ESTIMABLE="YES" EVENTS_1="852" EVENTS_2="758" I2="65.74941640961295" ID="CMP-001.04.03" LOG_CI_END="0.07692332201559739" LOG_CI_START="-0.018570768835592614" LOG_EFFECT_SIZE="0.029176276590002333" MODIFIED="2015-03-16 13:13:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="4.8132787883958805E-5" P_Z="0.23105167318542974" STUDIES="18" TAU2="0.0334685474690973" TOTAL_1="1317" TOTAL_2="1300" WEIGHT="47.202696118808575" Z="1.1976542382815123">
<NAME>Extensive Disease</NAME>
<DICH_DATA CI_END="0.905565033316812" CI_START="0.5579792306810722" EFFECT_SIZE="0.7108350586611456" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="69" LOG_CI_END="-0.04308035529310661" LOG_CI_START="-0.25338196623889814" LOG_EFFECT_SIZE="-0.1482311607660024" MODIFIED="2015-03-16 12:12:19 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.12353220727932133" STUDY_ID="STD-Chahinian-1989" TOTAL_1="105" TOTAL_2="103" VAR="0.015260206235301211" WEIGHT="3.078096404180307"/>
<DICH_DATA CI_END="1.2814721161673537" CI_START="0.8221899127436484" EFFECT_SIZE="1.0264567440350592" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="61" LOG_CI_END="0.10770916071425307" LOG_CI_START="-0.08502785578072948" LOG_EFFECT_SIZE="0.01134065246676179" MODIFIED="2015-03-16 13:13:37 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="0.11321467755277134" STUDY_ID="STD-de-Jong-2007" TOTAL_1="101" TOTAL_2="102" VAR="0.012817563213377986" WEIGHT="3.2674850402727436"/>
<DICH_DATA CI_END="1.4691344277530491" CI_START="1.0908389518469166" EFFECT_SIZE="1.2659340659340659" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="91" LOG_CI_END="0.16706153613082986" LOG_CI_START="0.03776063740136935" LOG_EFFECT_SIZE="0.10241108676609963" ORDER="120" O_E="0.0" SE="0.07595198796345641" STUDY_ID="STD-Evans-1987" TOTAL_1="145" TOTAL_2="144" VAR="0.005768704475601027" WEIGHT="3.972887108387197"/>
<DICH_DATA CI_END="1.4871472000141521" CI_START="0.5534873720783791" EFFECT_SIZE="0.907258064516129" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.17235395775526066" LOG_CI_START="-0.25689228318496815" LOG_EFFECT_SIZE="-0.04226916271485379" MODIFIED="2015-03-16 12:12:24 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="0.25214136673145143" STUDY_ID="STD-Farris-1993" TOTAL_1="31" TOTAL_2="30" VAR="0.0635752688172043" WEIGHT="1.434026940012005"/>
<DICH_DATA CI_END="1.490119266593373" CI_START="0.7188854100577965" EFFECT_SIZE="1.035" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.17322102998976224" LOG_CI_START="-0.1433403304038892" LOG_EFFECT_SIZE="0.014940349792936524" MODIFIED="2015-03-16 12:12:26 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.18594971009923714" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="25" TOTAL_2="23" VAR="0.03457729468599033" WEIGHT="2.110632766442331"/>
<DICH_DATA CI_END="1.891973727002494" CI_START="1.069103666987681" EFFECT_SIZE="1.4222222222222223" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="27" LOG_CI_END="0.2769151012533724" LOG_CI_START="0.029019819163714638" LOG_EFFECT_SIZE="0.15296746020854352" ORDER="123" O_E="0.0" SE="0.14561491580090175" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="50" TOTAL_2="48" VAR="0.021203703703703707" WEIGHT="2.697638861976817"/>
<DICH_DATA CI_END="1.5434585930436817" CI_START="1.156134523242972" EFFECT_SIZE="1.3358314881053768" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="103" LOG_CI_END="0.18849498298957176" LOG_CI_START="0.06300836981380205" LOG_EFFECT_SIZE="0.1257516764016869" MODIFIED="2015-03-16 13:13:34 +0100" MODIFIED_BY="[Empty name]" ORDER="124" O_E="0.0" SE="0.07371145774820044" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.0054333790033647385" WEIGHT="4.014112078809273"/>
<DICH_DATA CI_END="2.1735519030249377" CI_START="1.2084528346101986" EFFECT_SIZE="1.6206896551724137" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" LOG_CI_END="0.3371700153242737" LOG_CI_START="0.08222970474924905" LOG_EFFECT_SIZE="0.20969986003676136" MODIFIED="2015-03-16 12:12:30 +0100" MODIFIED_BY="[Empty name]" ORDER="125" O_E="0.0" SE="0.14975320040665968" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.02242602103203718" WEIGHT="2.630766273718196"/>
<DICH_DATA CI_END="1.6103757767636016" CI_START="0.9858568558393406" EFFECT_SIZE="1.26" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="50" LOG_CI_END="0.20692722928185106" LOG_CI_START="-0.006186139046725253" LOG_EFFECT_SIZE="0.10037054511756291" ORDER="126" O_E="0.0" SE="0.1251838474843926" STUDY_ID="STD-Havemann-1987" TOTAL_1="99" TOTAL_2="99" VAR="0.01567099567099567" WEIGHT="3.0483818688879287"/>
<DICH_DATA CI_END="0.9349520660282054" CI_START="0.5146904939358496" EFFECT_SIZE="0.6936936936936937" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="-0.029210654360724165" LOG_CI_START="-0.288453852867627" LOG_EFFECT_SIZE="-0.15883225361417555" MODIFIED="2015-03-16 12:12:33 +0100" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.1522807380774837" STUDY_ID="STD-Jones-1993" TOTAL_1="37" TOTAL_2="35" VAR="0.023189423189423197" WEIGHT="2.590657104027373"/>
<DICH_DATA CI_END="1.599105461822584" CI_START="0.8162705307212732" EFFECT_SIZE="1.1424984306340238" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.20387710663382114" LOG_CI_START="-0.0881658822659346" LOG_EFFECT_SIZE="0.057855612183943264" MODIFIED="2015-03-16 13:13:32 +0100" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.17154749731582647" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.029428543835323492" WEIGHT="2.303617527255112"/>
<DICH_DATA CI_END="1.7880014673166587" CI_START="0.3348885278248358" EFFECT_SIZE="0.7738095238095238" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2523678708621732" LOG_CI_START="-0.47509972970022535" LOG_EFFECT_SIZE="-0.11136592941902607" MODIFIED="2015-03-16 13:13:30 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.42731806959305224" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.18260073260073262" WEIGHT="0.6192317168716641"/>
<DICH_DATA CI_END="1.2715331300323067" CI_START="0.8214367170861385" EFFECT_SIZE="1.022" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="50" LOG_CI_END="0.10432768028268402" LOG_CI_START="-0.08542588868529612" LOG_EFFECT_SIZE="0.009450895798693935" MODIFIED="2015-03-16 13:13:31 +0100" MODIFIED_BY="[Empty name]" ORDER="130" O_E="0.0" SE="0.11146218570710668" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.012423818842605537" WEIGHT="3.3002167368960498"/>
<DICH_DATA CI_END="1.457739602645711" CI_START="0.7419706496530383" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" LOG_CI_END="0.16367995249081996" LOG_CI_START="-0.12961327389325922" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2015-03-16 13:13:29 +0100" MODIFIED_BY="[Empty name]" ORDER="131" O_E="0.0" SE="0.17228189300289343" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.02968105065666042" WEIGHT="2.2933338400706993"/>
<DICH_DATA CI_END="1.467020172645187" CI_START="0.950752221851024" EFFECT_SIZE="1.1810049486105825" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="71" LOG_CI_END="0.16643608576438393" LOG_CI_START="-0.02193265099498961" LOG_EFFECT_SIZE="0.07225171738469718" ORDER="132" O_E="0.0" SE="0.11064872841274118" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.012243141099356557" WEIGHT="3.315456864056839"/>
<DICH_DATA CI_END="1.1382608817897275" CI_START="0.5380808392074222" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.05624181086130978" LOG_CI_START="-0.26915247268988335" LOG_EFFECT_SIZE="-0.10645533091428679" MODIFIED="2015-03-16 13:13:27 +0100" MODIFIED_BY="[Empty name]" ORDER="558" O_E="0.0" SE="0.19113821288565186" STUDY_ID="STD-Sekine-2014" TOTAL_1="32" TOTAL_2="32" VAR="0.03653381642512077" WEIGHT="2.0455152011654825"/>
<DICH_DATA CI_END="1.4162856856354584" CI_START="0.7427452837709019" EFFECT_SIZE="1.0256410256410255" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="39" LOG_CI_END="0.15115086576946707" LOG_CI_START="-0.12916009716654075" LOG_EFFECT_SIZE="0.010995384301463145" MODIFIED="2015-03-16 13:13:28 +0100" MODIFIED_BY="[Empty name]" ORDER="133" O_E="0.0" SE="0.16465604719025584" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.02711161387631976" WEIGHT="2.4024680544867745"/>
<DICH_DATA CI_END="1.3434381199486194" CI_START="0.641640718978328" EFFECT_SIZE="0.9284420289855072" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.12821766720851" LOG_CI_START="-0.19270808321132402" LOG_EFFECT_SIZE="-0.03224520800140701" MODIFIED="2015-03-16 12:12:54 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.18851337440469584" STUDY_ID="STD-Wolf-1987" TOTAL_1="46" TOTAL_2="41" VAR="0.03553729232944503" WEIGHT="2.078171731291782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="62.42113151150872" CI_END="1.537770738999694" CI_START="1.1378279557800208" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3227692680185588" ESTIMABLE="YES" EVENTS_1="701" EVENTS_2="542" I2="45.531266132637555" I2_Q="0.19882489387817673" ID="CMP-001.05" LOG_CI_END="0.18689159280675408" LOG_CI_START="0.056076599929072046" LOG_EFFECT_SIZE="0.12148409636791306" METHOD="MH" MODIFIED="2015-03-16 13:14:20 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0020986625465221342" P_Q="0.3671473911042331" P_Z="2.722955945719322E-4" Q="2.003984419896194" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07401288782568734" TOTALS="YES" TOTAL_1="2799" TOTAL_2="2800" WEIGHT="100.0" Z="3.64032361027824">
<NAME>Complete response</NAME>
<GROUP_LABEL_1>Platinum regime</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum regime</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Non-Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="32.28298093091263" CI_END="1.768017622794642" CI_START="0.8968843885000966" DF="9" EFFECT_SIZE="1.2592487460694834" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="212" I2="72.12153357442268" ID="CMP-001.05.01" LOG_CI_END="0.24748658954827907" LOG_CI_START="-0.04726353540897213" LOG_EFFECT_SIZE="0.1001115270696534" MODIFIED="2015-03-16 13:14:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.7789720990613045E-4" P_Z="0.18305781032550306" STUDIES="10" TAU2="0.19221386635517804" TOTAL_1="1080" TOTAL_2="1095" WEIGHT="35.76418228038631" Z="1.3313988417971687">
<NAME>Undifferentiated</NAME>
<DICH_DATA CI_END="2.233704513564211" CI_START="0.9021746870285773" EFFECT_SIZE="1.4195744680851063" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="25" LOG_CI_END="0.3490257217714733" LOG_CI_START="-0.04470936238354363" LOG_EFFECT_SIZE="0.15215817969396483" MODIFIED="2015-03-10 13:29:06 +0100" MODIFIED_BY="[Empty name]" ORDER="542" O_E="0.0" SE="0.23128193745275688" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.053491334591900946" WEIGHT="4.630902962845079"/>
<DICH_DATA CI_END="1.2238790005114826" CI_START="0.2562344805891274" EFFECT_SIZE="0.56" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.08773848316268439" LOG_CI_START="-0.5913624291502834" LOG_EFFECT_SIZE="-0.25181197299379954" MODIFIED="2015-03-16 12:13:45 +0100" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.39890723749636847" STUDY_ID="STD-Postmus-1992" TOTAL_1="60" TOTAL_2="63" VAR="0.15912698412698412" WEIGHT="2.5326413556954077"/>
<DICH_DATA CI_END="2.9815107438582693" CI_START="0.80054628573211" EFFECT_SIZE="1.5449392712550607" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.4744363786624569" LOG_CI_START="-0.09661355311767343" LOG_EFFECT_SIZE="0.18891141277239176" ORDER="136" O_E="0.0" SE="0.33543755667040004" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.11251835442500785" WEIGHT="3.1654733772442194"/>
<DICH_DATA CI_END="2.4203710034199184" CI_START="0.9172396341963799" EFFECT_SIZE="1.4899866488651536" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="21" LOG_CI_END="0.3838819413475837" LOG_CI_START="-0.037517187543396655" LOG_EFFECT_SIZE="0.1731823769020935" ORDER="137" O_E="0.0" SE="0.24753193426989178" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.061272058483394023" WEIGHT="4.364563075775353"/>
<DICH_DATA CI_END="1.7260332103769238" CI_START="0.7248609331241305" EFFECT_SIZE="1.1185410334346504" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.237049147662321" LOG_CI_START="-0.13974530621523434" LOG_EFFECT_SIZE="0.04865192072354334" ORDER="138" O_E="0.0" SE="0.2213309273703037" STUDY_ID="STD-Smith-1991" TOTAL_1="47" TOTAL_2="48" VAR="0.04898737941059865" WEIGHT="4.800474784616384"/>
<DICH_DATA CI_END="5.396506447988355" CI_START="0.8867137093450067" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.7321127003115122" LOG_CI_START="-0.0522165769228104" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2015-03-16 13:14:11 +0100" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="0.4607188999399794" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.21226190476190473" WEIGHT="2.0625626029864415"/>
<DICH_DATA CI_END="0.8006453326872041" CI_START="0.38602575925085963" EFFECT_SIZE="0.5559403946838501" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="65" LOG_CI_END="-0.09655982370064836" LOG_CI_START="-0.41338371416958186" LOG_EFFECT_SIZE="-0.2549717689351151" ORDER="140" O_E="0.0" SE="0.18610392156500266" STUDY_ID="STD-Urban-1999a" TOTAL_1="191" TOTAL_2="203" VAR="0.034634669621872664" WEIGHT="5.434633739040658"/>
<DICH_DATA CI_END="2.784197942694553" CI_START="1.3439414781681818" EFFECT_SIZE="1.9343730505302559" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="35" LOG_CI_END="0.44470010822446093" LOG_CI_START="0.1283803578085921" LOG_EFFECT_SIZE="0.2865402330165265" MODIFIED="2015-03-16 12:13:53 +0100" MODIFIED_BY="[Empty name]" ORDER="141" O_E="0.0" SE="0.18580778720229896" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.03452453378501481" WEIGHT="5.440148407861629"/>
<DICH_DATA CI_END="3.243953549328264" CI_START="0.7919814452769107" EFFECT_SIZE="1.6028571428571428" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5110746268539005" LOG_CI_START="-0.101284993042129" LOG_EFFECT_SIZE="0.20489481690588573" ORDER="142" O_E="0.0" SE="0.3597030719559332" STUDY_ID="STD-Veronesi-1994" TOTAL_1="70" TOTAL_2="66" VAR="0.12938629997453527" WEIGHT="2.9029598778379264"/>
<DICH_DATA CI_END="27.557235411960782" CI_START="0.3157972804566171" EFFECT_SIZE="2.95" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.440235646270656" LOG_CI_START="-0.5005916143143301" LOG_EFFECT_SIZE="0.46982201597816303" ORDER="143" O_E="0.0" SE="1.1400515401175044" STUDY_ID="STD-White-2001" TOTAL_1="60" TOTAL_2="59" VAR="1.2997175141242938" WEIGHT="0.42982209648321285"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.088305519749743" CI_END="1.4016703947919864" CI_START="1.0170495436861628" DF="7" EFFECT_SIZE="1.1939716225361445" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="151" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.14664590054061882" LOG_CI_START="0.007342109289938028" LOG_EFFECT_SIZE="0.07699400491527844" MODIFIED="2015-03-16 12:14:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6491877124365028" P_Z="0.03026790991772612" STUDIES="8" TAU2="0.0" TOTAL_1="402" TOTAL_2="407" WEIGHT="24.40607675508682" Z="2.1665666857248307">
<NAME>Limited Disease</NAME>
<DICH_DATA CI_END="1.692840533100936" CI_START="0.5033380222508855" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.22861604915667721" LOG_CI_START="-0.29814026167510105" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2015-03-16 12:13:58 +0100" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.3094192644683782" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.09574028122415218" WEIGHT="3.4783426116510894"/>
<DICH_DATA CI_END="3.1667280519200007" CI_START="0.6088715483717853" EFFECT_SIZE="1.3885714285714286" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.5006107692065761" LOG_CI_START="-0.21547431938254055" LOG_EFFECT_SIZE="0.14256822491201773" MODIFIED="2015-03-16 12:13:59 +0100" MODIFIED_BY="[Empty name]" ORDER="145" O_E="0.0" SE="0.4206319257156034" STUDY_ID="STD-Farris-1993" TOTAL_1="25" TOTAL_2="27" VAR="0.1769312169312169" WEIGHT="2.3529529890365843"/>
<DICH_DATA CI_END="5.006753303066158" CI_START="0.42964192180065297" EFFECT_SIZE="1.4666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.69955619300535" LOG_CI_START="-0.36689334947229996" LOG_EFFECT_SIZE="0.16633142176652496" MODIFIED="2015-03-16 12:14:01 +0100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.6264377402617457" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="10" TOTAL_2="11" VAR="0.39242424242424234" WEIGHT="1.2658933928619347"/>
<DICH_DATA CI_END="2.550350810767604" CI_START="0.4261833911223819" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.40659992345417306" LOG_CI_START="-0.3704034792685807" LOG_EFFECT_SIZE="0.018098222092796223" ORDER="147" O_E="0.0" SE="0.4564156449882202" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="47" TOTAL_2="49" VAR="0.20831524099001303" WEIGHT="2.0913951572792486"/>
<DICH_DATA CI_END="1.3730516538663147" CI_START="0.9283801058473298" EFFECT_SIZE="1.1290322580645162" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="93" LOG_CI_END="0.13768687559592654" LOG_CI_START="-0.03227417456392053" LOG_EFFECT_SIZE="0.052706350516002996" MODIFIED="2015-03-16 12:14:03 +0100" MODIFIED_BY="[Empty name]" ORDER="148" O_E="0.0" SE="0.09983596218466106" STUDY_ID="STD-Goodman-1990" TOTAL_1="194" TOTAL_2="194" VAR="0.009967219345337074" WEIGHT="7.030946985652258"/>
<DICH_DATA CI_END="2.556535616722283" CI_START="0.9881170489202377" EFFECT_SIZE="1.5893886966551327" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="17" LOG_CI_END="0.40765184753711164" LOG_CI_START="-0.005191607346318125" LOG_EFFECT_SIZE="0.20123012009539673" ORDER="149" O_E="0.0" SE="0.2425062890065872" STUDY_ID="STD-Havemann-1987" TOTAL_1="51" TOTAL_2="53" VAR="0.058809300207746384" WEIGHT="4.445489794372597"/>
<DICH_DATA CI_END="2.9278842315564697" CI_START="0.26590761492946424" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.46655390073670333" LOG_CI_START="-0.5752692253818887" LOG_EFFECT_SIZE="-0.0543576623225927" MODIFIED="2015-03-16 12:14:08 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.611972061389708" STUDY_ID="STD-Jones-1993" TOTAL_1="17" TOTAL_2="15" VAR="0.37450980392156863" WEIGHT="1.316454423005188"/>
<DICH_DATA CI_END="4.8556926595196686" CI_START="0.9667919231339538" EFFECT_SIZE="2.1666666666666665" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.6862511903203382" LOG_CI_START="-0.014666986473952036" LOG_EFFECT_SIZE="0.3357921019231931" MODIFIED="2015-03-16 12:14:09 +0100" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.41172280664989824" STUDY_ID="STD-Wolf-1987" TOTAL_1="27" TOTAL_2="27" VAR="0.16951566951566951" WEIGHT="2.4246014012279193"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="21.131615082249358" CI_END="1.8036343221784583" CI_START="1.1671765711139304" DF="16" EFFECT_SIZE="1.4509168562338957" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="179" I2="24.284064716662076" ID="CMP-001.05.03" LOG_CI_END="0.25614849110053683" LOG_CI_START="0.06713656132365864" LOG_EFFECT_SIZE="0.16164252621209776" MODIFIED="2015-03-16 13:14:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1735068137563026" P_Z="8.01394973816397E-4" STUDIES="18" TAU2="0.045134935569045694" TOTAL_1="1317" TOTAL_2="1298" WEIGHT="39.82974096452688" Z="3.3523125246091117">
<NAME>Extensive Disease</NAME>
<DICH_DATA CI_END="1.1237134859581355" CI_START="0.2642988345626184" EFFECT_SIZE="0.544973544973545" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.0506555929686186" LOG_CI_START="-0.5779047519047625" LOG_EFFECT_SIZE="-0.26362457946807194" MODIFIED="2015-03-16 12:14:11 +0100" MODIFIED_BY="[Empty name]" ORDER="152" O_E="0.0" SE="0.36921945800251155" STUDY_ID="STD-Chahinian-1989" TOTAL_1="105" TOTAL_2="103" VAR="0.13632300816766837" WEIGHT="2.8072226025914264"/>
<DICH_DATA CI_END="2.1966809602483006" CI_START="0.5384680963346209" EFFECT_SIZE="1.0875856816450875" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.34176698579396836" LOG_CI_START="-0.268840023092616" LOG_EFFECT_SIZE="0.036463481350676216" MODIFIED="2015-03-16 13:14:16 +0100" MODIFIED_BY="[Empty name]" ORDER="550" O_E="0.0" SE="0.3586735795734208" STUDY_ID="STD-de-Jong-2007" TOTAL_1="101" TOTAL_2="102" VAR="0.128646736684011" WEIGHT="2.913553613835947"/>
<DICH_DATA CI_END="1.998506305097966" CI_START="1.0174903450980053" EFFECT_SIZE="1.4259946949602123" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="39" LOG_CI_END="0.3007055227562112" LOG_CI_START="0.007530296923740744" LOG_EFFECT_SIZE="0.15411790983997598" ORDER="153" O_E="0.0" SE="0.17221257889476635" STUDY_ID="STD-Evans-1987" TOTAL_1="145" TOTAL_2="144" VAR="0.02965717232958612" WEIGHT="5.695566111223408"/>
<DICH_DATA CI_END="11.526027449745381" CI_START="0.5078313287998661" EFFECT_SIZE="2.4193548387096775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0616796495381322" LOG_CI_START="-0.29428051042327735" LOG_EFFECT_SIZE="0.3836995695574274" MODIFIED="2015-03-16 12:14:19 +0100" MODIFIED_BY="[Empty name]" ORDER="154" O_E="0.0" SE="0.7964977100723754" STUDY_ID="STD-Farris-1993" TOTAL_1="31" TOTAL_2="30" VAR="0.6344086021505376" WEIGHT="0.833486405654752"/>
<DICH_DATA CI_END="6.5188425557238086" CI_START="0.5193560008635745" EFFECT_SIZE="1.84" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8141704920071943" LOG_CI_START="-0.2845348459881213" LOG_EFFECT_SIZE="0.2648178230095365" MODIFIED="2015-03-16 12:14:20 +0100" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.6453849542175853" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="25" TOTAL_2="23" VAR="0.4165217391304348" WEIGHT="1.2037064234033854"/>
<DICH_DATA CI_END="2.448901160408271" CI_START="0.26134170310626254" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3889712570089431" LOG_CI_START="-0.5827912830250558" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="156" O_E="0.0" SE="0.5708181263181237" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="50" TOTAL_2="48" VAR="0.32583333333333336" WEIGHT="1.476716922964339"/>
<DICH_DATA CI_END="2.8299844585920146" CI_START="1.171820105552988" EFFECT_SIZE="1.8210526315789475" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" LOG_CI_END="0.45178405051854387" LOG_CI_START="0.06886094516135154" LOG_EFFECT_SIZE="0.26032249783994765" MODIFIED="2015-03-16 13:14:15 +0100" MODIFIED_BY="[Empty name]" ORDER="157" O_E="0.0" SE="0.22493092758675653" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.050593922185038706" WEIGHT="4.738582757379323"/>
<DICH_DATA CI_END="6.288926694015676" CI_START="0.6360385793344134" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7985765324658621" LOG_CI_START="-0.1965165411378997" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-03-16 12:14:28 +0100" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.5845225972250061" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.3416666666666667" WEIGHT="1.420468423302567"/>
<DICH_DATA CI_END="3.17132902728571" CI_START="1.0216536890759216" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.5012413026772357" LOG_CI_START="0.00930370752937644" LOG_EFFECT_SIZE="0.25527250510330607" ORDER="159" O_E="0.0" SE="0.2889665785202218" STUDY_ID="STD-Havemann-1987" TOTAL_1="99" TOTAL_2="99" VAR="0.08350168350168351" WEIGHT="3.7486035507260094"/>
<DICH_DATA CI_END="7.991459001547201" CI_START="0.25193533472126156" EFFECT_SIZE="1.4189189189189189" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9026260757440279" LOG_CI_START="-0.5987109170661042" LOG_EFFECT_SIZE="0.15195757933896187" MODIFIED="2015-03-16 12:14:33 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.8818927813146435" STUDY_ID="STD-Jones-1993" TOTAL_1="37" TOTAL_2="35" VAR="0.7777348777348777" WEIGHT="0.6932330265407451"/>
<DICH_DATA CI_END="2.8283478030986644" CI_START="0.4540030694339069" EFFECT_SIZE="1.1331719128329298" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4515328137807604" LOG_CI_START="-0.3429412109453144" LOG_EFFECT_SIZE="0.054295801417723034" MODIFIED="2015-03-16 13:14:14 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.46667797483394463" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.21778833219511184" WEIGHT="2.023499700675619"/>
<DICH_DATA CI_END="72.45938986445702" CI_START="0.14405130711161593" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.86009467278967" LOG_CI_START="-0.8414827966075424" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="162" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="2.518315018315018" WEIGHT="0.2277719882466207"/>
<DICH_DATA CI_END="6.796031892352711" CI_START="1.9603351207034871" EFFECT_SIZE="3.65" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" LOG_CI_END="0.8322554082547329" LOG_CI_START="0.29233032065821657" LOG_EFFECT_SIZE="0.5622928644564748" MODIFIED="2015-03-16 13:14:17 +0100" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="0.31715466912648155" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.100587084148728" WEIGHT="3.3817856594810305"/>
<DICH_DATA CI_END="15.45289633526487" CI_START="0.06471278770685286" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1890098911741465" LOG_CI_START="-1.1890098911741465" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-16 13:14:17 +0100" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.3968605915391563" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="1.951219512195122" WEIGHT="0.29155156779182506"/>
<DICH_DATA CI_END="3.0086730221203957" CI_START="0.6339621947937157" EFFECT_SIZE="1.3810810810810812" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4783749918594023" LOG_CI_START="-0.19793663972396683" LOG_EFFECT_SIZE="0.14021917606771778" ORDER="165" O_E="0.0" SE="0.39726880018863997" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.15782249960332154" WEIGHT="2.5468919474153804"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-16 13:14:18 +0100" MODIFIED_BY="[Empty name]" ORDER="559" O_E="0.0" SE="0.0" STUDY_ID="STD-Sekine-2014" TOTAL_1="32" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9985049940516908" CI_START="0.6250346893376726" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.3007052378532574" LOG_CI_START="-0.20409587870414736" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2015-03-16 13:14:20 +0100" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.2965226746716467" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.08792569659442724" WEIGHT="3.646195151595545"/>
<DICH_DATA CI_END="3.0371759548039714" CI_START="0.5338091541558857" EFFECT_SIZE="1.2732919254658386" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.4824699529280941" LOG_CI_START="-0.2726139828802849" LOG_EFFECT_SIZE="0.10492798502390462" MODIFIED="2015-03-16 12:14:54 +0100" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="0.4435400416196053" STUDY_ID="STD-Wolf-1987" TOTAL_1="46" TOTAL_2="41" VAR="0.19672776851992121" WEIGHT="2.180905111698954"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.434771116214964" CI_END="1.6235561834234575" CI_START="0.7217456271236588" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="1.082494607735049" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="85" I2="35.45049178407466" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.2104673220526218" LOG_CI_START="-0.14161583872097683" LOG_EFFECT_SIZE="0.03442574166582256" METHOD="MH" MODIFIED="2015-06-05 14:25:43 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.059447040973442" P_Q="1.0" P_Z="0.7015121807975853" Q="0.0" RANDOM="YES" SCALE="1.3734867698719186" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2818728753123037" TOTALS="YES" TOTAL_1="1840" TOTAL_2="1856" WEIGHT="100.0" Z="0.3832799822510093">
<NAME>Toxic Death</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9909365658445851" CI_START="0.01608484644666934" EFFECT_SIZE="0.12625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.0039541457018195045" LOG_CI_START="-1.7935830807167827" LOG_EFFECT_SIZE="-0.898768613209301" MODIFIED="2015-06-05 14:25:36 +0200" MODIFIED_BY="[Empty name]" ORDER="551" O_E="0.0" SE="1.0512368952338906" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="1.10509900990099" WEIGHT="3.0838841513856097"/>
<DICH_DATA CI_END="3.0780570286479048" CI_START="0.4421981459222688" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4882766619534381" LOG_CI_START="-0.35438308269221164" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2015-03-16 12:16:15 +0100" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.4949825052378634" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.2450076804915515" WEIGHT="8.118084009953517"/>
<DICH_DATA CI_END="5.769514106059624" CI_START="0.29963320402334254" EFFECT_SIZE="1.3148148148148149" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7611392395088203" LOG_CI_START="-0.5234100617166068" LOG_EFFECT_SIZE="0.11886458889610681" ORDER="169" O_E="0.0" SE="0.7545506181614074" STUDY_ID="STD-Evans-1987" TOTAL_1="144" TOTAL_2="142" VAR="0.5693466353677621" WEIGHT="5.024862049754313"/>
<DICH_DATA CI_END="100.42750446643518" CI_START="0.2489357883860937" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0018526709975903" LOG_CI_START="-0.603912662325553" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-03-16 12:16:17 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.5306394555404428" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="2.342857142857143" WEIGHT="1.6296002200674977"/>
<DICH_DATA CI_END="4.8324933925977085" CI_START="0.2069325126303897" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.684171268896076" LOG_CI_START="-0.684171268896076" LOG_EFFECT_SIZE="0.0" ORDER="171" O_E="0.0" SE="0.8037711801039122" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.6460481099656358" WEIGHT="4.609509519763187"/>
<DICH_DATA CI_END="11.019609893966239" CI_START="0.8359422477268368" EFFECT_SIZE="3.0350877192982457" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0421662202964717" LOG_CI_START="-0.07782372538386367" LOG_EFFECT_SIZE="0.482171247456304" MODIFIED="2015-06-05 14:25:37 +0200" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.6578876381322732" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.4328161444072609" WEIGHT="5.9847856860946935"/>
<DICH_DATA CI_END="1.8101885225376957" CI_START="0.27353190871388744" EFFECT_SIZE="0.7036649214659686" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2577238069323215" LOG_CI_START="-0.5629920039921636" LOG_EFFECT_SIZE="-0.1526340985299211" MODIFIED="2015-03-16 12:16:23 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.4820925299458276" STUDY_ID="STD-Goodman-1990" TOTAL_1="191" TOTAL_2="192" VAR="0.23241320742956867" WEIGHT="8.316889682145097"/>
<DICH_DATA CI_END="36.509153040182404" CI_START="0.5319133796223402" EFFECT_SIZE="4.406779661016949" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5624017580595135" LOG_CI_START="-0.27415908540216605" LOG_EFFECT_SIZE="0.6441213363286737" MODIFIED="2015-06-05 14:25:38 +0200" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="1.0788049305721854" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="1.163820078226858" WEIGHT="2.958623132772179"/>
<DICH_DATA CI_END="3.6058475753088763" CI_START="0.14465529320853898" EFFECT_SIZE="0.7222222222222222" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5570073644825092" LOG_CI_START="-0.8396656700754478" LOG_EFFECT_SIZE="-0.14132915279646932" MODIFIED="2015-06-05 14:25:39 +0200" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.8204126541423669" STUDY_ID="STD-Lyss-2002" TOTAL_1="12" TOTAL_2="13" VAR="0.6730769230769229" WEIGHT="4.479042377349491"/>
<DICH_DATA CI_END="2.5204459816206706" CI_START="0.15533694044701907" EFFECT_SIZE="0.6257142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.4014773940433781" LOG_CI_START="-0.8087252530636929" LOG_EFFECT_SIZE="-0.20362392951015734" MODIFIED="2015-06-05 14:25:41 +0200" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.7108790255104119" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.5053489889106328" WEIGHT="5.433361050570876"/>
<DICH_DATA CI_END="2.5808121464871436" CI_START="0.096868731937846" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4117563940389685" LOG_CI_START="-1.0138163853669309" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2015-06-05 14:25:41 +0200" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.8373885073220924" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.7012195121951219" WEIGHT="4.350822638421041"/>
<DICH_DATA CI_END="4.052097403615489" CI_START="0.5403621519789593" EFFECT_SIZE="1.4797297297297298" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.6076798763092444" LOG_CI_START="-0.2673150774189223" LOG_EFFECT_SIZE="0.17018239944516098" ORDER="178" O_E="0.0" SE="0.5139763671148002" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.2641717059525279" WEIGHT="7.833171066946687"/>
<DICH_DATA CI_END="3.64367740379179" CI_START="0.1921972314048721" EFFECT_SIZE="0.8368421052631579" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5615399193561358" LOG_CI_START="-0.7162528726208907" LOG_EFFECT_SIZE="-0.07735647663237745" ORDER="179" O_E="0.0" SE="0.7505818111836368" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.5633730552797086" WEIGHT="5.0603740999153874"/>
<DICH_DATA CI_END="42.48131078167496" CI_START="0.5995453729604205" EFFECT_SIZE="5.046728971962617" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6281979086493508" LOG_CI_START="-0.22217794437383295" LOG_EFFECT_SIZE="0.7030099821377589" ORDER="180" O_E="0.0" SE="1.0869199355740133" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="1.1813949463482174" WEIGHT="2.9230880033792097"/>
<DICH_DATA CI_END="2.82628734185647" CI_START="0.008182614640968117" EFFECT_SIZE="0.15207373271889402" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.45121631343570673" LOG_CI_START="-2.087107901376991" LOG_EFFECT_SIZE="-0.817945793970642" MODIFIED="2015-06-05 14:25:42 +0200" MODIFIED_BY="[Empty name]" ORDER="560" O_E="0.0" SE="1.4910242086884862" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="2.2231531908951263" WEIGHT="1.7074715001678218"/>
<DICH_DATA CI_END="1.9911399694490113" CI_START="0.23155467353312112" EFFECT_SIZE="0.6790123456790124" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.29910179032510475" LOG_CI_START="-0.6353464490939166" LOG_EFFECT_SIZE="-0.16812232938440588" ORDER="181" O_E="0.0" SE="0.5488995214281189" STUDY_ID="STD-Urban-1999a" TOTAL_1="81" TOTAL_2="88" VAR="0.301290684624018" WEIGHT="7.33458142633904"/>
<DICH_DATA CI_END="16.291669083811417" CI_START="2.0117260449689067" EFFECT_SIZE="5.724890829694323" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="1.2119655801192" LOG_CI_START="0.30356883858119266" LOG_EFFECT_SIZE="0.7577672093501963" MODIFIED="2015-03-16 12:16:46 +0100" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.5335967426158168" STUDY_ID="STD-Urban-1999b" TOTAL_1="229" TOTAL_2="228" VAR="0.2847254837302102" WEIGHT="7.5490169481866785"/>
<DICH_DATA CI_END="15.594961559144458" CI_START="0.06412327444395831" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.192984308578766" LOG_CI_START="-1.1929843085787657" LOG_EFFECT_SIZE="0.0" ORDER="183" O_E="0.0" SE="1.4015297764534702" STUDY_ID="STD-Veronesi-1994" TOTAL_1="56" TOTAL_2="56" VAR="1.9642857142857144" WEIGHT="1.9042558415219355"/>
<DICH_DATA CI_END="3.8686336395720593" CI_START="0.2584891962296585" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5875576038887818" LOG_CI_START="-0.5875576038887818" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-06-05 14:25:43 +0200" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.6902684899626333" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.4764705882352941" WEIGHT="5.640268322769335"/>
<DICH_DATA CI_END="1.3211826656213956" CI_START="0.1028612108362126" EFFECT_SIZE="0.3686440677966102" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12096286696127688" LOG_CI_START="-0.9877483676642529" LOG_EFFECT_SIZE="-0.43339275035148805" ORDER="185" O_E="0.0" SE="0.6512624674281603" STUDY_ID="STD-White-2001" TOTAL_1="59" TOTAL_2="58" VAR="0.4241428014806156" WEIGHT="6.058308272496414"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="48.480912005581295" CI_END="1.8813705412952928" CI_START="1.2221581641186836" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5163549606792035" ESTIMABLE="YES" EVENTS_1="430" EVENTS_2="291" I2="56.68398317758047" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.2744743395118877" LOG_CI_START="0.08712741323802785" LOG_EFFECT_SIZE="0.18080087637495776" METHOD="MH" MODIFIED="2015-06-28 10:27:23 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="5.91175698851365E-4" P_Q="1.0" P_Z="1.5497271823706462E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11204988125053027" TOTALS="YES" TOTAL_1="1978" TOTAL_2="1983" WEIGHT="99.99999999999997" Z="3.7829625830123876">
<NAME>Nausea and Vomiting</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.84482413650977" CI_START="1.0921113702486183" EFFECT_SIZE="2.300236406619385" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="9" LOG_CI_END="0.6852780171082363" LOG_CI_START="0.03826692867838292" LOG_EFFECT_SIZE="0.36177247289330955" MODIFIED="2015-03-10 13:30:33 +0100" MODIFIED_BY="[Empty name]" ORDER="543" O_E="0.0" SE="0.38005751610023697" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.14444371554428187" WEIGHT="4.721628577613887"/>
<DICH_DATA CI_END="2.438894172007385" CI_START="0.41826333086047124" EFFECT_SIZE="1.01" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.3871929559060374" LOG_CI_START="-0.37855020834075226" LOG_EFFECT_SIZE="0.004321373782642578" MODIFIED="2015-03-16 13:14:48 +0100" MODIFIED_BY="[Empty name]" ORDER="552" O_E="0.0" SE="0.4498013251683595" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="0.2023212321232123" WEIGHT="3.8523498027682073"/>
<DICH_DATA CI_END="1.86124191819007" CI_START="0.6267090441909406" EFFECT_SIZE="1.0800264550264551" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.2698028249882639" LOG_CI_START="-0.2029340378453029" LOG_EFFECT_SIZE="0.033434393571480474" ORDER="186" O_E="0.0" SE="0.2776879733136486" STUDY_ID="STD-Evans-1987" TOTAL_1="144" TOTAL_2="142" VAR="0.07711061052304162" WEIGHT="6.402327913436733"/>
<DICH_DATA CI_END="1.3538450198747893" CI_START="0.39915943571023704" EFFECT_SIZE="0.7351190476190477" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.1315689517453663" LOG_CI_START="-0.398853600005723" LOG_EFFECT_SIZE="-0.1336423241301783" MODIFIED="2015-03-16 12:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.3115728325325667" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.09707762997236682" WEIGHT="5.7910481960001485"/>
<DICH_DATA CI_END="1.6103257424223556" CI_START="0.9203365187917316" EFFECT_SIZE="1.2173913043478262" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="23" LOG_CI_END="0.20691373555187884" LOG_CI_START="-0.03605334490262611" LOG_EFFECT_SIZE="0.08543019532462637" MODIFIED="2015-03-16 12:17:29 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.14272006576542146" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="0.020369017172086223" WEIGHT="9.14573003572513"/>
<DICH_DATA CI_END="1.3033008914643214" CI_START="0.8694804065518779" EFFECT_SIZE="1.064516129032258" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="62" LOG_CI_END="0.11504469231811024" LOG_CI_START="-0.06074020023088068" LOG_EFFECT_SIZE="0.027152246043614776" ORDER="189" O_E="0.0" SE="0.10325691603252898" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.010661990708548742" WEIGHT="9.869195842804974"/>
<DICH_DATA CI_END="4.012667793138969" CI_START="0.9208183837004156" EFFECT_SIZE="1.9222222222222223" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.6034332061881906" LOG_CI_START="-0.035826018809249474" LOG_EFFECT_SIZE="0.28380359368947056" MODIFIED="2015-03-16 13:14:47 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.3755040331476946" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.1410032789101849" WEIGHT="4.7858224565629"/>
<DICH_DATA CI_END="2.2192050578464753" CI_START="1.0441284751538877" EFFECT_SIZE="1.5222139117427076" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="35" LOG_CI_END="0.346197433541895" LOG_CI_START="0.01875393987077595" LOG_EFFECT_SIZE="0.1824756867063355" MODIFIED="2015-03-16 12:17:35 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.19234192905385006" STUDY_ID="STD-Goodman-1990" TOTAL_1="191" TOTAL_2="192" VAR="0.036995417672156285" WEIGHT="8.125499464626316"/>
<DICH_DATA CI_END="7.629768296486782" CI_START="0.5242623163067544" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8825113493460784" LOG_CI_START="-0.2804513580181161" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-03-16 12:17:36 +0100" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.4666666666666667" WEIGHT="2.0926781875513933"/>
<DICH_DATA CI_END="3.3801382140742957" CI_START="0.7037919618898496" EFFECT_SIZE="1.5423728813559323" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.5289344589707156" LOG_CI_START="-0.15255569761281668" LOG_EFFECT_SIZE="0.18818938067894944" MODIFIED="2015-03-16 13:14:46 +0100" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.400310691407848" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.1602486496554293" WEIGHT="4.447572642320316"/>
<DICH_DATA CI_END="1.581457860104591" CI_START="0.3296023734611707" EFFECT_SIZE="0.721978021978022" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.1990576240937461" LOG_CI_START="-0.4820096696163717" LOG_EFFECT_SIZE="-0.14147602276131283" MODIFIED="2015-03-16 13:14:46 +0100" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.4000622996627993" STUDY_ID="STD-Postmus-1996" TOTAL_1="70" TOTAL_2="73" VAR="0.16004984361148744" WEIGHT="4.450822202100695"/>
<DICH_DATA CI_END="10.323248585948573" CI_START="0.3874749277513839" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0138163853669309" LOG_CI_START="-0.41175639403896847" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2015-03-16 13:14:45 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.8373885073220924" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.7012195121951219" WEIGHT="1.4891344815895742"/>
<DICH_DATA CI_END="2.4557474539582085" CI_START="0.29114209251068907" EFFECT_SIZE="0.8455598455598455" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3901837024561708" LOG_CI_START="-0.5358950009384378" LOG_EFFECT_SIZE="-0.0728556492411335" ORDER="196" O_E="0.0" SE="0.5439832145375073" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.29591773769855967" WEIGHT="2.9685382867420347"/>
<DICH_DATA CI_END="18.596287648893874" CI_START="2.410131647307975" EFFECT_SIZE="6.6947368421052635" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="4" LOG_CI_END="1.2694262552654676" LOG_CI_START="0.3820407654536645" LOG_EFFECT_SIZE="0.8257335103595661" MODIFIED="2015-06-28 10:27:23 +0200" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.5212546293444712" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.2717063886130421" WEIGHT="3.155824651495337"/>
<DICH_DATA CI_END="2.182614041726222" CI_START="0.8824871840524421" EFFECT_SIZE="1.3878504672897196" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="24" LOG_CI_END="0.3389769448854973" LOG_CI_START="-0.054291592949454286" LOG_EFFECT_SIZE="0.14234267596802153" ORDER="198" O_E="0.0" SE="0.23100788583490897" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.05336464331791434" WEIGHT="7.3214096510627025"/>
<DICH_DATA CI_END="75.48800911134423" CI_START="0.1351042559048726" EFFECT_SIZE="3.193548387096774" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8778779716245122" LOG_CI_START="-0.8693309700979578" LOG_EFFECT_SIZE="0.5042735007632773" MODIFIED="2015-03-16 13:14:43 +0100" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="1.6137241312713606" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="2.6041055718475072" WEIGHT="0.4458756199760288"/>
<DICH_DATA CI_END="27.91286338913535" CI_START="1.5428874368640708" EFFECT_SIZE="6.5625" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.4458043900649478" LOG_CI_START="0.18833424276307875" LOG_EFFECT_SIZE="0.8170693164140133" MODIFIED="2015-03-16 13:14:44 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.7386441891027358" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.5455952380952381" WEIGHT="1.8415213022581849"/>
<DICH_DATA CI_END="2.4168803675304806" CI_START="1.0053386062963627" EFFECT_SIZE="1.5587761674718197" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="23" LOG_CI_END="0.38325515392142023" LOG_CI_START="0.002312360342206705" LOG_EFFECT_SIZE="0.19278375713181348" ORDER="200" O_E="0.0" SE="0.22376768264567043" STUDY_ID="STD-Urban-1999a" TOTAL_1="81" TOTAL_2="88" VAR="0.050071975796613474" WEIGHT="7.470106243905103"/>
<DICH_DATA CI_END="6.314727234973425" CI_START="1.126115324780301" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="6" LOG_CI_END="0.800354595919962" LOG_CI_START="0.0515828686246002" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="201" O_E="0.0" SE="0.43983221909312303" STUDY_ID="STD-Veronesi-1994" TOTAL_1="56" TOTAL_2="56" VAR="0.19345238095238096" WEIGHT="3.964185037022676"/>
<DICH_DATA CI_END="22.143710550118232" CI_START="1.1289887457396568" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3452503959654274" LOG_CI_START="0.05268961270660996" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2015-03-16 13:14:42 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.7592566023652967" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.5764705882352942" WEIGHT="1.7589418910170727"/>
<DICH_DATA CI_END="3.7793275451040893" CI_START="0.11364619847829956" EFFECT_SIZE="0.655367231638418" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.577414532792068" LOG_CI_START="-0.9444450870618444" LOG_EFFECT_SIZE="-0.1835152771348882" ORDER="203" O_E="0.0" SE="0.8939478740288024" STUDY_ID="STD-White-2001" TOTAL_1="59" TOTAL_2="58" VAR="0.7991428014806156" WEIGHT="1.3291014288782357"/>
<DICH_DATA CI_END="7.4459011446645675" CI_START="1.6077016410434957" EFFECT_SIZE="3.459882583170254" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="7" LOG_CI_END="0.8719172660199401" LOG_CI_START="0.20620545506474283" LOG_EFFECT_SIZE="0.5390613605423415" MODIFIED="2015-03-16 12:18:01 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.3910424130816935" STUDY_ID="STD-Wolf-1987" TOTAL_1="73" TOTAL_2="68" VAR="0.15291416882875383" WEIGHT="4.570686084542322"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.57705096127895" CI_END="1.2966126973362369" CI_START="0.9966072989500019" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1367557688776175" ESTIMABLE="YES" EVENTS_1="470" EVENTS_2="414" I2="57.772947574627366" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.11281027020230229" LOG_CI_START="-0.0014759364684922447" LOG_EFFECT_SIZE="0.05566716686690504" METHOD="MH" MODIFIED="2015-03-16 13:15:05 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.020336750110671042" P_Q="1.0" P_Z="0.056218179409041766" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.018236573603361488" TOTALS="YES" TOTAL_1="753" TOTAL_2="773" WEIGHT="99.99999999999997" Z="1.9093405120146814">
<NAME>Alopecia</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7862357205084254" CI_START="1.0430638901319151" EFFECT_SIZE="1.364975450081833" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="52" LOG_CI_END="0.25193876998422854" LOG_CI_START="0.01831091080614038" LOG_EFFECT_SIZE="0.13512484039518444" MODIFIED="2015-03-10 13:31:04 +0100" MODIFIED_BY="[Empty name]" ORDER="544" O_E="0.0" SE="0.1372341609577633" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.01883321493378129" WEIGHT="12.15745670269356"/>
<DICH_DATA CI_END="1.041231189285013" CI_START="0.6220816798490458" EFFECT_SIZE="0.8048172757475083" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="43" LOG_CI_END="0.017547168591542685" LOG_CI_START="-0.2061525883336236" LOG_EFFECT_SIZE="-0.09430270987104043" MODIFIED="2015-03-16 12:19:23 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.13140234454949828" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.017266576153105062" WEIGHT="12.693925812490297"/>
<DICH_DATA CI_END="1.4205973212868992" CI_START="0.7039292451249408" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.15247099142049697" LOG_CI_START="-0.152470991420497" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-03-16 12:19:23 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.17912443020795965" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="0.03208556149732621" WEIGHT="8.955787512127252"/>
<DICH_DATA CI_END="1.402992796367947" CI_START="1.050960346863869" EFFECT_SIZE="1.2142857142857142" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="70" LOG_CI_END="0.14705544115973418" LOG_CI_START="0.021586330240337556" LOG_EFFECT_SIZE="0.08432088570003587" MODIFIED="2015-03-11 08:15:26 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.07370117683616931" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.005431863467036299" WEIGHT="19.041153743183987"/>
<DICH_DATA CI_END="1.2374427732504705" CI_START="0.9778560021923477" EFFECT_SIZE="1.1000185649308456" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="126" LOG_CI_END="0.09252512369755723" LOG_CI_START="-0.009725094146586412" LOG_EFFECT_SIZE="0.04140001477548543" MODIFIED="2015-03-16 13:15:04 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.060062284108391345" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.0036074779723171196" WEIGHT="20.63144502094588"/>
<DICH_DATA CI_END="1.6852453434336367" CI_START="0.7638959371832329" EFFECT_SIZE="1.1346153846153846" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.2266631357966648" LOG_CI_START="-0.11696579978197474" LOG_EFFECT_SIZE="0.05484866800734502" MODIFIED="2015-03-16 13:15:05 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.2018493377495572" STUDY_ID="STD-Kanitz-1992" TOTAL_1="52" TOTAL_2="59" VAR="0.04074315514993482" WEIGHT="7.641173648041433"/>
<DICH_DATA CI_END="2.754333686801538" CI_START="1.2363407428808018" EFFECT_SIZE="1.8453441295546558" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="26" LOG_CI_END="0.4400165537705157" LOG_CI_START="0.09213818139886644" LOG_EFFECT_SIZE="0.266077367584691" ORDER="210" O_E="0.0" SE="0.20434547795682245" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.04175707436140221" WEIGHT="7.51203443042863"/>
<DICH_DATA CI_END="1.3994777106571146" CI_START="0.7886097857124625" EFFECT_SIZE="1.0505435819187487" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.14596598589206522" LOG_CI_START="-0.10313783814973973" LOG_EFFECT_SIZE="0.02141407387116274" ORDER="211" O_E="0.0" SE="0.14632481932597216" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.021410952750778395" WEIGHT="11.367023130088953"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="27.51775207938458" CI_END="1.0917964635005801" CI_START="0.43075189806671554" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6857794098362843" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="195" I2="60.02580454876309" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.038141683224503" LOG_CI_START="-0.3657728001989479" LOG_EFFECT_SIZE="-0.1638155584872225" METHOD="MH" MODIFIED="2015-03-16 13:15:22 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.003835414671315207" P_Q="1.0" P_Z="0.11187880882293752" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.32093708144060007" TOTALS="YES" TOTAL_1="1096" TOTAL_2="1088" WEIGHT="100.00000000000001" Z="1.5898048122511552">
<NAME>Infection</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5228322289954744" CI_START="0.2974055075874221" EFFECT_SIZE="0.3943262411347518" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="100" LOG_CI_END="-0.2816376490113907" LOG_CI_START="-0.5266509931352542" LOG_EFFECT_SIZE="-0.40414432107332243" MODIFIED="2015-03-10 13:31:36 +0100" MODIFIED_BY="[Empty name]" ORDER="545" O_E="0.0" SE="0.14392205117397117" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.020713556814123173" WEIGHT="16.476760162055413"/>
<DICH_DATA CI_END="0.3445465728152932" CI_START="0.03398765959843351" EFFECT_SIZE="0.10821428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="28" LOG_CI_END="-0.46275206562974297" LOG_CI_START="-1.4686787400500851" LOG_EFFECT_SIZE="-0.9657154028399142" MODIFIED="2015-03-16 13:15:19 +0100" MODIFIED_BY="[Empty name]" ORDER="553" O_E="0.0" SE="0.5908863079718544" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="0.3491466289486091" WEIGHT="8.400884155901249"/>
<DICH_DATA CI_END="0.9309951103040041" CI_START="0.2389098209624071" EFFECT_SIZE="0.4716183574879227" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" LOG_CI_END="-0.03105259997844881" LOG_CI_START="-0.6217659971646732" LOG_EFFECT_SIZE="-0.32640929857156104" ORDER="213" O_E="0.0" SE="0.34698797358566325" STUDY_ID="STD-Evans-1987" TOTAL_1="144" TOTAL_2="142" VAR="0.12040065381308492" WEIGHT="12.755074347994418"/>
<DICH_DATA CI_END="71.14657198220529" CI_START="0.1264994187246438" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8521539795421889" LOG_CI_START="-0.8979114701028642" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2015-03-16 13:15:20 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="1.6154020581650284" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="2.6095238095238096" WEIGHT="1.9209591375517852"/>
<DICH_DATA CI_END="3.597756455624597" CI_START="0.008675159504562026" EFFECT_SIZE="0.17666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5560317611334291" LOG_CI_START="-2.061722531371176" LOG_EFFECT_SIZE="-0.7528453851188734" MODIFIED="2015-03-16 13:15:20 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="1.5376818295099384" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="2.364465408805031" WEIGHT="2.0962576917925335"/>
<DICH_DATA CI_END="1.116907527796816" CI_START="0.2178236702236388" EFFECT_SIZE="0.49324324324324326" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.048017218030543526" LOG_CI_START="-0.6618949285795463" LOG_EFFECT_SIZE="-0.3069388552745015" ORDER="216" O_E="0.0" SE="0.41700590904056756" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.1738939281747501" WEIGHT="11.3761981693752"/>
<DICH_DATA CI_END="3.7374038530554707" CI_START="0.4534068428258066" EFFECT_SIZE="1.3017543859649123" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5725700289914676" LOG_CI_START="-0.34351192977839623" LOG_EFFECT_SIZE="0.11452904960653569" ORDER="217" O_E="0.0" SE="0.5381110772602483" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.28956353147018493" WEIGHT="9.220786198553515"/>
<DICH_DATA CI_END="5.214016141218641" CI_START="0.4396328159322617" EFFECT_SIZE="1.514018691588785" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7171723712955507" LOG_CI_START="-0.3569098975807081" LOG_EFFECT_SIZE="0.1801312368574213" ORDER="218" O_E="0.0" SE="0.6309212415308935" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.398061613014884" WEIGHT="7.829354446880377"/>
<DICH_DATA CI_END="10.808553602771239" CI_START="0.4210656928179768" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0337675806911957" LOG_CI_START="-0.3756501421627463" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2015-03-16 13:15:21 +0100" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.8278989471346528" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.6854166666666667" WEIGHT="5.593754319814195"/>
<DICH_DATA CI_END="4.200031063197353" CI_START="0.3269716330572937" EFFECT_SIZE="1.171875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6232525024277369" LOG_CI_START="-0.4854899236121111" LOG_EFFECT_SIZE="0.06888128940781288" MODIFIED="2015-03-16 13:15:22 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.6512807894193308" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.4241666666666667" WEIGHT="7.555049400886685"/>
<DICH_DATA CI_END="3.011180381744043" CI_START="0.43375762438485993" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4787367722678651" LOG_CI_START="-0.36275287831249164" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2015-03-16 13:15:22 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.4942951861918513" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.24432773109243694" WEIGHT="9.958687505260595"/>
<DICH_DATA CI_END="6.250064803114797" CI_START="0.3856426727183044" EFFECT_SIZE="1.552511415525114" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7958845203023575" LOG_CI_START="-0.41381491589808395" LOG_EFFECT_SIZE="0.19103480220213676" MODIFIED="2015-03-16 12:20:19 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.7105834369329235" STUDY_ID="STD-Wolf-1987" TOTAL_1="73" TOTAL_2="68" VAR="0.504928820843406" WEIGHT="6.816234463934046"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.893289687394745" CI_END="1.6657362823873765" CI_START="0.8561093238257758" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1941743433798595" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="147" I2="51.950985855664506" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.2216062454683159" LOG_CI_START="-0.06747077305337744" LOG_EFFECT_SIZE="0.07706773620746926" METHOD="MH" MODIFIED="2015-06-05 14:25:29 +0200" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.01829765790788107" P_Q="1.0" P_Z="0.29599981799464414" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.15469959300169728" TOTALS="YES" TOTAL_1="1112" TOTAL_2="1107" WEIGHT="99.99999999999999" Z="1.0450501261506397">
<NAME>Anaemia</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.081247057941745" CI_START="0.45376058755507637" EFFECT_SIZE="0.700447928331467" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="0.033924938765213845" LOG_CI_START="-0.3431732284834291" LOG_EFFECT_SIZE="-0.15462414485910767" MODIFIED="2015-03-10 13:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="546" O_E="0.0" SE="0.221509330107886" STUDY_ID="STD-Baka-2008" TOTAL_1="141" TOTAL_2="139" VAR="0.04906638332484442" WEIGHT="14.150463583025566"/>
<DICH_DATA CI_END="1.0002158781648949" CI_START="0.2776232430071701" EFFECT_SIZE="0.5269565217391304" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="23" LOG_CI_END="9.374457743760144E-5" LOG_CI_START="-0.5565441769520885" LOG_EFFECT_SIZE="-0.2782252161873255" MODIFIED="2015-06-05 14:25:25 +0200" MODIFIED_BY="[Empty name]" ORDER="554" O_E="0.0" SE="0.32697187050859383" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="0.10691060410388867" WEIGHT="11.021676751784424"/>
<DICH_DATA CI_END="6.763634989752608" CI_START="0.4254916036006323" EFFECT_SIZE="1.6964285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8301801621702862" LOG_CI_START="-0.37110900560499155" LOG_EFFECT_SIZE="0.22953557828264734" MODIFIED="2015-03-16 12:20:55 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.7056432036284822" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.4979323308270676" WEIGHT="4.41808456220249"/>
<DICH_DATA CI_END="2.188818991308803" CI_START="0.46761683408126986" EFFECT_SIZE="1.0116959064327486" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.34020984821657374" LOG_CI_START="-0.33010986274329046" LOG_EFFECT_SIZE="0.005049992736641626" MODIFIED="2015-06-05 14:25:26 +0200" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.3937491163539077" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.15503836662948314" WEIGHT="9.309104479482455"/>
<DICH_DATA CI_END="2.2356506221054393" CI_START="0.8211065257607717" EFFECT_SIZE="1.3548827680400637" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="23" LOG_CI_END="0.3494039348372962" LOG_CI_START="-0.08560049629229248" LOG_EFFECT_SIZE="0.13190171927250186" MODIFIED="2015-03-16 12:21:03 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.2555237561521826" STUDY_ID="STD-Goodman-1990" TOTAL_1="191" TOTAL_2="192" VAR="0.06529238995812008" WEIGHT="13.106764113286083"/>
<DICH_DATA CI_END="3.610561179357457" CI_START="0.4923826766713739" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5575747083203917" LOG_CI_START="-0.307697235103792" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2015-03-16 12:21:04 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.5082650227325635" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.2583333333333333" WEIGHT="6.98100040849898"/>
<DICH_DATA CI_END="3.597756455624597" CI_START="0.008675159504562026" EFFECT_SIZE="0.17666666666666667" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5560317611334291" LOG_CI_START="-2.061722531371176" LOG_EFFECT_SIZE="-0.7528453851188734" MODIFIED="2015-06-05 14:25:28 +0200" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="1.5376818295099384" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="2.364465408805031" WEIGHT="1.1445788685538398"/>
<DICH_DATA CI_END="4.799649331704858" CI_START="1.175216064794555" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.681209508444589" LOG_CI_START="0.0701177194771817" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2015-06-05 14:25:28 +0200" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.3589583417925963" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.12885109114249038" WEIGHT="10.168845249557414"/>
<DICH_DATA CI_END="3.227972574247427" CI_START="1.1398390279791761" EFFECT_SIZE="1.9181681681681682" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="18" LOG_CI_END="0.508929836179028" LOG_CI_START="0.056843523093870515" LOG_EFFECT_SIZE="0.28288667963644926" ORDER="228" O_E="0.0" SE="0.2655577381695631" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.07052091230173421" WEIGHT="12.802488936714262"/>
<DICH_DATA CI_END="2.2584403602830054" CI_START="0.385713577577914" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3538086264263115" LOG_CI_START="-0.41373507318119795" LOG_EFFECT_SIZE="-0.02996322337744321" MODIFIED="2015-06-05 14:25:29 +0200" MODIFIED_BY="[Empty name]" ORDER="563" O_E="0.0" SE="0.45085896855204016" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.20327380952380952" WEIGHT="8.054740958758597"/>
<DICH_DATA CI_END="27.9737812885403" CI_START="0.3217298336312841" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4467511750505695" LOG_CI_START="-0.49250866561124457" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="229" O_E="0.0" SE="1.1391308298957796" STUDY_ID="STD-Veronesi-1994" TOTAL_1="56" TOTAL_2="56" VAR="1.2976190476190477" WEIGHT="1.9853652957562895"/>
<DICH_DATA CI_END="5.400792805223521" CI_START="0.7157385987868226" EFFECT_SIZE="1.9661016949152543" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7324575164268821" LOG_CI_START="-0.14524556125733348" LOG_EFFECT_SIZE="0.2936059775847743" ORDER="230" O_E="0.0" SE="0.5155671325320131" STUDY_ID="STD-White-2001" TOTAL_1="59" TOTAL_2="58" VAR="0.26580946814728235" WEIGHT="6.856886792379585"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="125.4811565692734" CI_END="1.0474621184860151" CI_START="0.6733822782778948" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8398466691937898" ESTIMABLE="YES" EVENTS_1="526" EVENTS_2="649" I2="87.24908150558286" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.020138325643130048" LOG_CI_START="-0.17173831733224082" LOG_EFFECT_SIZE="-0.07579999584455538" METHOD="MH" MODIFIED="2015-06-05 14:27:22 +0200" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="0.12148999819902842" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.16803115345744507" TOTALS="YES" TOTAL_1="1277" TOTAL_2="1279" WEIGHT="99.99999999999997" Z="1.5485497304920441">
<NAME>Leukopenia</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4878518252251138" CI_START="0.2749792407560844" EFFECT_SIZE="0.36626373626373626" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="91" LOG_CI_END="-0.3117120658227183" LOG_CI_START="-0.5607000914984087" LOG_EFFECT_SIZE="-0.43620607866056355" MODIFIED="2015-06-05 14:27:22 +0200" MODIFIED_BY="[Empty name]" ORDER="555" O_E="0.0" SE="0.14625679879250533" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="0.02139105119303139" WEIGHT="6.706385901587096"/>
<DICH_DATA CI_END="1.410704332506909" CI_START="0.9538497678027154" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.14943600013557976" LOG_CI_START="-0.020520021681742873" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2015-03-16 12:21:45 +0100" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.09983300851137156" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="0.009966629588431586" WEIGHT="7.1368214871984526"/>
<DICH_DATA CI_END="1.410704332506909" CI_START="0.9538497678027154" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="25" LOG_CI_END="0.14943600013557976" LOG_CI_START="-0.020520021681742873" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2015-03-16 12:21:46 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.09983300851137156" STUDY_ID="STD-Farris-1993" TOTAL_1="31" TOTAL_2="31" VAR="0.009966629588431586" WEIGHT="7.1368214871984526"/>
<DICH_DATA CI_END="3.393710447195691" CI_START="1.36695611679872" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" LOG_CI_END="0.5306747853742467" LOG_CI_START="0.13575457269651817" LOG_EFFECT_SIZE="0.33321467903538243" MODIFIED="2015-03-16 12:21:47 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.2319780878134785" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="0.05381383322559794" WEIGHT="5.726243453634919"/>
<DICH_DATA CI_END="0.7513070997426861" CI_START="0.466638266534886" EFFECT_SIZE="0.5921052631578947" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="76" LOG_CI_END="-0.12418250712123974" LOG_CI_START="-0.3310196498896557" LOG_EFFECT_SIZE="-0.2276010785054477" MODIFIED="2015-06-05 14:27:13 +0200" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.12149716152253684" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.014761560258033405" WEIGHT="6.949611813810123"/>
<DICH_DATA CI_END="1.8643556010985156" CI_START="0.975997503661447" EFFECT_SIZE="1.3489278752436646" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="45" LOG_CI_END="0.27052875182999964" LOG_CI_START="-0.010551293140116593" LOG_EFFECT_SIZE="0.12998872934494152" MODIFIED="2015-06-05 14:27:13 +0200" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.16510780978410855" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.02726058885170537" WEIGHT="6.504823950541296"/>
<DICH_DATA CI_END="1.5203734849337154" CI_START="0.8952478615282168" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="36" LOG_CI_END="0.181950286971985" LOG_CI_START="-0.04805670771075857" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2015-03-16 12:21:51 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.1351072472296296" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.018253968253968255" WEIGHT="6.819322933816834"/>
<DICH_DATA CI_END="1.2059451329357134" CI_START="0.16103308890577764" EFFECT_SIZE="0.4406779661016949" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.08132754909325916" LOG_CI_START="-0.7930848764359116" LOG_EFFECT_SIZE="-0.35587866367132626" MODIFIED="2015-06-05 14:27:12 +0200" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.513634187167149" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.26382007822685793" WEIGHT="2.9416111603084616"/>
<DICH_DATA CI_END="0.883518518394665" CI_START="0.36957981688736674" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="-0.05378434332492273" LOG_CI_START="-0.4322917540476663" LOG_EFFECT_SIZE="-0.24303804868629447" MODIFIED="2015-06-05 14:27:11 +0200" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.22233712670044034" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.049433797909407655" WEIGHT="5.841577664496851"/>
<DICH_DATA CI_END="0.9327243750967067" CI_START="0.4871852902515848" EFFECT_SIZE="0.6740990990990992" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="60" LOG_CI_END="-0.030246673573082705" LOG_CI_START="-0.3123058329757741" LOG_EFFECT_SIZE="-0.17127625327442839" ORDER="239" O_E="0.0" SE="0.1656829464484978" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.027450838743855788" WEIGHT="6.498493229020035"/>
<DICH_DATA CI_END="1.8241977188443124" CI_START="0.9217774397288069" EFFECT_SIZE="1.296728307254623" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" LOG_CI_END="0.26107190830676014" LOG_CI_START="-0.035373925329732124" LOG_EFFECT_SIZE="0.11284899148851397" ORDER="240" O_E="0.0" SE="0.17413375010861845" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.030322562926890777" WEIGHT="6.404409384768252"/>
<DICH_DATA CI_END="0.9383615117014474" CI_START="0.6408599971331577" EFFECT_SIZE="0.7754729883747435" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="82" LOG_CI_END="-0.02762981376387747" LOG_CI_START="-0.19323683649291243" LOG_EFFECT_SIZE="-0.11043332512839493" ORDER="241" O_E="0.0" SE="0.09727838491901869" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.009463084172452764" WEIGHT="7.157068419113117"/>
<DICH_DATA CI_END="0.9129537491148914" CI_START="0.39082714919242695" EFFECT_SIZE="0.5973333333333334" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="-0.03955122357520326" LOG_CI_START="-0.4080152752119088" LOG_EFFECT_SIZE="-0.223783249393556" MODIFIED="2015-06-05 14:27:10 +0200" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.2164376078578723" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.046845238095238106" WEIGHT="5.911949626183297"/>
<DICH_DATA CI_END="3.4858515524746565" CI_START="0.5854570384908696" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5423088884211806" LOG_CI_START="-0.2325049684496942" LOG_EFFECT_SIZE="0.1549019599857432" ORDER="242" O_E="0.0" SE="0.45512949491639976" STUDY_ID="STD-Veronesi-1994" TOTAL_1="56" TOTAL_2="56" VAR="0.20714285714285716" WEIGHT="3.385997875180317"/>
<DICH_DATA CI_END="1.3576587816064802" CI_START="0.8005819811355948" EFFECT_SIZE="1.0425531914893618" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="47" LOG_CI_END="0.13279063306232886" LOG_CI_START="-0.09659418887673644" LOG_EFFECT_SIZE="0.018098222092796223" MODIFIED="2015-06-05 14:27:10 +0200" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.1347417798801882" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.01815534724528109" WEIGHT="6.822935056627876"/>
<DICH_DATA CI_END="0.4584422846421591" CI_START="0.07795798556312876" EFFECT_SIZE="0.18904823989569752" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="26" LOG_CI_END="-0.3387153318351093" LOG_CI_START="-1.1081393915929028" LOG_EFFECT_SIZE="-0.723427361714006" ORDER="244" O_E="0.0" SE="0.45196350141224984" STUDY_ID="STD-White-2001" TOTAL_1="59" TOTAL_2="58" VAR="0.20427100660882075" WEIGHT="3.4121166594612133"/>
<DICH_DATA CI_END="1.540644327024947" CI_START="0.4312070196044482" EFFECT_SIZE="0.815068493150685" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.18770238911481718" LOG_CI_START="-0.3653141778986298" LOG_EFFECT_SIZE="-0.08880589439190632" MODIFIED="2015-03-16 12:22:07 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.3248446689398549" STUDY_ID="STD-Wolf-1987" TOTAL_1="73" TOTAL_2="68" VAR="0.10552405893864394" WEIGHT="4.643809897053392"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="47.76863813665331" CI_END="2.6095287440517465" CI_START="1.3669130139992214" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8886499942152795" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="162" I2="62.31837309553015" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.41656208498696046" LOG_CI_START="0.13574087832631768" LOG_EFFECT_SIZE="0.27615148165663905" METHOD="MH" MODIFIED="2015-06-05 14:25:55 +0200" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.6295688895218152E-4" P_Q="1.0" P_Z="1.1585069734295761E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="19" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.28135745718830907" TOTALS="YES" TOTAL_1="1637" TOTAL_2="1639" WEIGHT="100.0" Z="3.854744196569553">
<NAME>Thrombocytopenia</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="47.76863813665331" CI_END="2.6095287440517465" CI_START="1.3669130139992214" DF="18" EFFECT_SIZE="1.8886499942152795" ESTIMABLE="YES" EVENTS_1="305" EVENTS_2="162" I2="62.31837309553015" ID="CMP-001.12.01" LOG_CI_END="0.41656208498696046" LOG_CI_START="0.13574087832631768" LOG_EFFECT_SIZE="0.27615148165663905" MODIFIED="2015-06-05 14:25:55 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.6295688895218152E-4" P_Z="1.1585069734295761E-4" STUDIES="19" TAU2="0.28135745718830907" TOTAL_1="1637" TOTAL_2="1639" WEIGHT="100.0" Z="3.854744196569553">
<NAME>New Subgroup</NAME>
<DICH_DATA CI_END="1.2385401446849695" CI_START="0.4740040206550997" EFFECT_SIZE="0.7662068965517241" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.0929100878961018" LOG_CI_START="-0.3242179744843164" LOG_EFFECT_SIZE="-0.11565394329410728" MODIFIED="2015-06-05 14:25:51 +0200" MODIFIED_BY="[Empty name]" ORDER="556" O_E="0.0" SE="0.24502308865946737" STUDY_ID="STD-de-Jong-2007" TOTAL_1="100" TOTAL_2="101" VAR="0.06003631397622521" WEIGHT="7.970387079442814"/>
<DICH_DATA CI_END="46.9646630187618" CI_START="0.7665337657297455" EFFECT_SIZE="6.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6717712105304205" LOG_CI_START="-0.11546870976313321" LOG_EFFECT_SIZE="0.7781512503836436" MODIFIED="2015-03-16 12:22:42 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="1.0498335761607211" STUDY_ID="STD-Eagan-1981" TOTAL_1="31" TOTAL_2="31" VAR="1.1021505376344087" WEIGHT="1.9667689040284395"/>
<DICH_DATA CI_END="6.085270157622609" CI_START="0.7734232130409793" EFFECT_SIZE="2.1694444444444443" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7842798636441934" LOG_CI_START="-0.1115827974241673" LOG_EFFECT_SIZE="0.336348533110013" ORDER="247" O_E="0.0" SE="0.5262341617032475" STUDY_ID="STD-Evans-1987" TOTAL_1="144" TOTAL_2="142" VAR="0.2769223929435197" WEIGHT="4.873972259700096"/>
<DICH_DATA CI_END="6.763634989752608" CI_START="0.4254916036006323" EFFECT_SIZE="1.6964285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8301801621702862" LOG_CI_START="-0.37110900560499155" LOG_EFFECT_SIZE="0.22953557828264734" MODIFIED="2015-03-16 12:22:47 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.7056432036284822" STUDY_ID="STD-Farris-1993" TOTAL_1="56" TOTAL_2="57" VAR="0.4979323308270676" WEIGHT="3.4916927496531884"/>
<DICH_DATA CI_END="7.750000724475854" CI_START="1.321290199065439" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.8893017431044846" LOG_CI_START="0.12099821353532728" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2015-03-16 12:22:47 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.4513052964327311" STUDY_ID="STD-Fukuoka-1986" TOTAL_1="34" TOTAL_2="34" VAR="0.2036764705882353" WEIGHT="5.610000346090525"/>
<DICH_DATA CI_END="2.9148457526595486" CI_START="0.8120031405318386" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="13" LOG_CI_END="0.4646155777772883" LOG_CI_START="-0.09044229106299932" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="250" O_E="0.0" SE="0.3260437397375481" STUDY_ID="STD-Fukuoka-1991" TOTAL_1="97" TOTAL_2="97" VAR="0.10630452022204598" WEIGHT="7.019105976988132"/>
<DICH_DATA CI_END="7.103101504836543" CI_START="1.8674843290484124" EFFECT_SIZE="3.642105263157895" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="10" LOG_CI_END="0.8514480208772385" LOG_CI_START="0.2712569661306193" LOG_EFFECT_SIZE="0.5613524935039289" MODIFIED="2015-06-05 14:25:52 +0200" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.340807097550204" STUDY_ID="STD-Gatzemeier-1994" TOTAL_1="171" TOTAL_2="173" VAR="0.11614947774059425" WEIGHT="6.845265487453034"/>
<DICH_DATA CI_END="4.330047758477452" CI_START="1.45855581751292" EFFECT_SIZE="2.513089005235602" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="16" LOG_CI_END="0.6364926864524042" LOG_CI_START="0.1639230538033151" LOG_EFFECT_SIZE="0.4002078701278597" MODIFIED="2015-03-16 12:22:50 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.2775897414754836" STUDY_ID="STD-Goodman-1990" TOTAL_1="191" TOTAL_2="192" VAR="0.07705606457242582" WEIGHT="7.59190247433951"/>
<DICH_DATA CI_END="6.213741028168057" CI_START="1.6709283509428394" EFFECT_SIZE="3.2222222222222223" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="9" LOG_CI_END="0.7933531490828966" LOG_CI_START="0.22295782783636586" LOG_EFFECT_SIZE="0.5081554884596312" MODIFIED="2015-03-16 12:22:51 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.33505303520258917" STUDY_ID="STD-Greco-2005" TOTAL_1="60" TOTAL_2="60" VAR="0.11226053639846745" WEIGHT="6.912896633350131"/>
<DICH_DATA CI_END="4.7203775945153845" CI_START="0.0411401558284584" EFFECT_SIZE="0.4406779661016949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6739767402983643" LOG_CI_START="-1.3857340676410168" LOG_EFFECT_SIZE="-0.35587866367132626" MODIFIED="2015-06-05 14:25:53 +0200" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="1.2098843243165265" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="1.463820078226858" WEIGHT="1.559176901761311"/>
<DICH_DATA CI_END="3.4991115269648176" CI_START="0.75465585467935" EFFECT_SIZE="1.625" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.5439577849446109" LOG_CI_START="-0.12225105431482455" LOG_EFFECT_SIZE="0.21085336531489318" MODIFIED="2015-06-05 14:25:52 +0200" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.3913343699679328" STUDY_ID="STD-Quoix-2005" TOTAL_1="41" TOTAL_2="41" VAR="0.1531425891181989" WEIGHT="6.262463090216948"/>
<DICH_DATA CI_END="7.0121896338920235" CI_START="0.9381565699852492" EFFECT_SIZE="2.5648648648648646" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8458536524073919" LOG_CI_START="-0.027724675686796478" LOG_EFFECT_SIZE="0.40906448836029763" ORDER="256" O_E="0.0" SE="0.5131442342049914" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.2633170050978271" WEIGHT="4.9957188946791575"/>
<DICH_DATA CI_END="3.0647003206933707" CI_START="0.4062342217208423" EFFECT_SIZE="1.1157894736842104" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.4863880137868109" LOG_CI_START="-0.391223493834966" LOG_EFFECT_SIZE="0.04758225997592244" ORDER="257" O_E="0.0" SE="0.5155133438240577" STUDY_ID="STD-Sculier-1990" TOTAL_1="95" TOTAL_2="106" VAR="0.2657540076606611" WEIGHT="4.973466427802245"/>
<DICH_DATA CI_END="0.9872045039865203" CI_START="0.20384862729201622" EFFECT_SIZE="0.4485981308411215" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.005592871896702469" LOG_CI_START="-0.6906922087225424" LOG_EFFECT_SIZE="-0.34814254030962244" MODIFIED="2008-05-27 01:35:08 +0200" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.4024307417479098" STUDY_ID="STD-Sculier-1993" TOTAL_1="107" TOTAL_2="108" VAR="0.16195050190377291" WEIGHT="6.13803665574806"/>
<DICH_DATA CI_END="3.2828239813115005" CI_START="0.47174078906599004" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5162475973213355" LOG_CI_START="-0.326296570859622" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2015-06-05 14:25:54 +0200" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="0.49491461505039047" STUDY_ID="STD-Sekine-2014" TOTAL_1="30" TOTAL_2="32" VAR="0.2449404761904762" WEIGHT="5.1701523607041855"/>
<DICH_DATA CI_END="132.45797781714737" CI_START="0.3699286430874132" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1220781205617074" LOG_CI_START="-0.4318820405331937" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="259" O_E="0.0" SE="1.5002088409338348" STUDY_ID="STD-Veronesi-1994" TOTAL_1="56" TOTAL_2="56" VAR="2.25062656641604" WEIGHT="1.0746673270151936"/>
<DICH_DATA CI_END="5.9161221144315395" CI_START="1.6243748546970949" EFFECT_SIZE="3.1" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="10" LOG_CI_END="0.7720371296717856" LOG_CI_START="0.21068625799675986" LOG_EFFECT_SIZE="0.4913616938342727" MODIFIED="2015-06-05 14:25:55 +0200" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.32974028075353967" STUDY_ID="STD-Wampler-1991" TOTAL_1="85" TOTAL_2="85" VAR="0.10872865275142315" WEIGHT="6.97548677934843"/>
<DICH_DATA CI_END="32.685938483935146" CI_START="1.8922171693609584" EFFECT_SIZE="7.864406779661017" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="2" LOG_CI_END="1.5143609590141323" LOG_CI_START="0.27697097881134125" LOG_EFFECT_SIZE="0.8956659689127366" ORDER="261" O_E="0.0" SE="0.7268489995503071" STUDY_ID="STD-White-2001" TOTAL_1="59" TOTAL_2="58" VAR="0.5283094681472823" WEIGHT="3.3606911898546947"/>
<DICH_DATA CI_END="2.763033217968831" CI_START="0.8194791039017613" EFFECT_SIZE="1.5047418335089568" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.44138610615930685" LOG_CI_START="-0.08646211613358096" LOG_EFFECT_SIZE="0.17746199501286294" MODIFIED="2015-03-16 12:23:02 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.31006065866568283" STUDY_ID="STD-Wolf-1987" TOTAL_1="73" TOTAL_2="68" VAR="0.09613761205219706" WEIGHT="7.208148461823899"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9375263825405475" CI_END="1.0026527781556431" CI_START="0.786373729060397" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8879525911393131" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="273" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.0011505614963444061" LOG_CI_START="-0.10437100371442729" LOG_EFFECT_SIZE="-0.05161022110904141" METHOD="MH" MODIFIED="2015-06-05 14:27:05 +0200" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.7472484473008492" P_Q="1.0" P_Z="0.055209634492695746" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="622" TOTAL_2="607" WEIGHT="100.0" Z="1.9172227858034872">
<NAME>Granulocytopenia</NAME>
<GROUP_LABEL_1>Platinum</GROUP_LABEL_1>
<GROUP_LABEL_2>Non-Platinum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Platinum</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Non-Platinum</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0727003284915677" CI_START="0.7012337761023197" EFFECT_SIZE="0.8673025435073628" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="83" LOG_CI_END="0.030478413615839178" LOG_CI_START="-0.1541371735514616" LOG_EFFECT_SIZE="-0.06182937996781117" ORDER="263" O_E="0.0" SE="0.10844410976396751" STUDY_ID="STD-Evans-1987" TOTAL_1="144" TOTAL_2="142" VAR="0.011760124942499433" WEIGHT="32.66974293813236"/>
<DICH_DATA CI_END="1.0490921115776386" CI_START="0.7120823163781136" EFFECT_SIZE="0.8643147232959828" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="107" LOG_CI_END="0.020813621457290946" LOG_CI_START="-0.14746979922495554" LOG_EFFECT_SIZE="-0.06332808888383229" MODIFIED="2015-03-16 12:24:15 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.0988505143251187" STUDY_ID="STD-Goodman-1990" TOTAL_1="191" TOTAL_2="192" VAR="0.009771424182340498" WEIGHT="39.318757595860454"/>
<DICH_DATA CI_END="1.340360364764633" CI_START="0.23468849323532973" EFFECT_SIZE="0.5608628659476117" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.12722157701274825" LOG_CI_START="-0.6295082033153747" LOG_EFFECT_SIZE="-0.2511433131513133" MODIFIED="2015-06-05 14:27:04 +0200" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.44450681883756477" STUDY_ID="STD-Kanitz-1992" TOTAL_1="59" TOTAL_2="52" VAR="0.19758631199309162" WEIGHT="1.9444679892866674"/>
<DICH_DATA CI_END="1.2537794792214156" CI_START="0.7761776326286443" EFFECT_SIZE="0.9864864864864865" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="70" LOG_CI_END="0.09822115740449089" LOG_CI_START="-0.11003887662553148" LOG_EFFECT_SIZE="-0.005908859610520279" ORDER="266" O_E="0.0" SE="0.12233297489302981" STUDY_ID="STD-Roth-1992" TOTAL_1="148" TOTAL_2="146" VAR="0.014965356746178663" WEIGHT="25.67264284494112"/>
<DICH_DATA CI_END="6.487930566098302" CI_START="0.1354678878027135" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8121061934038206" LOG_CI_START="-0.8681636406043076" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2015-06-05 14:27:05 +0200" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.9869988179661953" STUDY_ID="STD-Souhami-1997" TOTAL_1="80" TOTAL_2="75" VAR="0.9741666666666667" WEIGHT="0.39438863177940975"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-31 11:05:47 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAK8CAYAAADFzDkhAAA/p0lEQVR42u3df8QV+fv48TdJkiSS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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-07-29 22:56:50 +0200" MODIFIED_BY="Denise M Mitchell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApEAAAGvCAMAAAA0bX65AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Survival Graph.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2015-06-15 12:21:22 +0200" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Survival by Subgroup</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-07-31 11:09:02 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-07-31 11:09:02 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-05-01 13:56:12 +0200" MODIFIED_BY="[Empty name]">Search strategy used in original review</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-31 11:09:02 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (accessed through PubMed)</HEADING>
<P>#1 (carcinoma, small cell AND lung neoplasms[MeSH]) OR SCLC[ti] OR ((lung[ti] OR lungs[ti] OR pulmonary[ti] OR bronchus[ti] OR bronchogenic[ti] OR bronchial[ti] OR bronchoalveolar[ti] OR alveolar[ti]) AND (small-cell[ti] OR oat-cell[ti]) AND (cancer*[ti] OR carcinoma*[ti] OR malignan*[ti] OR tumor*[ti] OR tumour*[ti] OR neoplasm*[ti]))</P>
<P>#2 "Platinum Compounds"[MeSH] OR "Cisplatin"[MeSH] OR platinum[tiab] OR cisplatin[tiab] OR Platinol[ti] OR carboplatin[tiab] OR Paraplatin[ti] OR oxaliplatin[tiab] OR Eloxatin*[ti]</P>
<P>#3 combined searches #1 AND #2 above</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (accessed through Ovid)</HEADING>
<P>#1 ('small cell carcinoma' AND 'lung tumor') OR SCLC:ti OR ((lung:ti OR lungs:ti OR pulmonary:ti OR bronchus:ti OR brochogenic:ti OR bronchial:ti OR bronchoalveolar:ti OR alveolar:ti) AND (small-cell:ti OR oat-cell:ti) AND (cancer*:ti OR carcinoma*:ti OR adenocarcinoma*:ti OR malignan*:ti OR tumor*:ti OR tumour*:ti OR neoplasm*:ti))</P>
<P>#2 'platinum derivative' OR 'cisplatin' OR platinum:ti,ab OR cisplatin:ti,ab OR Platinol:ti OR carboplatin:ti,ab OR Paraplatin:ti OR oxaliplatin:ti,ab OR Eloxatin*:ti</P>
<P>#3 combined searches #1 AND #2 above</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (accessed through EBSCO)</HEADING>
<P>#1 (carcinoma, small cell AND lung neoplasms) OR SCLC OR ((lung OR lungs OR pulmonary OR bronchus OR brochogenic OR bronchial OR broncho alveolar OR alveolar) AND (small-cell OR oat-cell) AND (cancer* OR carcinoma* OR adenocarcinoma* OR malignan* OR tumor* OR tumour* OR neoplasm*))</P>
<P>#2 "Platinum Compounds" OR "Cisplatin" OR platinum OR cisplatin OR Platinol OR carboplatin OR Paraplatin OR oxaliplatin OR Eloxatin*</P>
<P>#3 combined searches #1 AND #2 above</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The Cochrane Central Register of Controlled Trials (CENTRAL)</HEADING>
<P>#1 (carcinoma, small cell AND lung neoplasms[MeSH]) OR SCLC[ti] OR ((lung[ti] OR lungs[ti] OR pulmonary[ti] OR bronchus[ti] OR brochogenic[ti] OR bronchial[ti] OR bronchoalveolar[ti] OR alveolar[ti]) AND (small-cell[ti] OR oat-cell[ti]) AND (cancer*[ti] OR carcinoma*[ti] OR adenocarcinoma*[ti] OR malignan*[ti] OR tumor*[ti] OR tumour*[ti] OR neoplasm*[ti]))</P>
<P>#2 "Platinum Compounds"[MeSH] OR "Cisplatin"[MeSH] OR platinum[tiab] OR cisplatin[tiab] OR Platinol[ti] OR carboplatin[tiab] OR Paraplatin[ti] OR oxaliplatin[tiab] OR Eloxatin*[ti]</P>
<P>#3 combined searches #1 AND #2 above</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-06-18 11:55:01 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2015-05-01 13:55:35 +0200" MODIFIED_BY="[Empty name]">Search strategy used in current update</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-18 11:55:01 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI/>
</UL>
<P>
<B>MEDLINE (accessed through PubMed; 01.08.2014)</B>
</P>
<P>#1 "carcinoma, small cell"[MeSH] AND lung neoplasms[MeSH]</P>
<P>#2 SCLC[tiab]</P>
<P>#3 lung[ti] OR lungs[ti] OR pulmonary[ti] OR bronchus[ti] OR bronchogenic[ti] OR bronchial[ti] OR bronchoalveolar[ti] OR alveolar[ti]</P>
<P>#4 (small-cell[ti] OR oat-cell[ti]) AND (cancer*[ti] OR carcinoma*[ti] OR malignan*[ti] OR tumor*[ti] OR tumour*[ti] OR neoplasm*[ti])</P>
<P>#5 #3 AND #4</P>
<P>#6 #1 OR #2 OR #5</P>
<P>#7 "Platinum Compounds"[MeSH]</P>
<P>#8 "Cisplatin"[MeSH]</P>
<P>#9 platinum[tiab]</P>
<P>#10 cisplatin[tiab]</P>
<P>#11 platinol[ti]</P>
<P>#12 carboplatin[tiab]</P>
<P>#13 paraplatin[ti]</P>
<P>#14 oxaliplatin[tiab]</P>
<P>#15 eloxatin*[ti]</P>
<P>#16 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15</P>
<P>#17 #6 AND #16</P>
<P>#18 (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals[mh] NOT (humans[mh] AND animals[mh]))</P>
<P>#19 #17 AND #18</P>
<P>#20 #17 AND #18 AND ("2007/01/01"[PDAT] : "3000/12/31"[PDAT])</P>
<P>
<B>EMBASE (accessed through Ovid &lt;</B> <B>1980 to 2014 Week 30&gt;; 01.08.2014)</B>
</P>
<P>1 exp lung small cell cancer/ (</P>
<P>2 SCLC.ti.</P>
<P>3 lung*.ti.</P>
<P>4 pulmonary.ti.</P>
<P>5 bronch*.ti.</P>
<P>6 bronchoalveolar.ti.</P>
<P>7 alveolar.ti.</P>
<P>8 2 or 3 or 4 or 5 or 6 or 7</P>
<P>9 (small cell or oat cell).ti.</P>
<P>10 (cancer* or carcinoma* or adenocarcinoma* or malignan* or tumor* or tumour* or neoplasm*).ti.</P>
<P>11 9 and 10</P>
<P>12 8 and 11</P>
<P>13 1 or 2 or 12</P>
<P>14 exp platinum derivative/</P>
<P>15 exp cisplatin/</P>
<P>16 (platinum or cisplatin or Platinol or carboplatin or Paraplatin or oxaliplatin or Eloxatin*).ti,ab.</P>
<P>17 14 or 15 or 16</P>
<P>18 13 and 17</P>
<P>19 (double-blind: or placebo:).mp. or blind:.tw.</P>
<P>20 18 and 19</P>
<P>21 limit 20 to yr="2007 -Current"</P>
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library: Issue 7 of 12, July 2014; 01.08.2014)</B>
</P>
<P>#1 MeSH descriptor: [Small Cell Lung Carcinoma] explode all trees</P>
<P>#2 SCLC:ti,ab</P>
<P>#3 (lung or lungs or pulmonary or bronchus or bronchogenic or bronchial or bronchoalveolar or alveolar):ti</P>
<P>#4 (small-cell or oat-cell):ti</P>
<P>#5 (cancer* or carcinoma* or malignan* or tumor* or tumour* or neoplasm*):ti</P>
<P>#6 #4 and #5</P>
<P>#7 #3 and #6</P>
<P>#8 #1 or #2 or #7</P>
<P>#9 MeSH descriptor: [Platinum Compounds] explode all trees</P>
<P>#10 MeSH descriptor: [Cisplatin] explode all trees</P>
<P>#11 platinum:ti,ab</P>
<P>#12 cisplatin:ti,ab</P>
<P>#13 Platinol:ti</P>
<P>#14 carboplatin:ti,ab</P>
<P>#15 paraplatin:ti</P>
<P>#16 oxaliplatin:ti,ab</P>
<P>#17 eloxatin*:ti</P>
<P>#18 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17</P>
<P>#19 #8 and #18</P>
<P>#20 #8 and #18 Publication Year from 2012 to 2014 267</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;32 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;32 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;32 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3,557 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3,557 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3,669 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;29 studies from original review&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3525 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;0 full-text articles excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>